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1. Introduction 
 
1.1. Cellular senescence 
Cellular senescence is defined as an irreversible arrest of cell proliferation 
accompanied by changes in cell function and morphology. Senescent cells are 
viable and metabolically active for long periods of time, but are incapable of 
further division (Campisi et al. 1996). Historically, the senescent state has been 
associated with an intrinsically defined number of cell divisions in vitro. However, 
recently it has been shown that many extrinsic factors can prematurely induce a 
virtually indistinguishable senescent phenotype.  
 
1.1.1. Cellular lifespan: the Hayflick limit 
It had been generally believed that cells could proliferate indefinitely and that the 
maintenance of a cell culture was just a question of finding the right conditions 
(Hayflick 1998). This idea was radically changed in the early 1960s by Leonard 
Hayflick, who first described the finite life span in cultures of human diploid 
fibroblasts (HDFs) (Hayflick 1965; Hayflick and Moorhead 1961). Despite 
optimized culture conditions, HDFs can undergo 60-80 population doublings and 
thereafter every cell has stopped dividing. Since then, many types of normal 
somatic cells from humans, rodents, birds and several other species have been 
shown to have finite capacity for cell division (Campisi et al. 1996). This 
phenomenon, known as ‘Hayflick limit’, is termed ‘replicative senescence’. When 
this limit is reached, cells stop dividing and undergo an array of biochemical and 
morphological changes. Senescent cells may remain metabolically active for a 
long period of time, even though they have permanently ceased to proliferate 
(Campisi 1996; Goldstein 1990). 
 
1.1.2. Replicative senescence and telomeres 
Replicative senescence depends on the overall number of cell divisions and not 
on the time in culture. The molecular mechanisms that determine this intrinsic 
replicative senescence appear to be mainly controlled by the shortening of 
telomeres (Mathon and Lloyd 2001).  
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1.1.2.1. Telomeres and their function 
Telomeres are DNA-protein structures at the ends of linear chromosomes (Figure 
1).  In every organism studied, telomere DNA consists of long head-to-tail arrays 
of repeated DNA sequences. Mammalian telomeres, like all vertebrate telomeres, 
are tandem repeats of the sequence TTAGGG which is repeated many hundreds 
to thousands of times. The length varies greatly among species. While telomeres 
are 15 to 20 kb in the human germ line, they are ranging 30-50 kb in laboratory 
mice (Campisi et al. 2001). Most of the telomeric tract is double stranded DNA, 
but there are also short (50-200 base pairs) single stranded 3’ overhangs at both 
chromosome ends (Campisi et al. 2001; Makarov et al. 1997). The telomere end 
folds back on itself, forming a protective structure called “T-loop” to hide the 
vulnerable 3’ overhang (Mathon and Lloyd 2001). The T-loop is formed in 
association with or bound by proteins, such as TRF1, TRF2 and Ku (Broccoli et 
al. 1997; Chong et al. 1995; Hsu et al. 1999; Song et al. 2000). Besides 
maintaining the telomeric structure, many of these proteins were found to be 
involved in DNA repair processes (Campisi et al. 2001).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Structure of the telomeres. Each of the 46 linear human 
chromosomes has 2 telomeres. Telomeres are complex structures comprising 
the underlying DNA and associated proteins.  
 
 
Telomeres share some basic functions and characteristics in all organisms. First, 
they enable cells to distinguish a chromosome end from a double strand break 
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(DSB) in the genomic DNA. DSBs can activate the checkpoints in the cell cycle, 
which cause that cell to stop dividing until the DNA strand break is rejoined. Thus, 
without a distinctive telomere structure, chromosome ends are at risk for 
degradation, recombination or random fusion by cellular DNA repair systems 
(Campisi et al. 2001; van Steensel et al. 1998). Second, telomeres provide a way 
to replicate the chromosome completely including restoration of a simple terminal 
repeat of characteristic length. This replication is achieved by the unique reverse-
transcriptase-like enzyme telomerase or alternatively through recombination 
(Dubrana et al. 2001; Kass-Eisler and Greider 2000). Finally, telomeres control 
the positions of chromosomes within the nucleus (Dubrana et al. 2001). 
 
1.1.2.2. The end replication problem 
Eukaryotic organisms have much larger genomes compared to bacteria and 
viruses. Their DNA is divided into multiple linear chromosomes to keep the 
molecules at a manageable size. However, there is a major problem with the 
replication of the very ends of linear DNA during cell division known as ‘end-
replication problem’ (Blackburn 1991; Klapper et al. 2001; Zakian 1995). It is a 
consequence of two properties of the semiconservative DNA replication 
machinery: the ability of DNA polymerases to work only in the 5’ to 3’ direction, 
and their requirement for a nucleic acid primer. DNA replication starts at many 
different sites (origins of replication) along each chromosome and is carried out 
by DNA polymerases. DNA polymerases initiate DNA replication only at a primer 
molecule, which is a short piece of RNA. The RNA primer will be degraded when 
DNA synthesis is complete. While replication is bidirectional where replication 
proceeds in both the 3’ and 5’ direction from an origin of replication, DNA 
polymerases work unidirectional and polymerize exclusively in 5’ – 3’ direction 
(Figure 2). Therefore, replication of the ‘lagging strand’ will form short gaps 
between Okazaki fragments after RNA primer degradation. Gaps are filled by 
DNA polymerase except for the one at the very end of the chromosome. This 
results in the loss of 50-200 bp in the new synthesized DNA strand at the 5’ end, 
and forms 3’ overhangs in the mother strand. Interestingly, there is a 3’ overhang 
at both ends of mammalian chromosomes (Makarov et al. 1997). This finding 
suggests that a 5’ – 3’ exonuclease specifically trims back the completely 
synthesized telomere (Campisi et al. 2001). 
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Figure 2. The end replication problem (Modified from Campisi et al. 2001; 
Greider and Blackburn 1985).  
 
 
1.1.2.3. Short telomeres cause replicative senescence 
The link between the Hayflick limit and the end-replication problem was first 
proposed by Alexey Olovnikof, a Russian theoretical biologist (Shay and Wright 
2000). During successive cellular divisions the telomeres shorten progressively in 
normal human cells. When the telomeres erode from their maximum size of 10-
15 kb (in the germ line) to an average size of 4-6 kb, replicative senescence is 
reached with an irreversible growth arrest. The underlying mechanisms are 
incompletely understood (Campisi 2001a; Mathon and Lloyd 2001). In human 
fibroblasts, senescent cells can be induced to bypass replicative senescence by 
functional inactivation of the tumor suppressor proteins p53 and pRb (Shay et al. 
1991c). Continued proliferation of cells beyond the Hayflick limit leads to further 
shortening of telomeres, and cells eventually reach a second proliferative block, 
which is characterized by genomic instability associated with telomere disfunction 
and massive cell death, termed “crisis” (Maser and DePinho 2002; Wright and 
Shay 1992). The hypothesis that telomere shortening is responsible for a limit in 
the proliferation lifespan has been generally accepted. Stable expression of 
telomerase is sufficient to bypass both senescence and crisis, and to confer 
immortality (Bodnar et al. 1998; Ramirez et al. 2001; Vaziri and Benchimol 1998). 
Thus, telomere shortening in normal human cells acts as a “mitotic clock” that 
ultimately limits the proliferative capacity of cells (Harley et al. 1992; Wright and 
Shay 1992).  
	
	

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1.1.2.4. Telomerase 
Continuously growing cells, such as germline and tumor cells, have to circumvent 
the end-replication problem. This is solved by the enzyme telomerase that adds 
telomeric sequences onto the chromosome ends (Greider and Blackburn 1985). 
Telomerase is a RNA-dependent DNA polymerase that adds single-stranded 
telomeric repeats to the end of the telomeric DNA. It consists of two essential 
components: one is a RNA subunit which serves as a template for the synthesis 
of telomeric DNA, the encoding gene in human is referred to as hTR (Feng et al. 
1995). The other is the catalytic protein (hTERT) with reverse transcriptase 
activity (Harrington et al. 1997; Lingner et al. 1997). Although hTR is highly 
expressed in all tissues regardless of telomerase activity, hTERT is – apart from 
some expression – repressed in somatic cells and upregulated in immortal cells 
suggesting that hTERT is the primary determinant for the enzyme activity (Avilion 
et al. 1996; Cong et al. 2002). Expression of telomerase is the major mechanism 
by which cancer cells stabilize their telomeres and, hence, avoid replicative 
senescence (Chiu and Harley 1997).  
 
1.1.3. Stress-induced premature senescence 
Recently, noxious stimuli with little or no impact on telomeres were shown to 
induce somatic cells to undergo growth arrest with a senescence phenotype. As 
these stimuli act before the replicative limit of a cell, this state of growth arrest 
has been termed premature senescence (Lloyd 2002). Stimuli that lead to 
premature senescence include DNA damage, genomic instability, oncogene 
upregulation and oxidative stress (Campisi 2001a).  
 
1.1.3.1. DNA damage and genomic instability 
The outcome of DNA damage is diverse. Acute effects from DNA damage trigger 
cell-cycle arrest or cell death. Long-term effects that resulted from mutations 
contribute to tumorigenesis (de Boer et al. 2002; Hoeijmakers 2001). Premature 
senescence can be induced by various types of DNA damage, with telomere 
dysfunction being the most efficient trigger. An early observation of DNA 
damage-induced senescence was the induction of a permanent and irreversible 
proliferation arrest in gamma irradiated human fibroblasts (Di Leonardo et al. 
1994). Further evidence for the causal role of DNA damage and genomic 
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instability in senescence comes from human diseases featured by deficiencies in 
DNA damage repair pathways. Cells obtained from ataxia telangiectasia (ATM) 
patients or individuals suffering from Werner’s and Bloom’s syndromes undergo 
senescence earlier than age-matched healthy individuals (Schulz et al. 1996; 
Shiloh et al. 1985). Telomere damage seems to induce senescence as implied 
by the recent finding that the knockout of two DNA damage repair enzymes with 
similar function led to different outcome. DNA-dependent protein kinase (DNA-
PK) and Ku86 are two proteins essential for the repair of DNA breaks through 
non-homologous end joining. Murine fibroblasts deficient in  the DNA-PK catalytic 
subunit (DNA-PKCs) do not undergo premature senescence, whereas deficiency 
in Ku86 leads to premature senescence (Goytisolo et al. 2001; Samper et al. 
2000). The dramatic differences in the induction of senescence between these 
two proteins with similar functions may be explained by the fact that Ku86 plays a 
specific role in the stabilization of telomeres (Serrano and Blasco 2001). In 
addition, disruption of TRF2 which is a critical protein involved in telomeric t-loop 
formation, causes immortal human tumor cells to die (Karlseder et al. 1999). 
Non-transformed cells, by contrast, undergo growth arrest with a senescent 
phenotype (van Steensel et al. 1998). Chromosomes that lack a protective 
telomeric structure are highly unstable, being subject to degradation, 
rearrangement and/or fusion, all of which could trigger the senescent program. 
Moreover, genomic instability, particularly in the absence of the senescence 
checkpoint and p53 function greatly increases the frequency of mutations (van 
Steensel et al. 1998). DNA damage and genomic instability might explain why 
mouse cells senesce after fewer doublings than human cells, despite having 
longer telomeres (Campisi 2001a). As has been reported, mouse and rat cells 
repair DNA damage far less efficiently than human cells and are much more 
sensitive to a variety of agents that produce oxidative stress (Hart and Setlow 
1974; Kapahi et al. 1999).  
 
1.1.3.2. Oncogene activation 
Primary cells can not be transformed by a single oncogene in vitro, such as Ras 
or Myc (Weinberg 1989). Cells in response to these oncogenic activations often 
exit the cell cycle (Ras) or die (Myc) (Mathon and Lloyd 2001). Although Ras 
signaling pathways are constitutively activated in a large proportion of human 
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tumors (Hanahan and Weinberg 2000), the overexpression of the Ras oncogene 
in primary cells instead leads to a senescence-like state (Serrano et al. 1997). 
Ras-induced premature senescence shares similar features with replicative 
senescence not only phenotypically but also in cell cycle control pathways. In 
human fibroblasts, both Ras-induced premature senescence and replicative 
senescence reveal an upregulation of the tumor suppressor p16INK4a which 
inactivates the D-type cyclins (Serrano and Blasco 2001).  
 
1.1.3.3. Oxidative stress 
Oxidative damage is another cellular stress that can induce senescence-like 
growth arrest. Culturing human fibroblasts in 2-3% oxygen results in 20-30% 
more population doublings compared to that under 20% oxygen (Balin et al. 1984; 
Chen et al. 1995b; Saito et al. 1995). Similarly, treatment of cultures of primary 
fibroblasts with non-lethal concentrations of hydrogen peroxide activates a rapid, 
senescence-like growth arrest (Chen and Ames 1994). The role of oxidants in 
cellular senescence was further underscored by the observation that Ras-
induced senescence is also mediated by ROS and can be abrogated by culturing 
cells under low oxygen tension or in the presence of antioxidants (Lee et al. 
1999). Oxidative stress is probably the most often used inducer of premature 
senescence and is likely to be the common denominator of the ‘stress-induced 
premature senescence’ (SIPS) (Toussaint et al. 2000c). Accumulation of cell 
damage as a result of oxidative damage to macromolecules is generally thought 
to play an important causal role in aging (Johnson et al. 1999). 
 
1.1.4. Senescent phenotypes and molecular pathways 
The universal characteristic of replicative senescence is a stable, irreversible loss 
of cell proliferative capacity (Campisi et al. 1996). Several phenotypic and 
biochemical changes are associated with replicative senescence and are used 
as markers to identify premature senescence. These changes include increased 
cell size which changes from a small, elongated or spindle-like shape in young 
cells to aged flattened cells with enlarged cytoplasm, expression of senescence 
associated β-galactosidase (SA-β-Gal), which is associated with an increased 
biogenesis of lysosomes. In addition, cellular senescence comprise an abrogated 
response to growth factors and other mitogens, a reduced membrane potential, a 
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decrease in respiration and energy metabolism, an increase in the duration of G1 
phase of the cell cycle and the upregulation of certain growth inhibitory genes, 
such as p16 and p21. Furthermore, distinct changes were found in cellular 
functions such as the adaption of matrix-degrading phenotype by senescent 
fibroblasts as well as an altered secretion pattern of steroid hormones by 
senescent adrenal cortical epithelial cells (Campisi 1997, 1998, 2000, 2001b; 
Campisi et al. 1996; Campisi et al. 2001). 
 
A number of regulatory proteins transduce senescence-inducing signals or 
mediate entrance of the cell into senescence, among which the most crucial are 
several tumor suppressors, such as p53 and p16INK4a (Figure 3). Although p53 
protein levels do not increase during replicative senescence, an increase in its 
activity in terms of DNA binding and transcriptional activity is observed (Atadja et 
al. 1995; Vaziri et al. 1997). p53 levels transiently increase in oxidative stress or 
oncogenic Ras-induced premature senescence (Chen et al. 1998; Dimri et al. 
2000; Serrano et al. 1997). A major cause of p53 upregulation or activation is 
related to the increase in the expression of p14ARF (p19ARF in mouse), a tumor 
suppressor encoded by the INK4a locus (Campisi 2001a). p14ARF could be 
induced by oncogenic Ras and DNA damage. p14ARF directly binds and 
sequesters MDM2, a protein that facilitates p53 degradation. Loss of MDM2 
function, in turn, results in the stabilization of p53 and activation of p53-mediated 
growth arrest (Bringold and Serrano 2000). Another cause for the increase in p53 
activity might be the promyelocytic leukemia (PML) tumor suppressor which can 
be induced by oncogenic Ras (Ferbeyre et al. 2000; Pearson et al. 2000). 
Activation of PML acetylates p53 and thus stimulates its activity (Pearson et al. 
2000). p53 induces the transcription of several genes responsible for the onset of 
senescence including the cyclin-dependent protein kinase (CDK) inhibitor p21, a 
well-recognized p53 target gene. Another pathway implicated in cellular 
senescence involves p16INK4a and Rb.  p16 is the second tumor suppressor 
encoded by the INK4a locus (Bringold and Serrano 2000; Lundberg et al. 2000). 
p16INK4a is involved both in replicative senescence and stress-induced premature 
senescence (Serrano and Blasco 2001). Upregulation of p16 is in part due to Ets, 
a transcription factor that stimulates p16 expression and accumulates in 
senescent cells (Campisi 2001a).  Ets activity is negatively regulated by the helix-
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loop-helix protein Id1 (Ohtani et al. 2001). It is not known how other senescence 
inducers stimulate Ets activity, or how Id1 is repressed in response to 
senescence-inducing signals. Nonetheless, these findings have identified p16 
expression as an important target for senescence-inducing signals (Campisi 
2001a). In human cells, p16/Rb appear to be the major factors controlling the cell 
cycle checkpoint in response to inadequate culture conditions and other kinds of 
stresses, whereas p14ARF/p53/p21 may initially have a more predominant role in 
human fibroblasts at their proliferative limits or in response to DNA damage. In 
each case, there are many overlapping roles for factors controlling these 
checkpoints of the cellular senescence (Wright and Shay 2001). 
 
 
 
 
 
 
 
 
 
Figure 3. Cellular senescence pathways (Adapted from Campisi 2001a; 
Lundberg et al. 2000). 
 
 
1.1.5. Role of cellular senescence in cancer and aging  
1.1.5.1. Implications for cancer 
One interpretation for the biological function of cellular senescence is that it 
serves as a mechanism for restricting cancer progression (Wright and Shay 
2001). Cancer is a complex condition involving a multi-faceted evolutionary 
process which occurs at the cellular level within organs and organisms. One 
hallmark of tumor cells is that they can proliferate indefinitely. The extended 
growth potential of cancer cells is critically dependent on the maintenance of 
functional telomeres. Most human malignant tumors express telomerase. Tumor 
cells that do not express telomerase stabilize their telomeres by a different 
mechanism – alternative lengthening of telomeres (ALT) (Bryan et al. 1997; Kim 
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et al. 1994). The expression of telomerase in nearly all malignancies suggests 
that overcoming the proliferative limits imposed by telomere shortening 
represents a key step in oncogenesis (Kim et al. 1994). Apart from replicative 
senescence, it has been speculated that premature senescence can also serve 
as a tumor-suppressing mechanism. Another hallmark that distinguishes cancer 
cells from primary cells is the loss of growth control, resulting from both gain-of-
function mutations in proto-oncogenes and loss-of-function mutations in tumor 
suppressors (Cong et al. 2002). The observation that many of the checkpoint 
control genes involved in premature senescence are oncogenes or tumor 
suppressors has been forwarded to argue that overcoming these proliferative 
checkpoints represents an important step in tumor development (Campisi 2001b; 
Mathon and Lloyd 2001).  
 
1.1.5.2. Implications for aging 
Aging is associated with a progressive decline in bodily functions, ultimately 
resulting in disease and death (Mathon and Lloyd 2001). The idea that cellular 
senescence reflects mechanisms also relevant for organismal aging is supported 
by several lines of evidence. First, limited inter-species comparisons showed an 
inverse correlation between species lifespan and the replicative life span of 
fibroblast cultures (Rohme 1981). Second, cells from patients with premature 
aging syndromes were observed to senesce after fewer doublings than age-
matched healthy individuals (Martin 1970). Third, cells expressing SA-β-
galactosidase are more prevalent in physiologically aged tissue than in young 
tissue (Campisi 2001b; Dimri et al. 1995). However, evidence for a role of 
replicative senescence in the aging process remains controversial, since the 
inverse correlation between donor age and the replicative ability of in vitro cell 
proliferation was not consistently observed in all studies (Cristofalo et al. 1998; 
Stanulis-Praeger 1987). 
 
Cellular senescence drives some of the dysfunctions associated with aging. 
Senescent cells remain metabolically active but cannot proliferate, and may 
rather be disruptive and destructive in the tissues in some instances. Senescent 
cells show changes in gene expression and secrete a number of proteins that 
contribute to degeneration of connective tissues seen in aging (Shelton et al. 
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1999). This senescence-associated secretory proteolytic phenotype is 
particularly striking in fibroblasts. Senescence of fibroblasts is accompanied by 
increased expression of matrix-degrading enzymes like collagenase and 
stromelysin (Campisi 1996; Kim et al. 2002). These enzymes could be potentially 
detrimental to the adjacent environment of the cell and, thus, could affect all 
other adjacent nonsenescent cells. In skin, for example, this could lead to a loss 
of integrity resulting in wrinkles and loss of elasticity commonly observed in skin 
aging (Smith and Pereira-Smith 1996). Though the factors released from 
senescent cells are incompletely characterized, and little is known on 
mechanisms responsible for their overexpression (Campisi 2001a), senescent 
fibroblasts have been shown to accumulate with age in skin biopsies (Dimri et al. 
1995).  
 
 
1.2. PUVA-treated fibroblasts as a model for stress-induced premature 
cellular senescence  
 
1.2.1. Psoralen phototherapy 
PUVA is a combination of psoralen (P) and long-wave ultraviolet radiation (UVA) 
that is widely used for the treatment of various skin disorders. Even though 
topical exposure to extracts, seeds and parts of plants (e.g. Ammi majus, 
Psoralea corylifolia) that contain natural psoralens and subsequent irradiation 
with sunlight as a remedy for the treatment of vitiligo has been used for 
thousands of years by ancient Arab and Indian healers, the modern era of its use 
began in Egypt in the mid-1940s when the active components 8-
methoxypsoralen (8-MOP), 5-methoxypsoralen (5-MOP) and 
isoamyleneoxypsoralen were isolated and chemically characterized (Lerner 
1988). PUVA treatment for psoriasis, by far the most prevalent use of PUVA, was 
developed clinically in 1970s at Harvard Medical School (Honigsmann 1986; 
Lerner 1988). Ten years later, photopheresis using 8-MOP was introduced for 
the treatment of T-cell lymphoma (Edelson et al. 1987; Gasparro et al. 1998).  
 
The combination of psoralen and UV irradiation results in beneficial therapeutic 
effects, which are not achieved by either of the single components alone. The 
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effectiveness of PUVA, as well as other kinds of phototherapy, provided 
treatment for a variety of different skin disorders besides psoriasis (Honig et al. 
1994; Honigsmann 2001). However, PUVA treatment also raises the potential 
risk of the development of skin cancer and possibly premature skin aging 
(Jacobson-Kram et al. 1982). A study by Stern et al. (1994) of 1380 patients 
showed a statistically significant increase in the incidence of squamous cell 
carcinoma (SCC) in PUVA patients (Stern and Laird 1994). Although PUVA is the 
most widely employed photochemotherapy treatment in dermatology, many of 
the biochemical and molecular events induced by PUVA have not yet been 
intensively characterized. 
 
1.2.2. 8-MOP photochemistry and photobiology 
8-methoxypsoralen, the most widely used psoralen derivative for PUVA 
treatment, is a naturally occurring aromatic tricyclic molecule (Figure 4). Its 
planar and extended aromatic structure enables it to intercalate with nucleic acid 
base pairs. Upon photoactivation three different types of psoralen-DNA 
photoadducts were formed including two kinds of monoaddition products, 3,4-
monoadducts and 4’5’-monoadducts, and one bi-adduct (psoralen-DNA 
interstrand crosslink (ICL)) (Gasparro 1988).  Psoralens react with DNA in three 
steps. First the psoralen intercalates into the DNA double strand in the absence 
of UV radiation. Upon UV irradiation, cyclobutane monoadducts with a pyrimidine 
base are formed. If the initial photoreaction occurs at a 5’-TpA site, the 4’5’-
monoadducts can absorb a second photon and undergo another cyclobutyl 
reaction with the adjacent thymine at the opposite strand resulting in the 
formation of a psoralen-DNA cross-link (Gasparro 1988; Gasparro et al. 1997). 
Because these DNA photoadducts are the most well-characterized psoralen 
photoadducts, most explanations of therapeutic efficacy have been based on the 
generation of DNA photoadducts, especially psoralen-DNA crosslink formation as 
the basis for the subsequent proliferation inhibitory or toxic effects (Schmitt et al. 
1995). However, there is scant direct evidence supporting the biological impact of 
the photoadduct. Psoralens have also been shown to undergo photoaddition 
reactions with other cellular components, such as proteins and lipids (Schmitt et 
al. 1995). In addition to direct modification of nearby biomolecules, the excited 8-
MOP can also react with molecular oxygen. The reactive oxygen species formed 
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by this reaction can directly lead to oxidative DNA damage or cause cell 
membrane damage by lipid peroxidation (Averbeck 1989; Gasparro et al. 1997).  
 
 
 
 
 
 
 
Figure 4. The chemical structure of 8-MOP. 
 
1.2.3. PUVA-induced senescent-like growth arrest of fibroblasts 
Previous work in our laboratory has shown that psoralen photoactivation 
promotes morphological and functional changes in fibroblasts in vitro reminiscent 
of replicative cellular senescence. A single non-toxic exposure of human dermal 
fibroblasts to PUVA with 50ng/ml 8-MOP and 90 kJ/m2 UVA resulted in a long-
term switch of mitotically active fibroblasts to growth-arrested fibroblasts without 
proliferative activity (Herrmann et al. 1998). In addition to arresting cell 
proliferation, PUVA treatment also induced a senescent-like phenotype with an 
enlarged phenotypic morphology, enhanced SA-β-Gal expression, and elevated 
expression of interstitial collagenase/matrix metalloproteinase-1 (MMP-1). 
Fibroblasts which had been subjected to PUVA treatment changed to a flattened 
and elongated phenotype at day 7 post treatment and revealed a substantial 
increase in size at day 14-21 after irradiation.  Similarly, SA-β-Gal positive 
fibroblasts were detected from day 7 post PUVA and at day 28 essentially all 
fibroblasts revealed de novo expression of SA-β-Gal. Furthermore, MMP-1 was 
induced following PUVA treatment. The induction of MMP-1 was prolonged within 
the growth arrest phase, while TIMP-1, the major inhibitor of MMP-1, was only 
slightly induced. The imbalance between matrix-degrading metalloproteinases 
and their inhibitors may lead to connective tissue damage, a hallmark of skin 
aging (West et al. 1989).  Interestingly, PUVA-treated fibroblasts could resume 
proliferation after a growth arrest period of about three months.  
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1.3. Aim of the study 
The aim of this study is a more detailed characterization and understanding of 
the molecular mechanisms involved in the initiation, maintenance and release 
from the PUVA-induced long-term senescence-like growth arrest with particular 
focus on the development of the senescent phenotype and factors influencing 
replicative senescence. In detail, the following questions were addressed: 
i) What are the molecular mechanisms underlying the initiation and 
maintenance of the long-term growth arrest as well as what mechanisms are 
involved and contribute to the development of senescent-like biochemical and 
morphological changes? 
ii) What molecular mechanisms determine the re-proliferation of PUVA-treated 
fibroblasts after the long-term growth arrest? Is it due to immortalization or 
transformation as a result of loss-of-function of tumor-suppressor genes 
controlling cellular senescence? Or does PUVA-induced long-term growth 
arrest represents a phenocopy of senescence, activated to serve a damage-
repairing function? 
 
Answers to these questions are of general relevance and may shed light to other 
premature senescence models with the identification of similarities and 
differences and potential identification of therapeutic strategies to prevent or treat 
aging and neoplastic conditions.   
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2 Materials and methods 
 
2.1. Materials 
 
2.1.1. Chemicals 
All analytical grade chemicals were purchased from Sigma-Aldrich (Deisenhofen), 
Molecular probes (MoBiTec, Goettingen), Merck (Darmstadt), USB (Amersham 
Life Sciences, Braunschweig), Merck (Darmstadt), Serva (Heidelberg), Bio-Rad 
(Munich), Pharmacia-Biotech (Freiburg); Radiochemicals were obtained from 
ICN (Eschwege). 
Molecular weight markers for proteins (Broad Range) were purchased from Bio-
Rad and DNA molecular weight standards from Roche (Mannheim) and New 
England Biolabs (Schwalbach). Antibodies were purchased from Santa-Cruz 
Biotechnology (Heidelberg). 
Restriction enzymes used were from Boehringer (Mannheim), New England 
Biolabs. 
Oligonucleotides were synthesized at MWG Biotech (Ebersberg).  
 
2.1.2. Cell culture material 
All plastic material for cell culture was from Greiner (Solingen). Cell culture 
medium and supplements were purchased from Gibco BRL (Eggenstein), and 
fetal calf serum (FCS) was from PAA Laboratories (Biochrom, Berlin). 
 
2.1.3. Cell strains, bacteria, vectors and plasmids 
The following cell strains had been used: two human dermal fibroblast strains, 
FF95 and FF-DA. The epithelial carcinoma cell line HeLa and the fibrosarcoma 
cell line HT1080. For transformation of plasmids the E. coli strain DH5 α (Gibco 
BRL, Eggestein) was used. The genotype is: F’, supE44, ∆lacU169 
(φ80lacZ∆M15), hsdR17, recA1, gyrA96, thi-1, relA1. The eukaryotic expression 
vector pEGFP-N1 was purchased from ClonTech Laboratories Inc. (Heidelberg). 
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2.1.4. Buffers 
PBS 
137 mM NaCl, 2.7 mM KCl, 8.4 mM Na2HPO4, 1.4 mM KH2PO4, 
pH7.4 
TBS 20 mM Tris, 137 mM NaCl, pH7.6 
TBS-T TBS, 0.1%(v/v) Tween 20 
20× SSC 3M NaCl, 0.3M Sodium citrate, pH7.0 
100× 
Denhards 2% ficoll, 2% polyvinylpyrrolidon, 2% BSA 
TBE 89 mM Tris base, 89 mM boric acid, 2 mM EDTA 
TSE 10 mM Tris, 150 mM NaCl, 10 mM EDTA 
TAE (10×) 2 M Tris, 5.7% (v/v) glacial acetic acid, 50 mM EDTA 
 
Protein extraction buffer 
50 mM Hepes (pH 7.4), 1% (v/v) Triton X-100, 50 mM NaCl, 100 mM NaF, 10 
mM EDTA, 10 mM Na3VO3, 0.1% (w/v) SDS; supplemented with a cocktail of 
protease inhibitors (Leupeptin 10 ng/ml, Aprotinin 10 µg/ml, Benzamidine and 
PMSF 2 mM). 
 
RIPA buffer  
50 mM Tris (pH 7.5), 5 mM NaCl, 1 mM EGTA, 1% Triton X-100, 50 mM NaF, 10 
mM Na3VO4, 1 mg/ml aprotinin, 1 mg/ml leupeptin, 1 mg/ml pepstatin A, 0.1 mM 
phenylmethylsulfonyl fluoride and 1 mM DTT 
 
Protein denaturing sample buffer (2×) 
0.5 M Tris-HCl, pH6.8, 10% glycine, 10% SDS, 0.1% Bromophenol. 
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2.2. Methods 
 
2.2.1. Methods of cell biology  
 
2.2.1.1. Cell culture 
Fibroblasts were established by outgrowth from foreskin of healthy human 
donors aged 3 to 6 years (Fleischmajer et al. 1981). Fibroblasts were maintained 
in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal 
calf serum (FCS). Fibroblasts were incubated in a humidified 5% CO2 - 95% air 
atmosphere at 37°C. For determination of growth rates and cumulative 
population doublings (CPDs), cells were counted at each transfer with a Fuchs-
Rosenthal haemocytometer. CPD was calculated according to the following 
equation: 
 
 
ai = Cell number per dish at the end of each passage. 
a0 = cell number seeded per dish at the beginning of each passage. 
 
2.2.1.2. Freezing and thawing of fibroblasts 
Subconfluent fibroblasts were trypsinized, resuspended in FCS (GIBCO BRL) 
supplemented with 10% DMSO (Sigma-Aldrich). Aliquots were placed in a 
freezing container filled with isopropanol and remained for 1-2 days at -80°C 
before storage in liquid nitrogen. For thawing frozen fibroblasts were quickly 
transferred from liquid nitrogen into a 37°C water bath, thawed, seeded on a 
Petri-dish at a density of 2×105~5×105 with subsequent change of medium one 
day later.  
 
2.2.1.3. Rho0  fibroblasts 
mtDNA depleted fibroblasts designated as Rho0 fibroblasts were prepared by 
treating human dermal fibroblasts with 0.1µg/ml ethidium bromide at 37°C for 7-
14 days in DMEM supplemented with 10% FCS, 110 µg/ml pyruvate, and 50 
µg/ml uridine. During cell growth, because mtDNA replication is inhibited, the 
initial number of mtDNA molecules present in these cells is decreased by a factor 
of two each time the cells divide. The depletion of mtDNA was confirmed by the 
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mitochondria transcription factor, mtTFA, which has been shown to correlate with 
mtDNA copy number (Shen and Bogenhagen 2001). Afterwards, Rho0 
fibroblasts were maintained in the same medium to ensure that mtDNA will not 
recover back.  
 
2.2.1.4. Generation of stably transfected cell line 
Fibroblasts (1×106) were seeded in a 10 cm diameter dishes 24 h before 
transfection. The plasmid (pEGFP-N1) containing GFP and neomycin resistant 
genes was transfected into skin fibroblasts using FuGENE 6 reagent according to 
the manufacturers’s instructions (ClonTech Laboratories Inc, Heidelberg). 
pEGFP-N1 (4 µg) and FuGENE reagent (24 µl) prediluted in 372 µl optimized 
MEM were mixed and incubated at room temperature for 45 min to allow the 
formation of DNA-lipid complexes. Fibroblasts were incubated with these 
complexes in serum free medium for 3-8 h at 37°C and 5% CO2. Thereafter, FCS 
was added to the cells without removing the transfection mixture. 24 h after 
transfection, cells were cultured in fresh selective medium containing 200 µg/ml 
geneticin (G418, Gibco BRL, Eggenstein, Germany). Selection was continued 
with changes of the medium every 3 days until colonies of cell become visible. 
Single clones were picked and expanded.  
 
2.2.1.5. Cell morphology 
In order to monitor fibroblast morphology at different time points after irradiation, 
fibroblasts were fixed using formaldehyde (3.7% in 1× PBS) for 10 min, washed 
briefly with 70% ethanol and stained with Coomassie Blue (0.05% in 20% 
methanol and 7.5% acetic acid) for at least 20-30 min (Bayreuther et al. 1988).  
 
2.2.1.6. MTT assay 
The cytotoxicity of reagents was determined by measurement of cell viability 
using MTT assay. This assay depends on the ability of mitochondrial 
dehydrogenases within viable cells to reduce MTT dye to a blue formazan 
product. The amount of the reduced dye is directly correlated to the number of 
viable cells. After treatment of fibroblasts with PUVA or chemicals, DMEM/10% 
FCS containing 0.5 mg/ml MTT (Sigma) was added to each dish. The cells were 
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incubated at 37°C for 1 h and then an equal amount of solubilization solution 
(0.04 N HCl in isopropyl alcohol) was added and mixed thoroughly to dissolve the 
crystals of MTT formazan. After all of the crystals were dissolved, the 
photoabsorption was measured at 540 nm was measure.  
 
2.2.1.7. Trypan blue dye exclusion assay 
Cell suspension in PBS was stained with 0.4% trypan blue (w/v, in PBS) for 5-15 
min at room temperature. The cells excluding or stained with the dye were 
counted using a haemocytometer. Membrane integrity was expressed as the 
percentage of cells that excluded the dye. 
 
2.2.1.8. PUVA treatment 
Crystalline 8-methoxypsoralen (8-MOP) was dissolved in DMSO at a 
concentration of 1 mg/ml and stored in the dark. A working solution of 8-MOP 
was prepared in DMEM or phosphate-buffered saline (PBS) immediately prior to 
use. For PUVA treatment, fibroblasts were pre-incubated with 50 ng/ml of 8-MOP 
and cultured in DMEM for 16-18 h. Thereafter the medium was changed to pre-
warmed PBS containing 8-MOP at a concentration of 50 ng/ml. Cells were 
irradiated at a dose of 90 kJ/m2 using a high intensity UVA source (UVASUN 
3000 equipped with the UVASUN safety filters, Mutzhas, Munich, Germany) 
emitting wavelengths in the 340-450 nm range. Fluencies were determined with a 
spectrum adapted UVA-ultraviolet meter (Dr. Hönle, Planegg, FRG). Under these 
non-toxic conditions of PUVA treatment > 85% of fibroblasts survived.  
 
2.2.1.9. β-galactosidase (β-Gal) Staining 
β-galactosidase staining was performed according to published method (Dimri et 
al. 1995). Cells were fixed in 2% formaldehyde/0.2% glutaraldehyde, rinsed with 
PBS, and stained in fresh senescence-associated β-galactosidase (SA-β-Gal) 
stain solution (1 mg/ml X-Gal, 40 mM citric acid/sodium phosphate/pH 6.0, 5 mM 
K3Fe[CN]6, 5 mM K4Fe[CN]6, 150 mM NaCl, 2 mM MgCl2) overnight at 37°C. To 
detect lysosomal β-Gal, staining was performed with citric acid/sodium 
phosphate at pH 4.0. 
 
 20 
2.2.1.10. Soft agar assay 
Fibroblasts regrowing post PUVA treatment and mock-treated (under a same 
experiment procedure but without psoralen and UVA irradiation) control 
fibroblasts were tested for anchorage independent growth in soft agar (Saitoh et 
al. 1999). 5x103 cells were suspended in 1.5 ml DMEM medium of 0.4% agar 
supplemented with 10% FCS and overlaid on 1.5 ml of a similarly prepared 0.8% 
agar-medium basal layer in 35 mm plastic tissue culture dishes. The epithelial 
carcinoma cell line HeLa and the fibrosarcoma cell line HT1080 (Rasheed et al. 
1974) served as positive controls. All cultures were incubated at 37°C in an 
humidified 5% CO2 95% air atmosphere. Thereafter colony formation was 
assessed and photographed at a magnification of x100. Three independent 
experiments were performed in triplicates. As no colony formation occurred in 
regrowing fibroblasts post PUVA treatment, numbers of single cells post PUVA 
treatment and the mock-treated control were calculated at different time points 
after seeding cells into soft agar. Data are expressed as the mean ± standard 
deviation of 10 randomly selected high power fields (x100 magnification). 
 
2.2.1.11. BrdU immunostaining 
BrdU incorporation was performed using an in situ proliferation kit (FLUOS, 
Roche, Mannheim). After PUVA treatment, cells were cultured in 35 mm plastic 
tissue culture dishes, and BrdU incorporation was determined at different time 
points post PUVA treatment. Fibroblasts were incubated with BrdU at a 
concentration of 10 µM for 10 to 14 hours, and subsequently stained with a 
fluorescence linked anti BrdU antibody. Microphotographs were taken with a 
CCD-camera attached to a fluorescence microscope (Nikon) at a magnification of 
×100. BrdU labelled nuclei as well as unlabelled and total nuclei were counted 
and calculated, repetitively, in 10 randomly selected high power fields (x100 
magnification). The results were expressed as percent BrdU positive cells of total 
cell number. 
 
2.2.1.12. Cell enucleation and fusion 
Reagents and solutions: Cytochalasin B was prepared as a 1 mg/ml solution in 
95 or 100% ethanol. Stored at -20°C, this solution is stable for more than 1 year. 
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Ficoll-400 is prepared as a 50% (w/w) solution in distilled water, dissolved by 
stirring overnight at room temperature and then sterilized by autoclaving. Fifty 
percent (w/v) solution of Polyethylene glycol 1000 (PEG) was prepared by first 
liquefying the PEG by briefly heating the Erlenmeyer flask in a microwave oven. 
The liquefied PEG is allowed to cool, and, before it solidifies, 8 ml DMEM and 2 
ml DMSO were added. The pH of the final solution was adjusted to pH 7.4 with 
10 N NaOH using the phenol red pH indicator dye (present in the DMEM) to 
visually estimate the pH of the solution. The exact pH of the solution has been 
found not to be critical for cell fusions. This PEG solution can be stored at 4°C up 
to 1 month. As the concentration of PEG is critical for successful cell fusions any 
evaporation that occurs during storage will adversely affect the results. Therefore, 
the PEG solution was kept in a tightly sealed container if not used immediately. If 
stored at 4°C, the PEG should be re-dissolved at 37°C prior to use. 
 
Ficoll gradient preparation: A discontinuous Ficoll gradient is prepared in a 14×89 
mm polypropylene ultracentrifuge tube. Two ml 25%, 2 ml 17%, 0.5 ml 16%, 
0.5ml 15% and 2 ml 12.5% Ficoll were prepared as shown in the following table 
and filled into tube in order. 
Final Ficoll 
Conc. (%) 
50% Ficoll  
Stock (ml) 
FCS free  
DMEM (ml) 
Cytochalasin 
B 
 [1 mg/ml] (µl) 
25 5 4.9 100 
17 3.4 6.5 100 
16 3.2 6.7 100 
15 3 6.9 100 
12.5 5 14.8 200 
 
Pipet exactly the stated volume of each concentration of Ficoll into polypropylene 
tube, mix thoroughly before pipetting since a gradient is formed in the stock. It is 
recommended that the interfaces of the Ficoll layers be marked on the outside of 
the centrifuge tube to facilitate their identification after centrifugation. The 
gradient is prepared at least 4 hr but less than 24 hr prior to use. The Ficoll 
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gradient was used 6-8 hours after preparation in the experiments. Keep at 37°C 
in CO2 incubator to maintain the temperature and the pH. 
Enucleation Procedure: Cells are trypsinized and collected by centrifugation. 
Resuspending in 3ml 12.5% ficoll with additional 30 µl cytochalasin B (final 
concentration is 20µg/ml). 1-3×107 cells are required. The cell suspension is 
layered on the gradient, incubated with cytochalasin B at room temperature for 
10 min before centrifugation. Centrifugation was performed with SW 41 swinging-
bucket ultracentrifuge rotor (Beckman Instruments Inc.). The rotor and centrifuge 
are prewarmed by prior centrifugation at 10,000 rpm for 2 hr. Centrifugation of 
the gradients is performed at 26,000 rpm for 1 hr at 29°C (The highest 
temperature provided. The cytoplasts and fragments of cytoplasts are found 
through the 12.5, 15, and 16% ficoll solution, collecting by a transfer pipette and 
diluting with 10-20 volumes of DMEM. The karyoplasts are collected from the 
pellet in the tube bottom. Wash with DMEM before collecting. 
 
 
 
 
 
 
 
 
 
 
 
 
Fusion of cytoplasts and karyoplasts: Mix the collected cytoplasts of normal cells 
and the karyoplasts of the PUVA-treated cells. For the fusion between the PUVA 
cytoplasts and mock-treated karyoplasts, treat cytoplasts with 20µg/ml Hoechst 
Ficoll 
gradient 
Cytochalasin B 
Centrifugation 
Debris 
Cytoplast 
Whole cell 
Karyoplast 
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33342 for 20-30 min in DMEM medium and wash once before mix. Centrifuge at 
1000-1100g for 5 min to pellet the cytoplasts and karyoplasts. Remove as much 
medium as possible with a pasteur pipette and add 200µl-500µl of fusion solution 
for exactly 1 min at room temperature. Quickly add 10 ml of complete growth 
medium, and centrifuge at 800g for 5 min. Decant the supernatant, gently 
resuspend fusion product using a Pasteur pipette and plate out in culture dishes 
at low density. Twenty four hours later, the medium is changed to remove the 
dead cytoplasts and other fragments. For the fusions between mock-treated 
cytoplasts and PUVA karyoplasts, the medium was discarded and new medium 
supplemented with 200µg/ml G418 was used for selection.  
 
 
 
 
 
 
2.2.2. Methods of molecular biology  
 
2.2.2.1. Isolation of genomic DNA 
Cell monolayers were trypsinized and washed with TSE. The pellets were 
thoroughly resuspended in 200-250 µl TSE. Two hundred-250 µl of TSE 
containing 0.4% SDS and 0.6-0.8 mg/ml proteinase K (final concentration 0.2% 
SDS and 0.3-0.4 mg/ml proteinase K) was added.  Incubation was carried out 
subsequently at 55°C overnight (at least 5-6 hours) or until no cellular debris is 
visible. An equal volume of phenol/chloroform/isoamyl alcohol (24:24:1) was 
added to the lysate, mixed by inversion and centrifuged for 10 min with 12600 g 
at 16°C. The upper aqueous phase containing genomic DNA was removed and 
mixed with an equal volume of chloroform. A further extraction was performed to 
remove any remaining phenol. The upper aqueous layer was then collected. Two 
to 3-fold volumes of pre-cooled ethanol were added and the solution was well 
mixed by inversion. DNA precipitates should be visible. Recovering DNA 
precipitates was carried out using a drawn out Pasteur pipet and with subsequent 
lifting the DNA out of the alcohol (spinning out). DNA was dipped into 70% EtOH 
PEG 
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and transferred to new Eppendorf tube. After briefly air drying the DNA was 
resuspended in TE. Isolated genomic DNA was stored at 4°C. 
 
2.2.2.2. Telomere repeat analysis 
Telomere length was analyzed using a commercially available assay 
(PharMingen, San Diego, USA). Isolated genomic DNA was digested with two 
frequently cutting restriction enzymes, RsaI and HinfI, which does not have a 
target sequence within the telomeric repeat (TTAGGG). The chromosomal DNA 
is therefore cut into small fragments except for the telomeres and subtelomeric 
regions (DNA adjacent to the telomere), which will be left intact and which 
together comprise the Terminal Restriction Fragments (TRF). Using multiple 
frequent cutters, it is assured that the chromosomal DNA is minimal in 
comparison to the DNA conferring the telomere length. The cleaved DNA is 
separated on a low percentage agarose gel and transferred for Southern blot 
analysis. Briefly, 1.5 µg of HinfI/RsaI-digested DNA of each sample was size-
fractionated by electrophoresis on 0.6% agarose gels in TAE buffer (0.04M Tris-
acetate, 0.001M EDTA, pH 8.0). After electrophoresis, blotting was carried out by 
alkaline transfer to a positively charged nylon membrane (Amersham Hybond-N+). 
Hybridization was carried out using a 51-mer biotinylated telomeric probe 
(TTAGGG)8-TTA, which was boiled for 5 min before being added to the 
hybridization buffer. Prehybridization was performed for 2 hours with subsequent 
hybridization overnight at 60°C. After washing and blocking unspecific binding, 
the membrane was probed with streptavidin-HRP (1:300) for 15 min at RT. The 
membranes were then washed with TBS-T again, incubated with North2South 
Luminol/Peroxide solution (PERBIO Science Deutschland, Bonn, Germany) for 
5-10 min and exposed to X-ray film. The TRF (terminal restriction fragments) 
length was estimated by comparing the position of the signal smear or calculated 
by positions relative to the molecular weight markers.  
 
2.2.2.3. Single strand telomere DNA length determination 
Genomic DNA isolated from growth-arrested fibroblasts at different time points 
post PUVA treatment as well as mock-treated control and regrowing fibroblasts 
were digested first with RsaI/HinfI (1U/µl) overnight at 37°C. After digestion, half 
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of the sample (20µl, 5µg DNA) was treated with alkaline buffer (0.4M NaOH, 4 
mM EDTA) for 5-10 min to separate DNA double strands, then subjected to 
electrophoresis and Southern blot as described above. The other half of the 
samples was used without denaturing as control for double-stranded telomere 
length determination. 
 
2.2.2.4. TRAP assay 
The TRAP assay was carried out according to published protocols (Blackburn 
1991; Greider and Blackburn 1985). Frozen samples or cell pellets from cell lines 
were homogenized in cold CHAPS lysis buffer. After a 30 min incubation period 
on ice, the homogenized lysates were centrifuged at 12,000 g for 30 min at 4°C 
and the supernatants were aliquoted and stored frozen at -80°C until use. The 
telomerase activity was determined by PCR. Briefly, 50 µl of TRAP reactions 
including cell extract, 0.1 µg TS forward primer (5'-AATCCGTCGAGCAGAGTT-
3'), 0.1 µg reverse primer (5'-GCGCGG(CTTACC)3CTAACC-3'), and 2.5 unit of 
Taq DNA polymerase were mixed. After 20 min incubation at 30°C for 
telomerase-mediated extension of the TS primer, the mixture was subjected to 
PCR amplification (94°C/30 sec, 58°C/30 sec, 72°C/15 sec for 35 cycles). The 
resulting PCR products were electrophoresed on a 14% polyacrylamide gel, and 
stained with SYBRTM green. Three independent experiments were carried out 
with similar results. 
 
2.2.2.5. Immunoblot 
Cells were treated with 0.4-0.6ml Ripa buffer and harvested by scraping. The cell 
pellet was sonicated and kept immediately on ice. Cell debris was clarified by 
centrifugation at 12000-14000g for 10-15 min and protein samples were stored at 
-80°C. Tween µg of total cell proteins were mixed with an equal volume of 2× 
protein denaturing sample buffer, boiled for 5 min and subsequently resolved by 
electrophoresis with 10%-20% (depends on protein molecular weight) 
polyacrylamide gels at 40mA for 40-60 min. The proteins were electro-blotted on 
nitrocellulose membrane as follows. Electro-transfer was preformed at 2.5 
mA/cm2 for 1 hour, using the transfer assembly as shown below. The 
membranes were blocked (RT, 1 hour) in TBS containing 0.05% Tween 20, 1% 
casein and 1% PVP. The membranes were then incubated in TBS containing 
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0.05% Tween 20, 0.5% casein, 0.5% PVP and 0.1% PEG-6000 with specific 
primary antibodies (at the appropriate dilution) overnight at 4°C. Thereafter 
membranes were washed two times with TBS containing 1% Tween-20 (TBS-T) 
and probed with HRP-conjugated secondary antibodies (1:2000) and HRP 
conjugated anti-biotin antibodies (1:3000) for 1 hour at RT. After incubation, the 
membranes were washed again with TBS-T and incubated with LumiGLO (New 
England Biolabs, Inc.) for 1 min at RT, wrapped in transparency foil and exposed 
to X-ray film. 
 
 
2.2.2.6. ELISA for MMP-1 expression  
A specific "sandwich" ELISA for MMP-1 was performed according to the 
manufacturer’s recommendations, (MMP-1 human ELISA system, Amersham 
Pharmacia Biotech, Freiburg) using precoated 96-well immunoplates, rabbit anti-
human MMP-1 antibodies and anti-rabbit horse-radish peroxidase substrate. 
3,3’,5,5’-tetramethylbensidine (TMB) was used as peroxidase substrate. 
Fibroblast monolayer cultures were incubated in FCS-free medium for 16 h, 
thereafter the supernatants were collected and MMP-1 concentrations were 
determined. Optical densities were read at 450 nm using a microtiter plate reader 
LP 400 (Sanofi Diagnostics Pasteur, Freiburg). Concentrations of MMP-1 were 
determined against standard curves using Graph Pad™ Software (San Diego, 
CA). 
 
1 mm Filter rinsed with Anode-II Buffer 
1 mm Filter rinsed with Anode-II Buffer 
1 mm Filter rinsed with Anode-II Buffer 
1 mm Filter rinsed with Anode-I Buffer 
1 mm Filter rinsed with Anode-I Buffer 
1 mm Filter rinsed with Anode-I Buffer 
1 mm Filter rinsed with Cathode Buffer 
1 mm Filter rinsed with Cathode Buffer 
1 mm Filter rinsed with Cathode Buffer 
PAGE Gel 
Cellulose Membrane 
Anode 
Buffer I 
30 mM Tris, 20% methanol, 
pH 10.4 
Anode 
Buffer II 
300 mM Tris, 20% methanol, 
pH 10.4 
Cathode 
Buffer 
25 mM Tris, 20% methanol, 
40 mM 6-aminohexanoic acid, 
pH not adjusted 
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2.2.2.7. ELISA for p53 and p21Cip1 expression 
p53 and p21Cip1 concentration were measured by sandwich ELISA 
immunoassays with p53 pan ELISA (Roche, Mannheim) and p21Cip1 ELISA 
(Oncogene, Cambridge, MA). Cell extracts were prepared by detergent lysis 
using Ripa buffer. The isolated proteins react first with biotin-labeled capture 
antibody which was pre-bound to the streptavidin-coated microtiter plate. The 
subsequent reaction with a peroxidase-labeled detection antibody forms a stable 
immuno-complex. After washing and peroxidase developing, p53/p21Cip1 
expression was determined by photometry at 450 nm. 
 
2.2.2.8. PCR Amplification 
The typical setup for 25µl reaction mixtures contains 100 ng genomic DNA, 200 
µM dNTPs, 1 µM primers (0.5 µM sense primer and 0.5 µM antisense primer), 
2.5 µl of 10× Taq DNA polymerase buffer (Amersham Biosciences Europe, 
Freiburg), Mg2+ concentrations ranging from 1.0 to 2.5 mM, and 2.5 units of Taq 
DNA polymerase (Perkin-Elmer, Heidelberg,Germany). Amplifications were 
performed in a thermal cycler under the following conditions: 94°C/3 min, 
94°C/0.5 min, 55 °C/1 min (subject to changes for different amplifications, 
ranging from 53-62°C), 72 °C/1 min, 30-35 cycles, 72 °C 10 min and then stored 
at 4°C. Hot start was utilized throughout all PCR reactions. Amplifications of PCR 
mixtures without template DNA served as negative controls. The PCR products 
(4 µl) were separated in an 1.5-2.0% agarose gel (80-120V for 1-2 hours), and 
then stained with ethidium bromide. PCR primers were designed based on the 
human DNA sequence. The following primer sets were used for PCR 
amplifications. 
 
• Human p53 (TP53) gene: It has 11 exons, as shown in table 1. The entire 
sequence was from NCBI GenBank with the accession number U94788. The 
numbering scheme of the NCBI GenBank was used. Due to the difficulty in 
sequencing DNA samples with a length longer than 1 kb, we subdivided the 
exon 11 into 2 regions, from nucleotides 500 to 1210 and 1200 to 1600. The 
products were designated as Exon 11-1 and Exon 11-2. 
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Table 1. Human p53 (TP53) gene exons and PCR products 
Exon Length and Location 
PCR product length and 
location 
1 107 bp, 843 - 949 220 bp, 801-1020 
2 102 bp, 11689 - 11790 229 bp, 11668-11896 
3 22 bp, 11906 - 11927 248 bp, 11774-12021 
4 279 bp, 12021 - 12299 402 bp, 11998-12399 
5 184 bp, 13055 - 13238 392 bp, 12922-13313 
6 213 bp, 13320 - 13432 186 bp, 13296-13481 
7 110 bp, 14000 - 14109 211bp, 13939-14149 
8 137 bp, 14452 - 14588 252 bp, 14360-14611 
9 74 bp, 14681 - 14754 254 bp, 14594-14847 
10 107 bp, 17572 - 17678 272 bp, 17540-17811 
11 1278bp, 18599 - 19876 1461 bp, 18523-19983 
11-1 617 bp, 18599-19215 752bp, 18481-19232 
11-2 690 bp, 19187-19876 800bp, 19187-19986 
 
Exon 1 Sense, 5’-ATG TGC TCA AGA CTG GCG-3’ 
Antisense, 5’-CGA GCT GAA AAT ACA CGG-3’  
Condition: AT, 52°C, 1.5mM Mg2+ 
 
Exon 2 Sense, 5’-TCC CCA CTT TTC CTC TTG-3’ 
Antisense, 5’-AAG AGC AGA AAG TCA GTC CC-3’  
Condition: AT, 60°C, 1.5mM Mg2+ 
 
Exon 3 Sense, 5’-TCA GAC CTA TGG AAA CTG TGA G-3’ 
Antisense, 5’-CTG TAG ATG GGT GAA AAG AGC-3’  
Condition: AT, 58°C, 1.5mM Mg2+ 
 
Exon 4 Sense, 5’-CTG CTC TTT TCA CCC ATC-3’ 
Antisense, 5’-AAG GGT GAA GAG GAA TCC-3’  
Condition: AT, 52°C, 2.5mM Mg2+ 
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Exon 5 Sense, 5’-CAA CTC TCT CTA GCT CGC-3’ 
Antisense, 5’-GCA ATC AGT GAG GAA TCA-3’  
Condition: AT, 55°C, 1.5mM Mg2+ 
 
Exon 6 Sense, 5’-TGA TTC CTC ACT GAT TGC-3’ 
Antisense, 5’-ACA ACC ACC CTT AAC CCC-3’  
Condition: AT, 55°C, 1.5mM Mg2+ 
 
Exon 7 Sense, 5’-TGC TTG CCA CAG GTC TCC-3’ 
Antisense, 5’-CAC AGC AGG CCA GTG TGC-3’  
Condition: AT, 60°C, 1.0mM Mg2+ 
 
Exon 8 Sense, 5’-GTT GGG AGT AGA TGG AGC-3’ 
Antisense, 5’-CGC TTC TTG TCC TGC TTG-3’  
Condition: AT, 55°C, 1.5mM Mg2+ 
 
Exon 9 Sense, 5’-CAA GCA GGA CAA GAA GCG-3’ 
Antisense, 5’-CCC AAT TGC AGG TAA AAC-3’  
Condition: AT, 52°C, 1.5mM Mg2+ 
 
Exon 10 Sense, 5’-ATA CTT ACT TCT CCC CCT-3’ 
Antisense, 5’-CAA TGA GAT GGG GTC AGC-3’  
Condition: AT, 60°C, 1.5mM Mg2+ 
 
Exon 11 Sense, 5’-ATT GGT CAG GGA AAA GGG-3’ 
Antisense, 5’-CAC ACT CAT TGC AGA CTC-3’  
Condition: AT, 49°C, 1.5mM Mg2+, 400nM dNTP, extension time 
(72°C) increases to 2 min. 
 
Exon 11-1 Sense, 5’-TGA TTT GAA TTC CCG TTG TCC-3’ 
Antisense, 5’-AAC CCA CCA GCC AAC AGG-3’  
Condition: AT, 60°C, 1.5mM Mg2+ 
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Exon 11-2 Sense, 5’-TTG AGG GTG CCT GTT CCC-3’ 
Antisense, 5’-GTC CAC ACT CAT TGC AGA CTC AG-3’  
Condition: AT, 60°C, 1.5mM Mg2+ 
 
• Human p21cip1 gene: It has 4 exons, as shown in table 2. [the entire sequence 
was from GenBank, accession number Z85996, and  the numbering scheme 
was adopted] 
 
Table 2. Human p21cip1 gene exons and PCR products 
Exon Length and Location PCR product length and 
location 
1 73bp, 3226- 3298 159bp, 3171- 3328 
2 452bp, 8594- 9045 631bp, 8549- 9179 
3 196bp, 10247- 10442 290bp, 10221- 10510 
4 1370bp, 10456- 11825 1705bp, 10348- 12206 
 
Exon 1 Sense, 5’-GCG GGG CGG TTG TAT ATC-3’ 
Antisense, 5’-GGT CCC CTG TTG TCT GCC-3’ 
Condition: AT, 58°C, 1.5mM Mg2+ 
 
Exon 2 Sense, 5’-GTC TAA TCT CCG CCG TGA C-3’ 
Antisense, 5’-GGT TGC TTC CCC TCT CTG-3’ 
Condition: AT, 58°C, 1.5mM Mg2+ 
 
Exon 3 Sense, 5’-CCT GGC TGA CTT CTG CTG-3’ 
Antisense, 5’-GAA CCT CTC ATT CAA CCG C-3’ 
Condition: AT, 58°C, 1.0mM Mg2+ 
 
Exon 4 Sense, 5’-CCC GCT CTA CAT CTT CTG CC-3’ 
Antisense, 5’-CCA GTT GCT CCA TAA CCT TGC -3’ 
Condition: AT, 62°C, 1.5mM Mg2+ 
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• Human p16INK4a gene: It has 3 exons, as shown in table 3. [Sequence was 
from GenBank accession numbers U12818, U12819 and U12820. The entire 
sequence was the composite and  the numbering scheme was adopted as 
U12818-U12819-U12820 (1-340)-(341-925)-(926-1347)] 
 
Table 3. Human p16INK4a gene exons and PCR products 
Exon Length and Location PCR product length and 
location 
1 126bp, 129 - 254 272 bp, 66 - 338 
2 307bp, 491 - 797 453 bp, 414 - 866 
3 14bp, 1199 - 1212 172 bp, 1071 - 1243 
 
Exon 1 Sense, 5’-GGA GAG GGG GAG AGC AGG-3’ 
Antisense, 5’-GCT ACC TGA TTC CAA TTC CCC-3’ 
Condition: AT, 60°C, 1.0mM Mg2+ 
 
Exon 2 Sense, 5’-AGG GGG CTC TAC ACA AGC TTC-3’ 
Antisense, 5’-GTG CTG GAA AAT GAA TGC TCT G-3’ 
Condition: AT, 60°C, 1.5mM Mg2+ 
 
Exon 3 Sense, 5’-AGC CAT TGC GAG AAC TTT ATC C-3’ 
Antisense, 5’-CCC GAG GTT TCT CAG AGC C-3’ 
Condition: AT, 62°C, 1.5mM Mg2+ 
 
2.2.2.9. PCR products purification and sequence analysis 
PCR products were purified using the QIAquick PCR purification kit (QIAGEN, 
Hilden), and then sequenced on both DNA strands using the same primers for 
PCR. The sequence data were compared to the human genome sequence from 
GenBank. Sensitivity of the method was evaluated by employing 2 positive 
controls: a) a fibroblast cell line derived from Li-Fraumeni patients which contains 
a single base pair deletion in its p53 gene at exon 5 (codon 184, from GATA to 
GAA); b) a lung fibroblast cell line which reveals a deletion and insertion of 
neomycin and hygromycin in its p21cip1 gene. 
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2.2.3. Additional methods 
 
2.2.3.1. ROS measurements  
Levels of intracellular ROS were assessed by loading cells with 10 µg/ml of 
fluorescent ROS indicator 2’-7’ dichlorodihydrofluorescin diacetate (H2DCF-DA) 
(Molecular Probes, MoBiTec, Goettingen) for 20 min and with subsequent 
detection using a Zeiss laser scanning confocal microscope. H2DCF-DA is a 
nonpolar compound that is converted into a nonfluorescent polar derivative by 
cellular esterases after incorporation into cells. H2DCF is membrane 
impermeable and is rapidly oxidized to the highly fluorescent 2',7'-
dichlorofluorescein (DCF) in the presence of intracellular ROS (Frenkel and 
Gleichauf 1991). The excitation wavelength is 488 nm and emission wavelength 
is 521 nm. The resulting image is an artificial colour made by the computer 
program based on intensity of the emitted photons. To determine the involvement 
of NADPH oxidase, two NADPH oxidase inhibitors, diphenylene iodonium (DPI, 
Sigma, 10µM) or 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF, Sigma, 
100µM) were added to control or PUVA-treated fibroblasts for 2 hours before 
ROS detection. 
 
2.2.3.2. Supplementation of fibroblast culture with N-acetyl cystein and 
subsequent determination of intracellular ROS Levels 
Immediately after PUVA treatment, fibroblasts were maintained in DMEM/10% 
FCS containing 5 mM NAC. The medium was changed every three days to 
ensure an efficient antioxidant capacity. PUVA-treated fibroblasts were fed with 
NAC until they started to reproliferate. ROS levels in these NAC supplemented 
fibroblasts were determined by DCF staining at different time points post PUVA 
treatment. 
 
2.2.3.3. Measurement of the mitochondrial membrane potential 
To measure ∆Ψm, cells (1×106 cells/ml) were resuspended in 5 mg/ml solution of 
JC-9 (Molecular Probes, MoBiTec, Goettingen) in phosphate buffered saline at 
different time points post PUVA treatment (Salvioli et al. 1997). The dye exists as 
a monomer at low concentrations (emission, 530 nm, green fluorescence) but at 
higher concentrations forms J-aggregates (emission, 590 nm, red fluorescence). 
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Because accumulation of the JC-9 dye is reversible, cells were maintained in a 
stable concentration of the dye throughout the time of measurement. After a 20 
min incubation period at 37 °C, cells were immediately analyzed by flow 
cytometry. Dead cells were excluded by forward and side scatter gating. Data 
were collected by analyzing an average population of 20,000 cells. JC-9 
aggregates were detectable in the propidium iodide channel (red fluorescence, 
emission at 590 nm), and JC-9 monomers were detectable in the fluorescein 
isothiocyanate channel (green fluorescence, emission at 527 nm) (Reers et al. 
1995). 
 
2.2.3.4. Measurement of mitochondrial biogenesis 
To stain mitochondria, cells were incubated in DMEM medium containing 25nM 
MitoTracker Red CMXRos (Molecular Probes, MoBiTec, Goettingen) for 30 min 
at 37°C. Cells were photographed using a 568-nm line of fluorescence excitation 
using a Zeiss laser scanning confocal microscope. 
 
2.2.3.5. ATP measurements 
ATP was measured by a bioluminescence assay (Kricka 1988) using an ATP 
determination kit (Merck Biosciences, Schwalbach). The assay is based on the 
requirement of luciferase for ATP to produce light (emission maximum ~560 nm 
at pH 7.8). Briefly, after PUVA treatment cells (~5×105) were resuspended in 
reaction buffer containing 1 mM DTT, 0.5 mM luciferin, and 12.5 µg/ml luciferase, 
gently mixed, and light production was monitored using a luminometer 
(Lumicount, Packard Instrument Co. Meriden, USA). ATP standard curves were 
run with different concentrations of ATP, and calculations were made against 
these curve. Cellular ATP levels were expressed both per cell and per total 
protein. 
 
2.2.3.6. Densitometry measurement 
The bands from Southern or Western blots were quantified with densitometry 
analysis using a computerized digital imaging system, Scanpac software (Alpha 
Innotech, San Leandro, CA). The intensity of each band or the distribution of 
DNA fragments was obtained by integrating the pixel values after subtracting the 
background. 
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2.2.3.7. Statistics 
Mean values standard errors was determined using the Microsoft Excel program. 
Student-t test was used to compare the differences between two groups and 
ANOVA test for comparing three or more groups. In all cases, the statistical 
significance of differences between the two variants was determined at the level 
of p < 0.05. All the data presented were from the average of at least three 
independent experiments. 
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3 Results 
 
3.1. Human dermal fibroblasts escape from PUVA-induced long-term 
senescence-like growth arrest 
As observed in our laboratory, a single PUVA treatment promotes morphological 
and functional changes in fibroblasts in vitro reminiscent of cellular senescence 
(Herrmann et al. 1998). In addition to long-term growth arrest, PUVA-treated 
fibroblasts showed an enlarged morphology, increased SA-β-Gal and MMP-1 
expression, markers which are often up-regulated in replicative-senescent cells 
(Bayreuther et al. 1988; Dimri et al. 1995; West et al. 1989). In contrast to the 
permanent growth arrest in replicative senescence PUVA-treated fibroblasts start 
to regrow after a three-month growth arrest post PUVA treatment. As growth 
arrest in replicative or premature senescence has earlier been claimed to be 
irreversible (Chen 2000; Dumont et al. 2000), it was the aim to further 
characterize the underlying mechanisms responsible for the escape of PUVA-
treated fibroblasts from the senescence-like state. 
 
3.1.1. Regrowth of fibroblasts from PUVA-induced long-term senescence-
like growth arrest 
After a single PUVA treatment, the growth-arrested fibroblasts gradually gained 
an enlarged phenotype. Figure 5A shows enlarged fibroblasts 28 days post 
PUVA treatment. At 90 to 110 days after PUVA treatment and the subsequent 
long-term growth arrest, multiple foci of small proliferating fibroblasts were 
observed in 4 independent experiments. Note the small spindle shaped, 
regrowing fibroblasts among the enlarged growth-arrested fibroblasts (Figure 5B). 
Figure 5C reveals the high magnification of the smaller regrowing fibroblasts 
adjacent to growth-arrested large fibroblasts. Concomitantly occurring foci were 
distributed throughout the dish. To further determine the time point of regrowth 
and to answer the question whether regrowing fibroblasts may result from rare 
fibroblasts which have never been growth-arrested instead of from concomitantly 
regrowing fibroblasts in multiple foci, BrdU incorporation was performed to 
monitor proliferation of PUVA-treated fibroblasts at different time points post 
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treatment. As shown in Figure 6, no positively stained nuclei were observed even 
at the  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 Regrowth of fibroblasts post PUVA treatment. (A) Growth-arrested 
fibroblasts showed a senescent-like morphology at day 28 after a combined 
treatment with 50ng/ml psoralen and 90 kJ/m2 UVA (magnification ×50). (B) and 
(C) Two independent foci of regrowing small fibroblasts occurred concomitantly 
between cells with enlarged cytoplasm at 90 to 110 days post PUVA treatment in 
the same dish (B, magnification ×20; C, magnification ×50). 
A 
B 
C 
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Figure 6. BrdU incorporation at different time-points post PUVA treatment. 
BrdU incorporation was performed using the “in situ proliferation kit FLUOS” as 
described in detail in Materials and Methods. BrdU labeled nuclei as well as 
unlabelled and total nuclei were counted and calculated, respectively, in 10 
randomly selected high power fields (x100 magnification). After PUVA treatment, 
cells were seeded in 35 mm plastic dishes with a total cell number of 3x104 
cells/dish. (A) At 56 days post PUVA treatment no BrdU incorporation into nuclei 
was detected. (B) At 98 days post PUVA treatment many concomitantly occurring 
BrdU labeled nuclei were detected. (C) One week later at day 105 post PUVA 
treatment even more cells revealed BrdU incorporation in nuclei. (D) The results 
are summarized in the graph and BrdU incorporation at different time points post 
PUVA treatment were expressed as percent of BrdU positive cells of total cell 
number/high power field. Cells in ten power fields were counted and the data are 
shown as mean ± standard deviation. *p < 0.006 compared with cells 98 days 
post PUVA treatment (students t-test). 
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end of 8 weeks post treatment (Figure 6A). Fourteen weeks post treatment 
scattered foci-like cell proliferation could be observed (Figure 6B). These data 
indicate that regrowth occurred around day 100 post PUVA treatment. After initial 
appearance of reproliferating fibroblasts at multiple regions of the dish, it took 
only 8 days until the dish revealed predominantly small reproliferating fibroblasts 
(Figure 6C, D). Confluence was reached at day 10-12 after the appearance of 
reproliferating cell foci.  
 
3.1.2. Regrowth is not due to immortalization or transformation 
As cellular senescence has been proposed to be activated as a barrier against 
tumorigenesis, and senescence induced growth arrest is controlled by tumor 
suppressor genes such as p53 and p16INK4a (Campisi 2001a), we studied 
whether the regrowth of fibroblasts after PUVA treatment was due to loss-of-
function of these tumor suppressors and other related cellular senescence 
controlling genes. In this case, it was expected that the regrowing fibroblasts 
were most likely either immortalized or transformed. 
 
3.1.2.1. Regrowing fibroblasts post PUVA treatment do not show any telomerase 
activity, but a reduction in  telomere length with increasing CPD 
Immortalization and the overall proliferation capacity of human cells depend on 
the maintenance of telomere length (Blackburn 1991). Since expression of 
telomerase is the most common mechanism for immortalized or cancer cells to 
stabilize their telomeres, we determined the telomerase activity in regrowing 
fibroblasts post PUVA treatment. Figure 7 shows that no telomerase activity was 
determined either in fibroblasts regrowing post PUVA treatment or in mock-
treated (under a same experiment procedure but without psoralen and UVA 
irradiation) control fibroblasts. The epidermal cell line HaCaT (Figure 7 lane 2 
and 3) and the fibrosarcoma cell line HT1080 (Figure 7 lane 6 and 7) with a high 
telomerase activity served as positive controls. In line with this, a decrease in 
telomere length occurred in fibroblasts regrowing post PUVA treatment with 
increasing CPD. As shown in Figure 29 (see page 79), the terminal restriction 
fragments (TRF), as an indication of telomere length, was determined in 
regrowing fibroblasts post PUVA treatment and mock-treated control fibroblasts. 
Lane 3, 5, 7, 9 showed telomere length of regrowing fibroblasts at different CPDs. 
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It can be seen that with increasing CPD, the telomere length in regrowing 
fibroblasts decreased. Interestingly, a significantly shorter telomere length was 
observed in regrowing fibroblasts post PUVA treatment compared to mock-
treated control fibroblasts at exactly the same CPD. The underlying mechanism 
will be discussed later. Taken together, regrowing fibroblasts did not reveal any 
telomerase activity and their telomere lengths, in fact, erode with increasing CPD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Telomerase activity does not differ in mock-treated control 
fibroblasts and in PUVA-treated fibroblasts during growth arrest and their 
regrowing phase. Telomerase activity was measured by the standard TRAP 
assay. Cell lyses and telomerase assay were performed using the TRAPeze kit. 
Fifty ng of total protein extract were used for each assay, each with or without 
RNase-inactivation. Products were separated in non-denaturing 10% 
polyacrylamide gels, visualized by autoradiography and photoimage scanning. 
Lane 1: Lyses buffer; Lane 2-11 represent the analysis of different cell lines 
without and with RNase-inactivation; lane 2, 3: HaCaT cells; lane 4,5: Mock-
treated control fibroblasts; lane 6,7: HT1080 (Fibrosarcoma cell line); lane 8,9: 
fibroblasts of the same strain as in lane 6,7 in their regrowing  phase post PUVA 
treatment; lane 10,11: PUVA-treated growth-arrested fibroblasts at 4 weeks post 
PUVA treatment; lane 12: 5 ng of total protein extract of HaCaT cells were used. 
 
1    2    3    4    5    6    7    8    9   1 0   1 1  1 2  
−   +   −   +   −   +   −   +   −   +   −   RNase 
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3.1.2.2. Regrowth of fibroblasts post PUVA treatment is anchorage dependent 
In a first attempt to study whether regrowing fibroblasts are transformed - a state 
which is characterized by anchorage independent growth (Saitoh et al. 1999) - 
fibroblast proliferation and colony formation were studied by means of the soft 
agar assay. For this purpose regrowing fibroblasts post PUVA treatment, mock-
treated control fibroblasts of the same strain at the same CPD and, as positive 
controls, two tumor cell lines (fibrosarcoma cell line HT1080, HeLa cell line) were 
placed into soft agar and cultured for 10 to 14 days. While the HeLa cell line and 
the fibrosarcoma cell line HT1080 formed numerous colonies confirming 
anchorage independent growth (Figure 8A, B), neither control fibroblasts nor 
fibroblasts with resumed growth post PUVA treatment formed any colony in the 
soft agar (Figure 8C, D). Following an extended observation period of 35 days, 
mock-treated control and regrowing fibroblasts did not form colonies, instead the 
number of cells gradually decreased and eventually disappeared (data not 
shown). Thus, the growth of regrowing fibroblasts was anchorage dependent. 
These data indicate that the regrowth of fibroblasts observed at days 100 to 130 
after a single PUVA treatment is not due to transformation.  
 
3.1.2.3. Regrowing fibroblasts post PUVA treatment reveal a decline in growth 
rates with increasing CPD 
To further confirm that regrowth of fibroblasts after PUVA treatment is not due to 
transformation and immortalization – as both states would show unlimited 
proliferation – the CPD was determined in regrowing fibroblasts and in mock-
treated fibroblasts of the same strain. Immortalized or transformed continuously 
dividing cells should show a constant and sustained linear increase in their CPD, 
while primary fibroblasts – due to the replicative senescence – are rather 
expected to reveal a saturation curve with increasing CPD. Fibroblasts in the 
regrowing phase post PUVA treatment and mock-treated fibroblasts with 
comparable CPD (~ 48) were passaged over a period of 5 months until the 
regrowing fibroblasts reached replicative senescence with no increase in cell 
numbers. Figure 9 reveals the CPD in regrowing fibroblasts and mock-treated 
control fibroblasts. The proliferation rate of regrowing fibroblasts decreased with 
time and reached a stationary phase (replicative senescence) after 90 day at a 
CPD of 62. By contrast, mock-treated control fibroblasts were still proliferating 
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even at 120 days at a CPD of 70. The observed CPD kinetics strongly indicates 
that regrowing fibroblasts post PUVA treatment were neither immortalized nor 
transformed. 
 
 
 
 
Figure 8. Fibroblasts regrowing post PUVA treatment do not show any 
anchorage independent growth in the soft agar assay. The epithelial 
carcinoma cell line Hela (A) and the fibrosarcoma cell line HT1080 (B) which 
served as positive controls, mock-treated fibroblasts (C) and fibroblasts of the 
same strain in their regrowing phase post PUVA treatment (D) were tested for 
anchorage independent growth in soft agar as detailed in Material and Methods. 
Briefly, 5x103 cells were suspended in 1.5 ml of 0.4% agar supplemented with 
10% FCS and overlaid on 1.5 ml of a 0.8% agar-medium basal layer in 35 mm 
plastic tissue culture dishes. All cultures were incubated at 37°C in a humidified 
5% CO2 - 95% air atmosphere without further feeding for 10 to 14 days. 
Thereafter, colony formation was assessed and photographed at x100 
magnification. Three independent experiments were performed in triplicates. 
 
A 
C D 
B 
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Figure 9. Fibroblasts regrowing post PUVA do not show constant 
proliferation rates. Comparable cumulative population doublings (CPD) of 
mock-treated fibroblasts (CPD = 47.9) and fibroblasts of the same strain in their 
regrowing phase post PUVA treatment (CPD = 48.4) were chosen for 
comparison. At different time points thereafter, cell numbers were determined in 
triplicates for each experimental group and equal cell numbers (2x105) were 
transferred to a new tissue plate for further observation. The data represent 
cumulative population doublings (CPDs) determined in a secondary human 
dermal fibroblast cell line and are representative for two additional fibroblast cell 
lines from independent donors. Each data point represents the mean ± standard 
deviation of three independent counting. Experimental groups: () mock-treated 
control fibroblasts; () fibroblasts of the same strain in their initial regrowing 
phase post PUVA treatment. 
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3.1.2.4. Senescence control genes, p53, p21Cip1 and p16INK4a do not reveal 
mutations in regrowing fibroblasts 
Cellular senescence is mainly controlled by two major senescence controlling 
pathways, namely the p53/p21Cip1 and/or pRb/p16INK4a pathway (Lundberg et al. 
2000). Among the tumor suppressors genes, a p53 and p16INK4a loss-of-function 
occurs most commonly in mammalian cancers. To answer whether the escape of 
regrowing fibroblasts from PUVA-induced growth arrest is due to disruption of 
these important check-point genes, their integrity in nucleotide sequence was 
determined in regrowing fibroblasts post PUVA treatment, in growth-arrested 
fibroblasts and in mock-treated control fibroblasts. For this purpose, all exons of 
p53, p21Cip1 and p16INK4a genes from the three experimental groups of fibroblasts 
were amplified by PCR. The sequence of each exon was then analyzed and 
compared with the genomic DNA sequence from the gene bank of NCBI. No 
major mutation, deletion or modifications were found, neither in growth-arrested 
fibroblasts nor regrowing fibroblasts post PUVA in the 11 exons of p53, 4 exons 
of p21Cip1 and 3 exons of p16INK4a (data not shown). In order to evaluate the PCR 
amplification protocol for detection of major deletions and single point mutations, 
2 positive controls were employed. As shown in Figure 10-A and B, both a single 
point mutation in exon 5 of p53 from Li-Fraumeni (a disease related to loss of 
p53 function) cells and an 18-base deletion in exon 2 of p16INK4a from p16INK4a-
deficient fibroblasts could be detected.  
 
In summary, the data indicate that PUVA-induced senescence-like growth arrest 
is reversible in a large proportion of cells between days 90 and 120 post PUVA 
treatment. The finally returning growth capacity is not due to immortalization, 
transformation or loss of function of the senescence controlling genes p53, p21 
and p16. This leads to important question as to whether the growth arrest 
triggered in PUVA-induced premature senescence is identical to replicative 
senescence or rather a phenocopy thereof. 
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Figure 10-A. PCR amplification and sequence analysis can detect point 
mutations if they are present in all cells. Exon 5 of the p53 gene was amplified 
and sequenced using the genomic DNA template either from p53 deficient Li-
Fraumeni cells or from wild type human dermal fibroblasts. The primer sequence 
and experimental conditions were used as described in Materials and Methods.  
M    wt    -/- 
P53 exon5 (wt) 
P53 exon5 (-/-) 
Li-Fraumeni 
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Figure 10-B. PCR amplification and sequence analysis can detect a DNA 
deletion if it is present in all cells. The deletion in exon 2 of p16INK4a deficient 
lung fibroblasts was detected after sequence analysis. The primer sequence and 
experimental conditions were used as described in Materials and Methods. 
M         1       2       3         M 
M. 100bp DNA length marker 
1. PCR product: exon 2 of normal 
human dermal fibroblasts. 
2. PCR product: exon 2 of p16INK4a 
deficient cells. 
3. PCR product: exon 2 of 
regrowing fibroblasts post 
PUVA. 
Exon 2 of p16INK4a (WT) 
(part of the sequence) 
Exon 2 of p16INK4a (+/-) 
(part of the sequence) 
Deleted part 
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3.2. PUVA-induced premature senescence does not fully reflect replicative 
cellular senescence 
 
Growth arrest in replicative and stress-induced premature senescence has been 
claimed to be irreversible (Chen 2000; Dumont et al. 2000). As PUVA-induced 
growth arrest shares many features similar to other stress-induced premature 
senescence models as occurring in response to oxidative stress, DNA damage 
or oncogenic Ras, the question was addressed whether stress-induced 
premature senescence is identical to replicative senescence or rather a 
phenotypic and functional mimic of replicative senescence. In fact, the results of 
the previous section already indicate that PUVA-induced premature senescence 
is different from replicative senescence in that PUVA-treated fibroblasts regain 
their proliferation capacity after 1-3 month of growth arrest post PUVA treatment. 
In order to further characterize different features between stress-induced 
premature senescence and replicative senescence, the following questions were 
experimentally addressed: 
− Are established senescent phenotypic and biochemical markers of cellular 
senescence reversible in PUVA-induced premature senescence? 
− Is the PUVA-induced senescence-like growth arrest controlled by the same 
molecular pathways as in replicative senescence? 
− Which mechanisms are involved and contribute to the senescence-like 
features? 
 
3.2.1. Reversibility of senescence-associated markers in regrowing 
fibroblasts post PUVA treatment 
In a first attempt to address the question whether fibroblasts which escape from 
growth arrest also lose senescence markers such as morphology and 
senescence associated β-galactosidase expression, these parameters were 
studied in PUVA-arrested and regrowing fibroblasts at different time points post 
PUVA treatment. After PUVA treatment growth-arrested fibroblasts revealed a 
substantial increase in cell size compared to mock-treated control fibroblasts with 
time after PUVA treatment (Figure 11A to Figure 11D). At 14-16 weeks post 
PUVA treatment, small regrowing fibroblasts were visible among  
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Figure 11. Cell morphology changes in growth-arrested fibroblasts at 
different time points post PUVA in regrowing fibroblasts and in mock-
treated control fibroblasts. Fibroblasts were fixed and stained with Coomassie 
blue as detailed in Materials and Methods and photographed at ×100 
magnification. A, mock-treated control fibroblasts; B-D, fibroblasts at 1, 2, 4 
weeks post PUVA treatment; E, 16 weeks post PUVA treatment; F, regrowing 
fibroblasts post PUVA treatment. 
E F 
D C 
A B 
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enlarged growth-arrested fibroblasts (Figure 11E). Regrowing fibroblasts did not 
show any difference in cell size compared to mock-treated control fibroblasts 
(Figure 11F).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. The induced expression of senescence-associated -
galactosidase (SA--Gal) in PUVA-treated fibroblasts is lost in regrowing 
fibroblasts post PUVA. (A) Fibroblasts 21 days post PUVA; (B) At 98 days post 
PUVA, SA--Gal staining was lost in some cells (arrows) which morphologically 
represent the smaller regrowing cells, while still maintained in those enlarged 
growth-arrested cells. (C) No staining was observed in fully regrowing fibroblasts 
post PUVA treatment or (D) in mock-treated fibroblasts.  Fibroblasts were stained 
for SA--Gal and photographed at ×100 magnification. Three independent 
experiments have been performed with similar results. 
 
A B 
C D 
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Figure 13. The increased release of MMP-1 from human dermal fibroblasts 
upon a single PUVA treatment is no longer detectable in fibroblasts in their 
regrowing phase post PUVA treatment. Confluent fibroblasts were PUVA-
treated (50 ng/ml 8-MOP / 90 kJ/m² UVA) or mock-treated. Supernatants were 
collected from mock-treated fibroblasts(Control), at 14 days post PUVA 
treatment(PUVA), at 130 days post PUVA treatment in the regrowing phase of 
the same fibroblast strain (Regrowing) and at 110 days post PUVA treatment in 
the regrowing phase of another fibroblast strain (Regrowing 1). All supernatants 
were subjected to ELISA detection of MMP-1, as detailed in Materials and 
Methods. Three independent experiments were performed to determine specific 
MMP-1 protein concentrations. *p ≤ 0.0001 compared with PUVA-treated cells; #p 
= 0.32 compared with mock-treated cells (One way ANOVA). 
 
 
Reversal of changes in the enlarged cell morphology and growth arrest post 
PUVA treatment was also accompanied by the loss of biochemical markers of 
senescence. While all fibroblasts revealed SA--Gal expression at 4 weeks post 
PUVA treatment (Figure 12A) and SA-β-gal expression was sustained during > 2 
months of growth arrest, SA--Gal staining was lost at 98 days post PUVA 
treatment in some cells, which morphologically represent regrowing cells (Figure 
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12B). No SA--Gal expression was observed in regrowing fibroblasts post PUVA 
treatment (Figure 12C) and in mock-treated fibroblasts (Figure 12D).  
 
Besides morphological changes and SA-β-gal expression, another senescence-
associated marker, matrix-metalloprotease-1 (MMP-1) which was up-regulated 
after PUVA treatment, completely returned back in regrowing fibroblasts to levels 
of mock-treated control fibroblasts (Figure 13).  
 
 
 
Figure 14. Expression of p53 at different time points after PUVA treatment. 
p53 expression of fibroblasts at different time post PUVA treatment as well as 
mock-treated and regrowing fibroblasts was determined by an ELISA specific for 
p53, as described in Materials and Methods. The results were expressed as the 
mean of triplicates, three experiments were performed with similar results. 
Control represents values of p53 concentration in mock-treated fibroblasts. P-6h, 
P-12h represent values of p53 concentration at 6 hour and 12 hour post PUVA 
treatment. P-1d, P-2d represent values of p53 concentration at 1 day and 2 day 
post PUVA treatment. P-1w, P-2w and P-4w represent values of p53 
concentration at 1, 2 and 4 weeks post PUVA treatment. 
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3.2.2. Activation of the senescence control pathways p21/p53 and p16/Rb in 
PUVA-induced growth arrest 
As PUVA-induced growth arrest showed many senescence-like features, and it 
has earlier been shown that the terminal replicative growth arrest is controlled 
either by the p53/p21Cip1 or the pRb/p16INK4a pathway, the time-dependent 
expression of these important cell cycle control proteins was determined in 
PUVA-treated fibroblasts. p53 and p21Cip1 protein levels increased concomitantly 
at day 1 after PUVA treatment, and reached their maximum 2 days later (Figure 
14, Figure 15). Thereafter, both p53 and p21Cip1 protein amounts decreased with 
time and are almost back to levels of mock-treated control fibroblasts at 4 weeks 
post PUVA treatment.  
 
Figure 15. Expression of p21Cip1 at different time points after PUVA 
treatment. p21Cip1 expression of fibroblasts at different time post PUVA 
treatment as well as mock-treated and regrowing fibroblasts was determined by 
ELISA specific for p21Cip1, as described in Materials and Methods. The results 
were expressed as the mean of triplicates, three experiments were performed 
with similar results. Control represents values of p53 concentration in mock-
treated fibroblasts. P-6h, P-12h represent values of p21Cip1 concentration at 6 
hour and 12 hour post PUVA treatment. P-1d, P-2d represent values of p21Cip1 
concentration at 1 day and 2 day post PUVA treatment. P-1w, P-2w and P-4w 
represent values of p21Cip1 concentration at 1, 2 and 4 weeks post PUVA 
treatment. 
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However, as fibroblasts did not reproliferate at the end of 4 weeks post PUVA 
treatment, and continued to be arrested for another 2 months, there must be 
other mechanisms controlling the prolonged growth arrest stage. Similar to the 
decrease in p53 and p21Cip1, p16INK4a concentrations started to increase 1 week 
after PUVA treatment and remained elevated for up to 10 weeks post PUVA 
treatment (Figure 16). These data provide correlative evidence that p16INK4a 
might be involved in maintaining fibroblasts in this long-term growth arrest stage. 
 
 
 
 
 
 
Figure 16. Expression of p16INK4a at different time points after PUVA 
treatment. Lysates derived from PUVA-treated fibroblasts at different time points 
post PUVA treatment, mock-treated fibroblasts and regrowing fibroblasts post 
PUVA treatment were subjected to Western blot analysis for expression of the 
p16INK4a. Western blot was performed as described in Materials and Methods. P-
1d represents values of p16INK4a at 1 day post PUVA treatment. P-1w, P-2w, P-
4w, P-7w, P-11w represent values of p16INK4a at 1, 2, 4, 7, 10 weeks post PUVA 
treatment. 
 
 
3.2.3. PUVA treatment of fibroblasts with a null mutation in cell cycle 
controlling genes results in a similar growth arrest as in wild type 
human dermal fibroblasts 
To further address the question whether p16INK4a, p21Cip1 and p53 are causally 
involved in the growth arrest following PUVA treatment, the effect of PUVA 
treatment on human fibroblasts with homozygous deficiencies in these genes 
was studied in terms of their proliferation rate and cell phenotype. Following 
selection of non-cytotoxic conditions fibroblasts were incubated with 50 ng/ml 8-
MOP and irradiated with 10 - 90 kJ/m2 UVA. Growth rate and cell morphology 
were monitored over 28 days in p16INK4a, p21Cip1 and p53 deficient cells. 
Unexpectedly, p16INK4a, p21Cip1 and p53 deficient cells ceased proliferation and 
arrested with similar features compared to PUVA-treated wild type fibroblasts 
with functional p16INK4a, p21Cip1 and p53 genes (Figure 17). The lack in mitotic 
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activity was accompanied by prominent alterations in cell morphology similar to 
wild type fibroblasts. p16INK4a, p21Cip1 and p53 deficient fibroblasts, which had 
been subjected to combined 8-MOP/UVA treatment changed to an elongated 
and flattened phenotype at day 7 post PUVA treatment and revealed a 
substantial increase in size at day 28 (Figure 18). However, it was also obvious 
that p16INK4a, p21Cip1 and p53 deficient fibroblasts are more sensitive to PUVA-
induced toxic effects. When the same dose of PUVA (50ng/ml 8-MOP and 
90kJ/m2 UVA) is applied on fibroblasts deficient for cell cycle control genes as on 
wild type fibroblasts, a large proportion of deficient fibroblasts died after PUVA 
treatment, especially p53 deficient fibroblasts. The PUVA treatment that results in 
growth arrest without cytotoxic effect on p53 deficient fibroblasts is 50ng/ml 8-
MOP and 10kJ/m2 UVA. 
 
In summary, the data suggest that senescent markers of replicative senescence, 
such as cell enlargement and SA-β-gal expression, are reversible in PUVA-
treated fibroblasts. The senescence controlling genes p53, p21 and p16 were all 
upregulated after PUVA treatment, but after regrowth returned, apart from p16, 
back to the level of mock-treated control fibroblasts. However, these senescence 
controlling genes are not exclusively required for the long-term growth arrest. 
These data indicated that stress-induced premature senescence after PUVA 
treatment definitely differs from the irreversible growth arrest and permanent 
expression of distinct senescence-associated phenotypic and biochemical 
features.  
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Figure 17. PUVA treatment of p16INK4a, p21Cip1 or p53-deficient fibroblasts 
results in growth arrest. p16INK4a and p21Cip1 Fibroblasts were PUVA-treated 
with 50 ng/ml 8-MOP plus 45  kJ/m2 UVA, and p53-deficient fibroblasts were 
PUVA-treated with 50 ng/ml 8-MOP plus 10  kJ/m2 UVA. At different time points 
thereafter, cell numbers were determined in triplicates for each experimental 
group and equal cell numbers were plated for further culture. The data represent 
growth curves expressed as the increase in cumulative population doublings. A: 
p16INK4a deficient fibroblasts treated with PUVA or UVA irradiation only. B: p21Cip1 
deficient fibroblasts treated with PUVA or UVA irradiation only. C: p53 deficient 
fibroblasts treated with PUVA or UVA irradiation only. 
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Figure 18. Combined 8-MOP/UVA treatment of p16INK4a, p21Cip1 or p53 
deficient fibroblasts promotes the senescence-like phenotype. Fibroblasts 
were fixed and stained at day 28 after PUVA or UVA treatment, and 
photographed at 100X magnification. A,B: p16INK4a deficient fibroblasts irradiated 
with UVA (45 kJ/m2) or PUVA (50 ng/ml 8-MOP plus 45  kJ/m2 UVA). C, D: 
p21Cip1 deficient fibroblasts irradiated with UVA (45 kJ/m2) or PUVA (50 ng/ml 8-
MOP plus 45  kJ/m2 UVA). E,F: p53 deficient fibroblasts treated with UVA (10  
kJ/m2)  or PUVA (50 ng/ml 8-MOP plus 10  kJ/m2 UVA). 
p16-/- UVA p16-/- PUVA 
p21-/- UVA p21-/- PUVA 
p53-/- UVA p53-/- PUVA 
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3.3. PUVA treatment of human dermal fibroblasts increases the generation 
of intracellular reactive oxygen species 
In a first attempt to address the mechanisms by which PUVA-treated fibroblasts 
gained their senescence-like phenotypic and biochemical changes, it was studied 
whether reactive oxygen species (ROS) are produced at high concentrations and 
whether ROS play a role for the long-term senescence-like growth arrest. To 
determine ROS generation after PUVA treatment, fibroblasts were loaded with 
the peroxide-sensitive fluorophore 2’-7’ dichlorodihydrofluorescin diacetate 
(H2DCFDA). H2DCFDA is cell membrane permeable and can be deesterified to 
H2DCF by intracellular esterases located in the cell membrane (LeBel et al. 1992). 
The resulting H2DCF is membrane impermeable and  can  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Increased ROS production in human dermal fibroblasts at 
different time points after PUVA treatment. ROS levels were determined by 
DCF staining in PUVA-treated fibroblasts, regrowing fibroblasts and mock-treated 
control fibroblasts, as described in Materials and Methods. A melanoma cell line 
(MV3) was included as positive control. Fluorescence intensity was recorded with 
a Zeiss laser scanning confocal microscope (×100 magnification). 
 
PUVA(24h) PUVA(1w) PUVA(6w) 
Control MV3 Regrowing No PUVA 
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be rapidly oxidized to the highly fluorescent 2',7'-dichlorofluorescein (DCF) in the 
presence of intracellular ROS and RNS (reactive nitrogen species), particularly 
H2O2 and Nitric oxide (NO). As shown in Figure 19, PUVA treatment resulted in a 
moderate 2-fold increase in DCF fluorescence intensity at 24h post PUVA 
treatment which time-dependently increased to 5-fold at 1 week and >20 fold 6 
weeks post PUVA treatment compared to mock-treated and regrowing fibroblasts. 
The DCF fluorescence intensity was not related to NO, since inhibition of NO 
production by specific NO inhibitors was not able to decrease the fluorescence. 
These results derived from experiments with inducible NO synthesis (iNOS) 
inhibitors, which controls the intracellular level of NO (Amin et al. 1999). Culture 
medium was supplemented with the iNOS inhibitor 1400w for one day in PUVA-
treated fibroblasts at different time points post treatment. Independent of all 
tested concentrations of the iNOS inhibitor 1400w, no decrease in DCF 
fluorescence was observed indicating that the increasing intensity of DCF 
fluorescence post PUVA treatment is not due to NO production, but rather to 
enhanced generation of ROS. 
 
3.3.1. Increase in the number of mitochondria and decrease in the relative 
mitochondrial transmembrane potential in PUVA-treated fibroblasts 
The mitochondrion is the main site of ROS production in mammalian cells. Both 
unbalanced mitochondria biogenesis and damages of the mitochondrial electron 
phosphorylation chain may lead to enhanced ROS generation. To study whether 
mitochondria are involved and contribute to the enhanced ROS production of 
PUVA-treated fibroblasts, mitochondrial proliferation and mitochondrial 
membrane integrity were determined after PUVA treatment. To measure 
changes in the number of mitochondria, fibroblasts were stained with the 
mitochondria-selective vital dye MitoTracker Red at different time points post 
PUVA treatment. MitoTracker probes are specifically sequestered in 
mitochondria where they react with thiols on proteins and peptides to form an 
aldehyde-fixable conjugate.  As shown in Figure 20, PUVA-treated fibroblasts 
showed a progressive increase in mitochondria mass with time after PUVA 
treatment, Figure 20 B and C represent PUVA-treated cells at 16 days and 7 
weeks post PUVA, respectively. Figure 20 A and D showed the number (mass) 
of mitochondria in mock-treated (A) and in regrowing fibroblasts (D).  
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Figure 20. The number of mitochondria per cell increases at different time 
points after PUVA treatment. Fibroblasts at different time post PUVA treatment, 
mock-treated and regrowing fibroblasts were stained for mitochondria using 
MitoTrack Red as described in Material and Methods. A: mock-treated fibroblasts; 
B and C: PUVA-treated fibroblasts at 16 days and 7 weeks post PUVA; D, 
regrowing fibroblasts. 
 
A B 
D C 
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To monitor the integrity of the mitochondrial membrane as a means for the 
functional integrity of the oxidative phosphorylation chain, the mitochondrial 
membrane potential (∆Ψm) was measured using a polarization-sensitive dye JC-
9. JC-9 is directed into mitochondria and exists in two interchangeable forms, 
either as a monomer (J-monomer) or as a dimer (J-aggregate). J-monomer leads 
to the emission of green fluorescence and J-aggregates to the emission of red 
fluorescence. In cells with intact mitochondrial membranes, JC-9 is driven into 
mitochondria due to a high ∆Ψm. Accumulation of JC-9 in negatively charged 
mitochondria forms J-aggregate and results in red fluorescence. When ∆Ψm 
decreases, JC-9 subsequently diffuses out of the mitochondria and leads to 
decrease in the intensity of red fluorescence. Since the green fluorescence is 
relatively constant due to potential-independent interactions of JC-9 monomer 
with the mitochondrial membrane, which is only related to the mitochondria 
number, changes in the ratio between J-aggregate (red fluorescence) and J-
monomer (green fluorescence) indicates ∆Ψm value changes (Reers et al. 1991; 
Smiley et al. 1991). In order to determine ∆Ψm changes, the same number of 
PUVA-treated fibroblasts at different time points post PUVA treatment was 
monitored for the intensity of green and red fluorescence by FACS analysis. As 
shown in Figure 21, JC-9 green fluorescence was greatly increased in PUVA-
treated fibroblasts 2 weeks (PUVA-2w) and 11 weeks (PUVA-11w) post PUVA 
treatment. The majority of fibroblasts at 2 or 11 weeks post PUVA treatment 
revealed a fluorescent value around 1000 while the fluorescent value of mock-
treated control fibroblasts was 30, indicating a 33-fold increase in the number of 
mitochondria. However, no similar increase in the red fluorescence was observed. 
The peak of the red fluorescence in fibroblasts at 2 weeks post PUVA treatment 
revealed a value of about 50, and in fibroblasts at 11 weeks post PUVA 
treatment the fluorescent value was 35. Compared to the value of 20 in mock-
treated fibroblasts, there was only a 1.8-2.5 fold increase in the intensity of red 
fluorescence. Thus, the red/green fluorescence ratio, which represents the ∆Ψm 
value, revealed a 4-fold decrease in PUVA-treated fibroblasts as calculated in 
Figure 22. These data indicate that the ∆Ψm is significantly decreased in PUVA-
treated fibroblasts. 
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Figure 21. JC-9 fluorescent staining for PUVA-treated fibroblasts at 
different time post PUVA treatment. After incubation with JC-9, 1×106 cells/ml 
of PUVA-treated fibroblasts 4 days (PUVA-4d), 2 weeks (PUVA-2w) and 11 
weeks (PUVA-11w) post PUVA treatment, regrowing fibroblasts post PUVA 
treatment and mock-treated control fibroblasts were determined for red and 
green fluorescence by FACS, as described in Materials and Methods.  
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Figure 22. The ratio of J-aggregates/J-monomer decreases after PUVA 
treatment. After incubation with JC-9, 1×106 cells/ml of PUVA-treated fibroblasts 
4 days, 16 days, 4 weeks and 11 weeks post PUVA treatment, regrowing 
fibroblasts post PUVA treatment and mock-treated control fibroblasts were 
determined for red and green fluorescence by FACS, as described in Materials 
and Methods. The data are measured in triplicates and shown as mean ± 
standard deviation. 
 
 
3.3.2. Changes in ATP content  in PUVA-treated fibroblasts  
Depolarization of mitochondrial membrane potential should lead to reduced ATP 
production. ATP concentrations were measured in PUVA-treated fibroblasts at 
different time points post treatment, in regrowing and mock-treated control 
fibroblasts. PUVA-treated fibroblasts showed a dramatic increase in total ATP 
content per cell resulting in a 3-fold increase in ATP concentrations at 2 weeks 
and a 4.2-fold increase at 4 weeks post PUVA treatment compared to much 
lower ATP concentrations in regrowing and mock-treated fibroblasts (Figure 23). 
However, considering that PUVA-treated fibroblasts reveal a great increase in 
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cell size and mitochondria mass, the average ATP concentration per unit total 
protein was constant (Figure 23).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. Changes in ATP concentrations at different time points post 
PUVA treatment. The ATP content was determined by a luminescent method as 
described in Materials and Methods. The upper panel showed ATP content per 
cell, the lower panel show ATP content as a ratio of total ATP per total protein 
content. Experiments were performed in triplicates and expressed as mean ± 
standard deviation. 
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3.3.3. PUVA-treated Rho0 fibroblasts still have a high ROS level 
To further investigate whether mitochondria are responsible for PUVA-induced 
ROS production, fibroblasts depleted in their mitochondrial DNA (mtDNA), 
designated as Rho0 fibroblasts, were generated using low concentrations of 
ethidium bromide. Low ethidium bromide concentrations lead to the depletion of 
the mtDNA resulting in the disruption of electron transport/oxidative 
phosphorylation (King and Attardi 1989). The number of mitochondria was 
decreased by a factor of two with each cell division since - due to lack of mtDNA 
- no new mitochondria were generated. The depletion of mtDNA was confirmed 
by the mitochondria transcription factor mtTFA, which plays a role in controlling 
mtDNA copy number and varies concomitantly with levels of mtDNA (Shen and 
Bogenhagen 2001). The mtTFA expression was completely suppressed 1 week 
after incubation of fibroblasts with ethidium bromide as shown by immunoblotting 
(Figure 24). To ensure that mtDNA would not recover, Rho0 fibroblasts were 
maintained in ethidium bromide-containing medium. Rho0 fibroblasts were then 
subjected to PUVA treatment and ROS levels were determined by DCF staining. 
As shown in Figure 25H and I, PUVA-treated Rho0 fibroblasts still revealed a 
high intensity of DCF fluorescence at 3 weeks and 6 weeks post treatment 
compared to mock-treated Rho0 fibroblasts (Figure 25G).  The overall 
unchanged DCF intensity indicates that other factors may contribute alone or in 
conjunction with mitochondrial dysfunction to the enhanced ROS concentration in 
PUVA-treated fibroblasts.  
 
 
 
 
 
 
 
Figure 24. The expression of the mitochondrial transcription factor mtTFA 
is suppressed after incubation of human dermal fibroblasts with ethidium 
bromide. Human dermal fibroblasts were incubated with ethidium bromide at a 
concentration of 0.1 µg/ml as described in Materials and Methods. One week 
after treatment, Rho0 fibroblasts as well as mock-treated control fibroblasts were 
studied for mtTFA expression by Western blot analysis.  
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Figure 25 The generation of reactive oxygen species after PUVA treatment 
of human dermal fibroblasts is due to both mitochondria and NADPH 
oxidase. Human dermal mitochondria competent or mitochondria incompetent 
fibroblasts were subjected to PUVA treatment. ROS generation was monitored at 
3 and 6 weeks post PUVA treatment in the presence and absence of the NADPH 
oxidase inhibitor AEBSF by loading fibroblasts of the differently treated 
experimental groups with 10 µg/ml of the fluorescent ROS-indicator H2DCF-DA 
as described in Material and Methods. Depletion of mitochondrial function was 
achieved by treating human dermal fibroblasts with 0.1 µg/ml ethidium bromide at 
37°C for 7 to 14 days. The depletion of mitochondria DNA was confirmed by a 
complete suppression of the expression of the mitochondrial transcription factor 
which correlate with the mitochondria number. A-F: mitochondria competent 
fibroblasts showing in A: mock-treated, B: PUVA-treated 3 weeks after PUVA 
A B C 
D E F 
G H I 
J K L 
Mock-treated PUVA-3week PUVA-6 week 
Mitochondria 
competent 
Mitochondria 
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treatment. C:  PUVA-treated 6 weeks after PUVA treatment. D: mock-treated 
after incubation with the NADPH oxidase inhibitor AEBSF for 1 hour. E: PUVA-
treated 3 weeks after PUVA treatment after incubation with the NADPH oxidase 
inhibitor AEBSF for 1 hour. F: PUVA-treated 6 weeks after PUVA treatment after 
incubation with the NADPH oxidase inhibitor AEBSF for 1 hour. G-L: 
mitochondria in competent fibroblasts showing in G: mock-treated. H: PUVA-
treated 3 weeks after PUVA treatment. I:  PUVA-treated 6 weeks after PUVA 
treatment. J: mock-treated after incubation with the NADPH oxidase inhibitor 
AEBSF for 1 hour. K: PUVA-treated 3 weeks after PUVA treatment after 
incubation with the NADPH oxidase inhibitor AEBSF for 1 hour. L: PUVA-treated 
6 weeks after PUVA treatment after incubation with the NADPH oxidase inhibitor 
AEBSF for 1 hour.  
 
 
3.3.4. Inhibition of NADPH Oxidase does not abrogate the ROS increase in 
PUVA-treated mitochondria-competent fibroblasts, whereas ROS 
production is suppressed in PUVA-treated Rho0 fibroblasts  
Among other sources for ROS production, cyclooxygenase 2 (COX-2) and 
NADPH oxidase are involved. These two enzymes are not constitutively 
expressed in cells, but can be induced or activated under certain conditions 
(Finkel 1999). In the first attempt to study whether these enzymes are activated 
and may play a role in the high ROS production in PUVA-treated fibroblasts, 
specific inhibitors for each of the enzymes were employed. Although inhibition of 
COX-2 with the selective COX-2 inhibitor NS398 (Liu et al. 1998) post PUVA 
treatment did not reveal any decrease in ROS levels in fibroblasts at different 
time point post PUVA treatment (data not shown), inhibition of NADPH oxidase in 
PUVA-treated Rho0 fibroblasts almost completely blocked ROS production.  
 
In detail, the human NADPH oxidase consists of two membrane components and 
several cytosolic components, and is activated in case these cytosolic 
components translocate into the plasma membrane. Activated NADPH oxidase 
catalyzes the reaction:  
2O2 + NADPH → 2O2• − + NADP+ + H+ 
Two NADPH oxidase inhibitors, 4-(2-aminoethyl)-benzenesulfonyl fluoride) 
(AEBSF) and diphenylene iodonium (DPI), were employed in this study. As 
shown in Figure 25D, E and F, AEBSF did not result in a decrease of ROS 
production in PUVA-treated fibroblasts at different time post PUVA treatment 
compared to PUVA-treated fibroblasts in the absence of AEBSF treatment 
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(Figure 25A, B and C). However, the intensity of DCF fluorescence of PUVA-
treated Rho0 fibroblasts at different time post treatment (as shown in Figure 25G, 
H and I) was almost completely abrogated in the presence of AEBSF in the 
culture (Figure 25J, K and L). The alternative inhibitor of the NADPH oxidase, 
DPI, showed similar results (data not shown). Trypan blue staining revealed a 
more than 85% exclusion rate after incubation with these inhibitors indicating that 
the used concentrations are not toxic to Rho0 fibroblasts. Moreover, PUVA-
treated Rho0 fibroblasts were incubated with corresponding concentrations of 
these inhibitors for up to 1 week or longer with no detectable increase in cell 
death as compared to that of without inhibitors. These results exclude the 
possibility that the decrease in ROS levels is due to cytotoxicity related cell death.  
 
3.3.5. ROS contribute to the PUVA-induced senescence-like morphology 
Under PUVA-induced long-term growth arrest fibroblasts showed senescence-
like features. To determine whether the increase in ROS levels after PUVA 
treatment was simply correlative or alternatively whether ROS may play a causal 
role in the initiation and maintenance of these senescence-like features, the role 
of enhanced ROS levels in the increase in SA-β-gal-positive cells and phenotypic 
changes was tested under conditions with reduced ROS levels. For this purpose, 
PUVA-treated fibroblasts were exposed to the antioxidant N-acetyl cysteine 
(NAC). NAC is a reduced glutathione (GSH) provider and a direct and efficient 
scavenger of hydroxyl, H2O2 and possibly other kinds of ROS (Staal et al. 1990). 
As shown in Figure 26, ROS levels of PUVA-treated fibroblasts incubated with 
NAC were substantially decreased compared to PUVA-treated fibroblasts without 
NAC. At different time points post PUVA treatment, NAC-supplemented (NAC(+)) 
and non-supplemented fibroblasts (NAC(-))  were examined for phenotypic 
changes and for SA-β-Gal expression. As shown in Figure 27, NAC(+) and 
NAC(-) fibroblasts showed a similar morphology at 2 days after PUVA treatment. 
At 1 week after PUVA treatment, NAC(-) fibroblasts changed to an elongated 
phenotype and revealed – as expected – a substantial increase in cytoplasmic 
size at 2 weeks after PUVA treatment, while phenotypic changes in NAC(+) 
fibroblasts were not apparent. Although a moderate enlargement could be seen 
in some NAC(+) fibroblasts at 4 weeks after PUVA treatment, overall these 
changes were neglectable when compared to the greatly enlarged NAC(-) 
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PUVA(1d) PUVA(1w) PUVA(4w) 
NAC-PUVA(1d) NAC-PUVA(1w) NAC-PUVA(4w) 
fibroblasts at the same time points suggesting that the high ROS production after 
PUVA treatment is involved and contributes to the phenotypic changes. SA-β-gal 
positive fibroblast numbers of NAC(+) dishes, on the contrary, did not show any 
difference compared to that of NAC(-) dishes at the same time points after PUVA 
treatment. As shown in Figure 28, at 1 week after PUVA treatment, the 
percentage of SA-β-gal positive fibroblasts increased with time and over 90% of 
fibroblasts were positive at the end of 4 weeks post PUVA treatment. This 
suggests that SA-β-gal expression represents a marker which is either not 
downstream of ROS or that the low levels of ROS maintained in NAC(+) 
fibroblasts are already sufficient to up-regulate SA-β-gal expression.  
 
Figure 26. Supplementation of human dermal fibroblasts with N-acetyl 
cystein (NAC) during the growth arrest stage post PUVA treatment leads to 
a decrease in ROS levels. Immediately after PUVA treatment, fibroblasts were 
maintained in culture medium containing 5 mM NAC. The medium was changed 
every three days to ensure an efficient antioxidant capacity. ROS levels in 
fibroblasts at different time points post PUVA treatment were determined by DCF 
at day 2 after NAC treatment. PUVA (1d) (1w) (4w) represents PUVA-treated 
fibroblasts at 1 day, 1 week and 4 weeks after PUVA treatment; NAC-PUVA (1d) 
(1w) (4w) represents PUVA-treated fibroblasts at 1 day, 1 week and 4 weeks 
after PUVA treatment which had been cultured in the presence of NAC. 
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Figure 27. Incubation with N-acetyl cystein prevented PUVA-treated 
fibroblasts from enlargement. After PUVA treatment fibroblasts were cultured 
in the presence (NAC(+)) or absence (NAC(-)) of NAC at a concentration of 5 
mM. The medium was changed every 3 days to ensure an efficient antioxidant 
capacity. Fibroblasts were fixed at 1 week (1w), 2 weeks (2w) and 4 weeks (4w) 
with Comassie blue. Photographs were taken at ×100 magnification. 
NAC(+)-2d NAC(-)-2d 
NAC(+)-1w NAC(-)-1w 
NAC(+)-2w NAC(-)-2w 
NAC(-)-4w NAC(+)-4w 
 69 
 
Figure 28. Senescence-associated β-galactosidase expression in PUVA-
treated fibroblasts with or without N-acetyl cystein. After PUVA treatment 
fibroblasts were seeded in 35 mm plastic dishes at a density of 3×104 cells per 
dish in the presence (PUVA-NAC) or absence (PUVA) of 5 mM NAC. SA-β-gal 
positive as well as negative cells were counted and calculated in 10 randomly 
selected high power fields (x100 magnification) at 2 days (PUVA-2d), 4 days 
(PUVA-4d), 1 week (PUVA-1w), 2 weeks (PUVA-2w), 3 weeks (PUVA-3w) and 4 
weeks (PUVA-4w) after PUVA treatment. P > 0.6 for each of the group indicating 
that there is no significant difference in the β-galactosidase expression of PUVA-
treated fibroblasts with or without NAC (student t-test). 
 
 
 
 
In summary, PUVA treatment leads to an enhanced ROS production which 
contributes to the senescent-like phenotypes, at least cell enlargement can be 
abrogated by antioxidants. Both mitochondrial dysfunction and NADPH oxidase 
activation are likely to be involved in the enhanced ROS production in PUVA-
treated fibroblasts. 
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3.4. Molecular mechanisms of the decline in the overall life span in 
regrowing fibroblasts post PUVA treatment 
 
As shown in Figure 9, regrowing fibroblasts revealed a reduced total life span as 
judged by the much lower CPD at which the replicative senescence stage was 
reached. Studies into the detailed mechanism are of potential interest not only for 
the understanding of replicative cellular senescence and stress-induced 
premature senescence, but also for premature skin aging, which is observed 
after repetitive long-term PUVA treatment of patients. As an increasing level of 
ROS production was observed during the growth arrest stage, the herein 
described study was focused on the question whether oxidative stress is involved 
and contributes to the early onset of cellular replicative senescence. In case ROS 
play a role, identifying the underlying molecular targets which finally lead to 
replicative senescence is of interest. In particularly the following questions were 
addressed: In what fashion does oxidative stress interact, if at all, with other 
proposed determinants of cellular senescence such as telomere length? Is the 
premature senescence controlled by telomere erosion, by activation of telomere-
independent mechanisms or a combination of both? 
 
3.4.1. Fibroblasts regrowing post PUVA treatment reveal a decline in the 
overall life-span 
The population doublings (CPDs) of regrowing fibroblasts post PUVA treatment 
was measured and compared with that of non-PUVA-treated control fibroblasts. 
As shown in Figure 9, starting from CPD 48, regrowing and mock-treated control 
fibroblasts showed a similar growth rate for the first 10 PDs. Afterwards, the 
growth rate of regrowing fibroblasts was slowed down and reached the 
replicative senescence stage after 150 days where the CPD increasing rate was 
lower than 0.02 PD/week with a final CPD of 62. By contrast, even at a CPD of 
70 mock-treated control fibroblasts of the same strain did not show any sign of 
proliferation stop. Thus, even though PUVA-treated fibroblasts escape from the 
long-term growth arrest, they reveal a reduced life-span and reach the stage of 
replicative senescence much earlier after regrowth post PUVA treatment 
compared to mock-treated control fibroblasts.  
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3.4.2. Fibroblasts regrowing post PUVA treatment reveal enhanced 
reduction in telomere lengths 
As telomere length is thought to serve as a “mitoclock” for replicative senescence, 
cells stop dividing when a critical telomere length is reached. In a first attempt to 
study whether the reduced life span of regrowing fibroblasts is due to a PUVA-
induced telomere shortening, telomere length of regrowing fibroblasts post PUVA 
treatment was determined and compared with that of mock-treated control 
fibroblasts at the same CPD. For this purpose, fibroblasts of the same strain at 
an early passage (CPD = 18.6) were either PUVA-treated or frozen down for later 
use. After 13 weeks the PUVA-treated fibroblasts started to regrow. PUVA-
treated fibroblasts in their reproliferating stage as well as mock-treated control 
fibroblasts of the same strain at the same CPD were collected and cultured for 
further CPD determination. Genomic DNA was collected from regrowing and 
mock-treated control fibroblasts at comparable CPDs and subjected to telomere 
length measurement. Figure 29A shows the terminal restriction fragment (TRF) 
pattern. The mean telomere length was estimated by the size of the median of 
each band to the molecular weight markers. Lane 3, 5, 7, 9 represent the TRF 
patterns of regrowing fibroblasts at different CPDs (CPD 20.9, 28.4, 32.8 and 
39.8, respectively), and Lane 2, 4, 6, 8 represent TRF patterns of mock-treated 
control fibroblasts with comparable CPDs (20.2, 29.4, 32.6, 41). Compared to 
mock-treated control fibroblasts at comparable CPDs, the mean TRF lengths in 
regrowing fibroblasts are significantly decreased with a 1 to 2 kb reduction. Since 
the CPD of regrowing fibroblasts before PUVA treatment was 18.6, and no CPD 
increase occurred during the growth arrest stage after PUVA treatment, the 
difference in telomere length between regrowing and mock-treated control 
fibroblasts happened either during the growth arrest stage or during the first 2.3 
PDs of proliferation between initiation of regrowth and collection of genomic DNA. 
During their regrowing phase post PUVA treatment, regrowing fibroblasts 
showed a similar rate in telomere shortening compared to mock-treated control 
fibroblasts.  
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Figure 29 Regrowing fibroblasts post PUVA treatment showed a reduced 
telomere length compared to mock-treated fibroblasts at the same CPD. A, 
Terminal restriction fragment (TRF) analysis as an indication for telomere length 
was performed as indicated in Material and Methods. Briefly, genomic DNA was 
prepared from regrowing fibroblasts at different CPDs or from mock-treated 
fibroblasts and of the same strain at the same CPD. 1.5 µg of HinfI/RsaI-digested 
DNA of each sample was subjected to electrophoresis on 0.6% agarose gels 
followed by Southern blot hybridization using a 51-mer biotinylated telomeric 
probe and visualized by chemiluminescence. B represents the principle for this 
analysis, as described in Materials and Methods. 
B 
A 
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3.4.3. Accumulation of single strand breaks  in telomere regions 
In an attempt to investigate why the telomere lengths of regrowing fibroblasts are 
substantially reduced compared to mock-treated control fibroblasts, telomere 
lengths of growth-arrested fibroblasts at different time points post PUVA 
treatment were determined. The strategy allows to study whether the long-term 
growth arrest itself could damage telomeres and, thus, led to telomere length 
reduction. As shown in Figure 30 lane 2 through lane 7, growth-arrested 
fibroblasts at different time points post PUVA treatment did not show any 
difference in telomere lengths when compared to each other. In addition no 
reduction was observed when compared to mock-treated control fibroblasts. 
However, PUVA-treated fibroblasts in their regrowing stage showed significantly 
shorter telomere lengths when compared to mock-treated control fibroblasts at 
comparable CPDs. Regarding these results, it should be noted that the above 
detected telomeres are double-stranded. The constant double-stranded telomere 
length does not necessarily mean that the telomere is intact and not damaged. 
Possibly, single strand breaks (SSBs) were generated in telomere region during 
growth arrest stage which, if not repaired, would result in telomere loss during 
DNA replication and cell division after fibroblasts start to regrow. To analyze 
whether single strand breaks are formed in the telomere region, the terminal 
restriction fragments (TRF) of the same batches used for double-stranded 
telomere length determination were denatured before being subjected to 
electrophoresis. As shown in Figure 30 Lane 10 to 14, a clear reduction in the 
lengths of single-stranded telomeres of growth-arrested fibroblasts at different 
time points post PUVA treatment was found with time after PUVA treatment. In 
fibroblasts at 11 weeks post PUVA treatment, single-stranded telomere length 
was comparable to that of regrowing fibroblasts at an early passage (CPD 20.9), 
while their double-stranded telomere lengths were significantly different (Lane 6 
and 7). Thus, single strand DNA breaks did form in the telomere region and most 
likely are responsible for the significant telomere length reduction in regrowing 
fibroblasts post PUVA treatment. Notably in growth-arrested fibroblasts at 1 day 
post PUVA treatment, the mean of the single-stranded TRF length (Lane 10) is 
even increased when compared to that of mock-treated fibroblasts (Lane 9). This 
might suggest that psoralen-DNA interstrand cross-links were also formed in the 
telomere region. 
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Figure 30. Double-stranded telomere lengths are constant throughout the 
growth arrest stage post PUVA treatment while single-stranded telomere 
lengths are clearly decreasing with time. The same strain of fibroblasts (FF95, 
P9, CPD=22) were PUVA-treated as indicated in Materials and Methods and 
genomic DNA was collected at different time points post PUVA treatment. Ten µg 
DNA of each sample was digested first with HinfI/RsaI. Half of the sample (20µl, 
5µg DNA) was treated with alkaline buffer (0.4M NaOH, 4 mM EDTA) for 5-10 
min to separate DNA double strands, and subjected to electrophoresis and 
Southern blot analysis as described in Materials and Methods. The other half of 
the samples which had not been denatured allowed to study telomere length of 
double-strand DNA. 
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Figure 31. Supplementation with N-acetyl cystein (NAC) during the growth 
arrest stage after PUVA treatment protects telomeres from length reduction. 
NAC was supplemented during the growth arrest stage at a concentration of 5 
mM and the medium was changed every three days to ensure an efficient 
antioxidant capacity. Thereafter genomic DNA of regrowing PUVA-treated 
fibroblasts with NAC supplementation (PUVA-NAC(+)) and without NAC 
supplementation (PUVA-NAC(-)) were collected at comparable CPD. Telomere 
lengths (TRF) were determined as described in Materials and Methods. Briefly, 5 
µg of HinfI/RsaI-digested DNA of each sample was subjected to electrophoresis 
with 0.6% agarose gels followed by Southern blot hybridisation using a 51-mer 
biotinylated telomeric probe and visualized by chemiluminescence. 
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3.4.4. Scavenging of reactive oxygen species by N-acetyl cystein rescues 
telomere length 
Since ROS are produced in human dermal fibroblasts after PUVA treatment and 
increase with time, the question arises whether ROS are involved in and 
contribute to telomere length reduction. The causal role of ROS on telomere 
length reduction was investigated by scavenging ROS accumulation with N-
acetyl-L-cycteine (NAC) in PUVA-treated fibroblasts during the growth arrest 
stage. Thereafter telomere length of fibroblasts in their regrowing phase was 
compared to that of identically PUVA-treated fibroblasts without exposure to NAC. 
NAC is a reduced glutathione (GSH) provider and a direct scavenger of ROS 
(Staal et al. 1990). As shown in Figure 26, with continuous supplementation of 
NAC, ROS levels in PUVA-treated fibroblasts were evidently decreased 
compared with mock-treated control fibroblasts. However, even with the 
decreased ROS level, PUVA-treated fibroblasts did not start to regrow at an 
earlier time point post PUVA treatment when compared to PUVA-treated 
fibroblasts without NAC. To explore whether ROS are involved in telomere 
reduction mediated by PUVA treatment, in their regrowing phase genomic DNA 
from regrowing PUVA-treated fibroblasts which had been cultivated in the 
presence of NAC (PUVA-NAC(+)) and in the absence of NAC (PUVA-NAC(-)) 
were collected at comparable CPDs and telomere lengths were determined. As 
shown in Figure 31, lane 3, 5 and 7 represent the TRF of PUVA-NAC(+) 
fibroblasts. Compared to the TRF lengths of PUVA-NAC(-) fibroblasts (lane 2, 4 
and 6), the telomere lengths in PUVA-NAC(+) fibroblasts were visibly longer as 
judged by the median of the TRF lengths.   
 
3.4.5. Partial restoration of the total life-span of PUVA-treated fibroblasts in 
the presence of N-acetyl cystein 
Since telomere length in PUVA-NAC(+) fibroblasts was well protected compared 
to PUVA-NAC(-) fibroblasts, it was studied whether this would rescue the total life 
span, which had been shown to be substantially reduced in PUVA-treated 
fibroblasts in their regrowing phase (Figure 9). Therefore, total CPD of PUVA-
NAC(+) fibroblasts in their regrowing phase were determined before reaching the 
replicative stage and compared with PUVA-NAC(-) fibroblasts as well as with 
mock-treated control fibroblasts.  As shown in Figure 32, starting from CPD 21, 
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fibroblasts of the different experimental groups were cultured for over 300 days 
until reaching the replicative senescence stage where CPDs did not increase any 
more. Compared to PUVA-NAC(-) fibroblasts which reached replicative 
senescence at a CPD of 64.2, PUVA-NAC(+) fibroblasts showed 6 PDs more 
with a final CPD of 70. Compared to the total life-span of mock-treated fibroblasts 
with a total CPD of 73.9, the life-span of PUVA-NAC(+) fibroblasts was still not 
fully restored. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32. N-acetyl cystein (NAC) supplementation during the PUVA-
induced growth arrest stage extended the life-span of PUVA-treated 
fibroblasts in their regrowing phase. Starting from the same CPD, mock-
treated control fibroblasts (triangle), regrowing fibroblasts which had been treated 
with NAC (open circle) during the growth arrest stage and regrowing fibroblasts 
without NAC treatment (square), were passaged for more than 9 months until 
reaching the replicative senescent stage with no  increases in population 
doubling. At each passage, cell numbers were determined in triplicates for each 
group and equal cell numbers (2×105) were transferred to a new tissue plate for 
further observation. Results were expressed as mean with standard deviation. 
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3.4.6. Up-regulated expression of p16INK4a is maintained in regrowing 
fibroblasts post PUVA treatment 
Beside telomere length reduction, an upregulated though low p16INK4a expression, 
which might be involved and contribute to the early onset of replicative 
senescence of PUVA-treated fibroblasts in there regrowing phase was observed. 
As shown before in Figure 16 (see page 57), p16INK4a expression was enhanced 
one week post PUVA treatment and maintained during the whole growth arrest 
stage. In contrast to p53 and p21Cip1, which were initially also upregulated after 
PUVA treatment but completely returned to base levels of mock-treated control 
fibroblasts in regrowing fibroblasts (Figure 14 and Figure 15), p16INK4a was still 
expressed at a higher level when compared to mock-treated control fibroblasts.  
 
In summary, the results show that even though PUVA-treated fibroblasts could 
escape from long-term growth arrest after PUVA treatment, a recollection of the 
PUVA-damage contribute to the earlier occurring replicative senescence state 
when compared to control fibroblasts. The reduced total life-span in PUVA-
treated fibroblasts is due to oxidative stress-induced telomere reduction as the 
abrogation of ROS production by the antioxidant NAC convincingly rescues 
telomere length reduction and partly restores total life-span of PUVA-treated 
fibroblasts in their regrowing phase comparable to that of mock-treated control 
fibroblasts.  
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3.5. Characterization of molecular mechanisms involved in the induction of 
growth arrest in PUVA-treated fibroblasts 
 
3.5.1. Short-term incubation with 8-MOP during UVA-irradiation does result 
in growth arrest while long-term preincubation with 8-MOP does not 
In accordance with the clinical PUVA regimen, where psoralen is ingested prior 
to UVA irradiation, the herein reported PUVA treatment of fibroblasts represents 
a two-step process as well. Fibroblasts are initially incubated with 8-MOP in the 
dark for 16 hours and thereafter cells were subjected to UVA irradiation in PBS 
containing the same concentration of 8-MOP. The irradiation time was 2-3 
minutes depending on the UVA intensity. It was observed that the long pre-
incubation of 8-MOP is not required for the induction of growth arrest. As shown 
in Table 4B, 16 hours pre-incubation with 8-MOP and subsequent UVA 
irradiation in PBS without 8-MOP (8-MOP-PRE) did not lead to growth arrest. By 
contrast, omitting the pre-incubation step, while fibroblasts were UVA irradiated 
for 3 minutes in PBS containing 8-MOP (8-MOP-UV) led to growth arrest. This 
result is intriguing since it was generally hypothesized that the proliferation 
inhibiting effect after PUVA treatment is due to psoralen-DNA interstrand 
crosslinks (ICLs). However, 3 minutes of 8-MOP incubation with fibroblasts 
during UVA irradiation may not be as sufficient to lead to the formation of 
interstrand DNA crosslinks as the long preincubation regimen with 8-MOP.  
 
 
 
Table 4 Different regimens in PUVA treatment procedure lead to different results 
A)  fibroblasts 
Pre-incubation  
In Medium with 8-MOP 
for 16 hrs 
UVA irradiation 
In PBS with 8-MOP 
for ~3 min 
Induction of 
Growth arrest 
Pre-incubation 
In Medium with 8-MOP 
for 16 hrs 
UVA irradiation 
In PBS without 8-
MOP for ~3min 
Continuation of 
Proliferation 
 
Without 
Pre-incubation 
UVA irradiation 
In PBS with 8-MOP 
for ~3min 
 
Induction of 
Growth arrest 
B)  fibroblasts 
C)  fibroblasts 
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3.5.2. The number of DNA interstrand crosslinks is not related to growth 
arrest 
We first determined the numbers of ICLs in 8-MOP-Pre and 8-MOP-UV cells. For 
this purpose, genomic DNA isolated from differently treated fibroblasts was 
digested first with certain restriction enzymes and then subjected to alkaline gel 
electrophoresis. As described in Material and Methods, this technique was used 
to determine and compare crosslink numbers by the degree of retardation of 
DNA fragments after electrophoresis. DNA double strands cannot be separated 
by alkaline denaturation if psoralen-DNA ICLs are present, and this will result in a 
retarded DNA fragment pattern after electrophoresis compared to DNA without 
ICLs. Figure 33B reveals the electrophoresis pattern of DNA from differently 
treated fibroblasts after combined restriction digestion with Hae II and Nde I. Both 
restriction enzymes are 6-base pair frequency cutters recognizing sequences 
within which psoralen-DNA ICL could be potentially formed. All DNA was isolated 
immediately after treatment. Lane 2 of Figure 33B shows DNA isolated from 
mock-treated fibroblasts serving as control to show the standard DNA pattern 
after restriction and denaturation. Lane 3 represents the DNA pattern of 
fibroblasts when 8-MOP was present both during pre-incubation and UVA 
irradiation. Compared to mock-treated fibroblasts (Lane 2), more of the large 
DNA fragments were found in lane 3 indicating a high amount of ICLs formed 
after PUVA treatment. Lane 4 represents the DNA fragments distribution of 
fibroblasts which had been preincubated with 8-MOP and UVA-irradiated in the 
absence of 8-MOP (8-MOP-PRE). A similar pattern as PUVA-treated fibroblasts 
where 8-MOP was present both in preincubation and UVA-irradiation step 
(PUVA-1h) suggesting that ICL amounts under both conditions are similar. Lane 
5 represents the DNA fragment pattern of fibroblasts which had been exposed to 
8-MOP only during UVA irradiation (8-MOP-UV), large DNA fragments were 
substantially less than those in lane 3 and lane 4 suggesting reduced ICL 
formation under this condition. A similar DNA fragment pattern was found when 
using a single restriction enzyme for digestion as shown in Figure 33C. This 
experiment clearly shows that PUVA-treated fibroblasts when 8-MOP is present 
only during the preincubation step (8-MOP-PRE) resulted in the same amounts 
of ICLs as that in PUVA-treated fibroblasts when 8-MOP is present in both steps 
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(PUVA-1h), while fibroblasts with 8-MOP present only during the UVA irradiation 
step (8-MOP-UV) had a substantially lower amount of ICLs.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33. Determination of DNA interstrand crosslinks (ICL) and growth 
status of fibroblasts after different regimen of PUVA treatment. A, The 
growth curve of PUVA-treated fibroblasts with 8-MOP exclusively present during 
pre-incubation (8-MOP-PRE) or only during UVA irradiation (8-MOP-UV). B and 
C, ICL determination was performed by alkaline electrophoresis as described in 
Materials and Methods. Briefly, genomic DNA was isolated from mock-treated 
fibroblasts, PUVA-treated fibroblasts immediately after treatment (PUVA-1h), 8-
MOP-PRE fibroblasts and 8-MOP-UV fibroblasts immediately after treatment.  
Thereafter DNA was digested with Hae II and Nde I, or Hae II only and subjected 
to alkaline gel electrophoresis.  
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Taken together, fibroblasts with 8-MOP present only during UVA irradiation step 
(8-MOP-UV) were growth-arrested, while fibroblasts with 8-MOP present only 
during preincubation step (MOP-PRE) were still proliferating (Figure 33A). This 
observation contradicts the traditional view that DNA interstrand cross-links are 
the exclusive reason responsible for proliferation inhibiting effects of PUVA.  
 
3.5.3. Characterization of the contribution of changes in the karyoplast and 
the cytoplast post PUVA treatment to PUVA-induced growth arrest 
To further investigate what mechanism may initiate the long-term senescence-
like growth arrest after PUVA treatment with particular interest on whether it was 
exclusively due to DNA damage in the nucleus or whether other targets located 
in the cytoplast may be involved, cell fusion experiments were performed as 
follows: Cytoplasts (enucleated cells) of PUVA-treated fibroblasts were separated 
and fused with karyoplasts (minicells) of untreated primary fibroblasts. Vice versa 
the karyoplasts of PUVA-treated fibroblasts were fused to the cytoplasts of 
untreated primary fibroblasts. The behavior of these newly constructed 
fibroblasts should allow getting more insight in the targets of PUVA treatment 
(cytoplast or nucleus or both) responsible for the long-term growth arrest. 
 
3.5.3.1. Rationale for  fusion of cytoplasts and karyoplasts 
The development of efficient methods to enucleate mammalian cells in order to 
obtain cytoplasts and karyoplasts was the first step for cell fusion. Previous work 
of cytogeneticists had developed methods for enucleation of cells with 
cytochalasin B, an inhibitor of microfilament-assembly. The underlying 
mechanism is that the cytoskeleton of the cell can be altered with the formation 
of very soft cellular membranes. In addition cytochalasin B inhibits cytokinesis 
and, thus, the chromosomes are more compacted making it easier to remove the 
nucleus with only a minimal volume of cytoplasm (Shay 1987; Veomett 1982). 
High speed centrifugation with a Ficoll gradient was employed to facilitate 
enucleation and separation of different cellular components. Fusion of cytoplasts 
and karyoplasts was promoted by the addition of Polyethylene glycol (PEG) with 
a so far not fully clarified mechanism. 
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3.5.3.2. Experimental design for the identification of fused fibroblasts 
The techniques for isolation of cytoplasts and karyoplasts yield fractions which 
are contaminated considerably with non-enucleated cells. The use of these 
contaminated fractions for fusion may give rise to difficulties in the interpretation 
of the results. Thus, the development of appropriate selection markers is a critical 
step to isolate and interpret specific fusion. Here four selection markers were 
used: neomycin resistance, GFP expression, Hoechst 33342 and latex beads. 
The experimental design is shown in Figure 34. Fibroblasts stably transfected 
with the nucleus-encoded neomycin resistance gene and the GFP-expression 
gene were PUVA-treated and used as supplier for PUVA-cytoplasts and PUVA-
karyoplasts. Non-PUVA-treated fibroblasts were labeled with red-fluorescent 
latex beads which were located in the cytoplast region. Two different hybrids 
were generated:  
1. PUVA-cytoplasts fused with Mock-treated-karyoplasts 
2. PUVA-karyoplasts fused with Mock-treated-cytoplasts 
Although the separated karyoplasts were almost pure, the cytoplast fraction was 
hardly free of contaminated non-enucleated fibroblasts.  Thus, the following 
strategy was used as shown in Figure 34 and table 5. For fusion experiment 1: 
after enucleation, the PUVA-cytoplast fraction was stained first with Hoechst 
33342 before being fused with Mock-treated-karyoplasts. Hoechst 33342 is a cell 
membrane permeable DNA stain, which can be used for staining living cells in 
culture. This stain incorporates into DNA double strands and gives rise to blue 
fluorescence. After this procedure, all the contaminated non-enucleated 
fibroblasts were labeled, and could be identified by their blue-fluorescent nuclei. 
The intended fusions, thus, could be identified as non-fluorescent nuclei. The 
strategy for fusion experiment 2 is dependent on neomycin resistance, GFP 
expression, as well as the latex beads. Since PUVA-karyoplasts have the 
neomycin resistant gene, after fusing with Mock-treated-cytoplasts, fibroblasts 
are cultured in medium containing G418, thus all the contaminated non-
enucleated normal fibroblasts will be killed while correctly fused fibroblasts will 
survive. The correct fusions are further identified by green fluorescence due to 
the expression of the GFP gene located in PUVA-karyoplasts and red 
fluorescence of latex beads in Mock-treated-cytoplasts. 
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Figure 34. Scheme for selection and identification of fusions. Fibroblasts 
stably transfected with neomycin resistant gene (Neo(r)) and GFP (GFP(+)) gene 
were PUVA-treated. Non-PUVA-treated fibroblasts were labeled with red-
fluorescent latex beads which are located in the cytoplast region. Two different 
hybrids were generated: 1) PUVA-cytoplasts fused with Mock-treated-karyoplasts, 
2) PUVA-karyoplasts fused with Mock-treated-cytoplasts. For the first hybrids, 
the PUVA-cytoplast fraction was stained first with Hoechst 33342 after 
enucleation and before fusing with Mock-treated-karyoplasts to identify the 
contaminating non-enucleated PUVA-treated fibroblasts. The intended fusions 
could thus be identified as revealing non-fluorescent nuclei. For the second 
hybrid, separated PUVA-karyoplasts have neo(r) and GFP (+) genes. After fusing 
with Mock-treated-cytoplasts, fibroblasts are cultured in medium containing G418. 
Thus, all the contaminating non-enucleated normal fibroblasts will be killed, while 
fusions will be left. The correct fusions are further identified by green 
fluorescence due to the expression of GFP gene located in PUVA-karyoplasts 
and red fluorescence of latex beads in Mock-treated-cytoplasts. 
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Table 5 Selection and identification of fusions 
Fusion 
experiments 
Cell types after 
fusion GFP Neor 
Latex 
beads Hoechst 
KpCn  
(intended 
fusion) + + + n.u 
KnCn 
(Contamination) - - + n.u Kp × Cn 
 Kp, Cn Not stable 
KnCp 
(intended 
fusion) n.u n.u - - 
KpCp 
(Contamination) n.u n.u - + Kn × Cp 
 Kn, Cp Not stable 
 
Kp: PUVA-karyoplast; Kn: Normal-karyoplast; Cp: PUVA-cytoplast; Cn: Normal-
cytoplast.  KpCn and KnCp represent fusions with cytoplasts and karyoplasts being 
from different sources, while KnCn and KpCp represent non-enucleated whole 
cells contained in the cytoplast fraction. n.u: not used as a marker in this 
experiment. 
 
 
3.5.3.3. Fusions of cytoplast/karyoplasts of  fibroblasts immediately or  at an 
early stage post PUVA with mock-treated karyoplasts/cytoplasts 
We initially used fibroblasts immediately post PUVA treatment for the cell fusion 
experiments, as PUVA-induced damages will be repaired with time after PUVA 
treatment. After fusing with mock-treated karyoplasts or cytoplasts, a striking cell 
death was observed within the first 3 days with cells, including non-fused 
cytoplasts, being detached from bottom of culture dishes (data not shown). No 
fusions had been identified in fibroblasts which survived as detected by GFP 
fluorescence or Hoechst staining. A conclusive explanation might be that both 
cytoplasm and nuclear components are substantially damaged and can not 
survive the new stresses generated during fusion process. Based on these 
results, PUVA-treated fibroblasts at later time points after PUVA treatment were 
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used for fusion. Experiments with PUVA-treated fibroblasts taken within the first 
week after PUVA treatment (at day 1 or at 1 week after PUVA treatment) were 
studied without yielding stable fusions. Similar to the above results, substantial 
cell death occurred within the first 3 to 5 days after fusion. Thereafter, no cells 
could be positively recognized as intended fusions, neither by GFP fluorescence 
(for fusions of PUVA-karyoplasts and Mock-treated-cytoplasts) nor by Hoechst 
staining (for fusions of PUVA-cytoplasts and Mock-treated-karyoplasts). Fusions 
of PUVA-karyoplasts and Mock-treated-cytoplasts did not successfully occur as 
no cells were found to be green-fluorescent (GFP expression) even in the first 
three days after fusion when fibroblasts were still viable. For fusions of PUVA-
cytoplasts with Mock-treated-karyoplasts, there were some cells that did not 
show Hoechst-stained nuclei at the first day after fusion which might represent 
the intended fusions. However, no intended fusions were observed after 3 days.  
 
3.5.3.4. Fusions of cytoplast/karyoplasts of  fibroblasts 2 weeks or 4 weeks post 
PUVA treatment with mock-treated karyoplasts/cytoplasts 
Fibroblasts at 2 and 4 week post PUVA treatment were used for cell fusion 
experiments. The number of dead cells was reduced after fusion and stably 
fused cells were observed in fusions both between PUVA-karyoplasts and Mock-
treated-cytoplasts as well as between PUVA-cytoplasts and Mock-treated-
karyoplasts, respectively.  
 
For fusions between PUVA-karyoplasts and Mock-treated-cytoplasts, the 
successfully fused cells were identified by latex beads and GFP expression. 
Figure 35 shows changes of fusions with time after fusion using PUVA-treated 
fibroblasts 2 weeks post PUVA treatment. As shown in Figure 35A, green-
fluorescent cells with yellowish-red-fluorescent cytoplasmic latex beads, which 
represent intended fusions, could be observed 2-3 days after fusion. At the same 
time point, contaminated non-enucleated normal fibroblasts, which reveals 
cytoplasmic latex beads but had no green-fluorescence, were also observed in 
another region of the same dish (Figure 35C). These cells should be eliminated 
by G418 supplemented in medium due to lack of the neomycin resistance gene, 
though they may still be able to proliferate at the beginning. Fused cells appear 
morphologically to proliferate instead of being growth-arrested within the first 
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three days after fusion as green-fluorescent cells were cluster-like (Figure 35A 
and B). However, compared with those contaminated fibroblasts which revealed 
only red latex beads but no green fluorescence, the proliferation rate is lower as 
judged by the density of cell clusters (Figure 35B and D). Thereafter, numbers of 
dead cells increased with time, most probably due to the toxicity of G418 to the 
contaminating non-fused mock-treated fibroblasts. Fused fibroblasts are still 
stable at 7 days after fusion, and cell numbers didn’t show any increase or 
decrease (Figure 35E and F). This might suggest that cell proliferation was 
stopped. Fusions of PUVA-treated karyoplasts with mock-treated cytoplasts were 
not stable for a longer time. These fused cells died off gradually after 12-14 days 
(Figure 35G and H). When using PUVA-treated fibroblasts 4 weeks post PUVA 
treatment for cell fusion, a similar cellular changing process was observed: fused 
fibroblasts with GFP green fluorescence and cytoplasmic red latex beads could 
be identified 3 days after fusion. However, fused fibroblasts were still not stable, 
and died off at around 15-17 days after fusion, though they apparently live longer 
compared to fusions with PUVA-2w cytoplasts (12-14 days).  
 
 
 
 
Figure 35. Cell fusions between PUVA-karyoplasts from fibroblasts two 
weeks post PUVA treatment and Mock-treated-cytoplasts. A shows a power 
field of the Petri-dish with fused cells 3 days post fusion, where cells reveal green 
fluorescence and the yellowish-red fluorescence of latex beads indicating that a 
successful fusion between PUVA-karyoplasts and Mock-treated-cytoplasts has 
occurred. C shows another high power field of the same dish where cells reveal 
only latex beads without green fluorescence indicating that they are 
contaminating non-PUVA-treated fibroblasts.  E represents cell hybrids 7 days 
post fusion which reveal green fluorescence and yellowish-red fluorescence of 
latex beads. G represents cell hybrids 12 days post fusion which reveal green 
fluorescence and the yellowish-red fluorescence of latex beads. B, D, F, H are 
the phase contrast photographs taken of the same power fields as in A, C, E, G, 
respectively. Photographs were taken at a magnification of ×100. 
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For fusions between PUVA-cytoplasts and Mock-treated-karyoplasts, fused cells 
did not show any proliferation at 1 week after fusion. Figure 36A and B represent 
fusions between PUVA-cytoplasts at 2 weeks post PUVA treatment and Mock-
H G 
F E 
C D 
A B 
3 days post 
fusion 
3 days post 
fusion 
7 days post 
fusion 
12 days 
post fusion 
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treated-karyoplasts. All non-enucleated contaminations in the PUVA-cytoplast 
fraction are identified as pre-labeled with Hoechst 33342 before fusion as 
described above and, thus, reveal the bright blue nuclear fluorescence. The 
normal-karyoplast fraction was pure after separation. Figure 36A and B show 
cells 3 days post fusion. Part A represents an area where contaminated cells 
were found which reveal Hoechst-stained nuclei, and part B shows an area with 
mainly fused fibroblasts which do not reveal Hoechst-stained nuclei. Interestingly, 
the intended fusions of PUVA-cytoplasts with Mock-treated-karyoplasts did not 
reveal a growth arrest as long as found in PUVA-treated fibroblasts. When using 
PUVA-2w cytoplasts for fusions, re-proliferation of cells could be observed 26 
days after fusion, as shown in Fig 17 C and D. Re-proliferation of cells could be 
observed even earlier when using PUVA-4w cytoplasts, which took only 12 days, 
as shown in Figure 36 E and F. These results indicate that cytoplast changes 
could affect cell growth. However, PUVA-dependent cytoplast changes were 
temporal and shorter-termed compared to PUVA-treated fibroblasts suggesting 
that apart from cytoplasmic damage other additional mechanisms are 
responsible for the long-term growth arrest.  
 
 
 
 
Figure 36. Cell fusions between PUVA-cytoplasts and Mock-treated-
karyoplasts. Panel 1) represent fusions between Mock-treated-karyoplasts and 
PUVA-cytoplasts derived from PUVA-treated fibroblasts two weeks post PUVA 
treatment. A and B represent fibroblasts 3 days post fusion. A shows an area 
with contamination of non-enucleated PUVA-treated fibroblasts as indicated by 
the Hoechst stained nuclei. B shows mainly successful fusions between PUVA-
cytoplasts and Mock-treated-karyoplasts as only the cytoplastic fluorescence is 
evident with no Hoechst stained nuclei. C and D represent the same cells 26 
days post fusion, D was the phase contrast photograph of C. E and F were 
fusions using PUVA-cytoplasts from fibroblasts 4 weeks post PUVA; 12 days 
post fusion, many cells start to proliferate. Photographs were taken at a 
magnification of ×100. 
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In summary, herein it is shown that the number of psoralen-DNA interstrand 
crosslinks does not correlate with the long-term growth arrest. When 
reconstructing cells by fusing PUVA-cytoplasts with mock-treated karyoplasts, it 
is found that these cell hybrids start to regrow earlier after PUVA treatment. The 
reconstructed cells with PUVA-karyoplasts and non-PUVA-treated cytoplasts, 
however, can not survive for longer than 18 days, making it difficult to finally 
evaluate the overall effects of PUVA-induced nuclear damage for the 
maintenance of the growth arrest. 
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4 DISCUSSION 
 
4.1. The escape of human dermal fibroblasts from PUVA-induced 
senescence-like growth arrest is not due to immortalization or 
transformation 
The data shown in this thesis demonstrate that PUVA-induced long-term growth 
arrest, although with some functional and morphological changes reminiscent of 
cellular senescence, is reversible between day 90 to 120 post PUVA treatment. 
The capacity of PUVA-treated fibroblasts to regrow after long-term growth arrest 
is neither due to immortalization nor transformation. This finding further 
strengthens the view that PUVA-induced changes are indeed a transient 
phenocopy of senescence.  
 
Immortalization and transformation have been reported to be critical for regrowth 
of senescent cells. At least, introduction of oncogenic Ras with subsequently 
enhanced intracellular ROS levels provokes premature senescence in murine 
and human fibroblasts (Lee et al. 1999; Serrano et al. 1997). Additional 
inactivation of either p53 or p16INK4a in rodent cells and E1A in human cells 
reversed this Ras-induced growth arrest suggesting that prematurely enhanced 
senescence can be effectively reversed by disrupting important cell cycle 
regulating proteins. Regrowth of senescent cells has also been described in 
fibroblasts double-deficient for p53 and BRCA1, the latter being involved in the 
control of the G2 phase of the cell cycle. These fibroblasts adopt a senescent 
phenotype upon -irradiation, however, following continued cultivation they form 
distinct proliferative foci, which according to the authors are most likely due to 
additional mutations (Shen et al. 1998). In this thesis several lines of evidence 
are provided that regrowth of long-term growth-arrested PUVA-treated human 
dermal fibroblasts is neither due to transformation nor immortalization.  
 
First, four independently tested regrowing fibroblast strains did not show 
anchorage-independent growth in the soft agar assay. By contrast, the 
transformed cell lines HT1080 and HeLa, which served as positive controls, 
formed growing colonies in the soft agar assay. Second, telomerase activity 
which is mainly responsible for the maintenance of the telomere length in 
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immortalized and transformed fibroblasts (Bryan et al. 1995; Kim et al. 1994), 
was not detected in regrowing fibroblasts post PUVA treatment. In accordance 
with this, telomere length of regrowing fibroblasts continuously shortens with 
increasing CPD. Third, in contrast to the unlimited growth of immortalized or 
transformed cells, regrowing fibroblasts in their proliferative phase post PUVA 
treatment revealed a continuous decline in their proliferation rates with time. In 
addition, p53, p21cip1 and p16INK4a genes, which were known to be the main 
players involved in both cellular senescence and other tumor suppressor 
mechanisms (e.g. apoptosis), did not show major mutations detectable by the 
applied PCR method in regrowing fibroblasts post PUVA. Thus, immortalization 
and transformation are not the reason for the resumed growth after PUVA-
induced long-term senescence-like growth arrest.  
 
Recently, the term stress-induced premature senescence (SIPS) has been 
introduced (Brack et al. 2000; Chen 2000; Toussaint et al. 2000b). Exposure of 
human fibroblasts to oxidative stress triggers a growth arrest state with 
appearance of several biomarkers for cellular senescence starting from 48 to 72 
h after exposure to the respective stressors (Chen 2000; Toussaint et al. 2000b). 
Both chronic and acute oxidative stress protocols have been used to induce 
SIPS: continuous chronic stresses such as hyperoxia for several weeks, or short 
repeated discontinuous subcytotoxic stresses, with H2O2 or tert-
butylhydroperoxide, followed by recovery periods of several days (Dumont et al. 
2001).  
 
Independent of the used protocols to induce oxidative stress, it was observed 
that there was no all-or-none response of cells, neither to chronic nor to acute 
oxidative stresses (Toussaint et al. 2000c). Under both protocols, senescent 
growth arrest occurred only in a certain fraction of cells though repeated 
stresses, with a stress every day or every two days, lead to an increased fraction 
of SIPS cells (Toussaint et al. 2000a). In the PUVA-treated fibroblasts, however, 
a more homogenous response of switching to a senescence-like long-term 
growth arrest was found. PUVA-treated fibroblasts without any exception 
revealed senescence-like features during the growth arrest stage, as evidenced 
by SA-β-gal expression with all fibroblasts being positive at 3-4 weeks post 
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PUVA treatment. No proliferating fibroblasts were found at least in the first 8 
weeks post PUVA treatment as determined by BrdU incorporation. These data 
indicate that resumed growth was not due to the escape of rare non-senescence-
like fibroblasts, which may have received no or less damage. However, the 
results do not necessarily mean that all treated fibroblasts recover from the 
growth-arrested stage at exactly the same time. Due to non-homogenous 
damages produced after PUVA in different fibroblasts and their expected 
different antioxidant and damage repair capacities, it is possible that some 
fibroblasts resumed growth earlier while others were still growth-arrested for an 
extended period. This prediction reflects exactly the data. The major finding, 
however, is that PUVA-induced senescence-like growth arrest is reversible and 
the earliest regrowth occurred at 90 days after PUVA treatment.  
 
In summary, the herein reported data indicate that the long-term growth arrest 
following a single PUVA treatment, although sharing senescent markers currently 
used for the identification of replicative cellular senescence, is not identical to 
replicative senescence since the senescence-like growth arrest is still reversible. 
The regrowth post PUVA treatment is neither due to immortalization nor to 
transformation as a result of loss-of-function of tumor-suppressor genes involved 
in cellular senescence, such as p53, p21 and p16. The onset of regrowth is also 
not due to an escape mechanism of rare non-senescence-like fibroblasts which 
received no or less damage.  
 
4.2. PUVA-induced growth arrest represents a phenocopy of senescence 
with ROS contributing to senescence-like phenotype changes 
The observation that PUVA-treated fibroblasts were growth-arrested for longer 
than 90-120 days with biomarkers widely used for the identification of premature 
senescence with final regrowth makes it mandatory for re-evaluation of 
previously reported premature senescence models. In particular it is necessary to 
reconsider whether those models for stress-induced premature senescence are 
identical to replicative senescence in terms of irreversibility or whether they 
represent rather a “stress-induced mimic” of replicative cellular senescence. 
Thus, the important question is addressed whether senescence-like mechanisms 
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could be initiated in a non-senescence state and what mechanisms are involved 
and contribute to senescence-like features. 
 
4.2.1. Senescence features in PUVA-induced long-term growth arrest are 
reversible 
Established biomarkers of replicative cellular senescence also positive in SIPS 
and other premature senescence models include terminal growth arrest (Chen 
and Ames 1994; von Zglinicki et al. 1995), enlarged cell morphology (Chen and 
Ames 1994; Dumont et al. 2000), senescence associated -galactosidase 
(Dumont et al. 2000), matrix metalloproteinase-1 (MMP-1) (reviewed in Campisi 
2001b), accelerated shortening of telomere length (von Zglinicki et al. 1995), and 
lipofuscin accumulation (von Zglinicki et al. 1995). However, as these reported 
SIPS models have only been followed for several days or longest for a few 
weeks after the SIPS-inducing challenge, it is currently not clear whether the 
senescent-like growth arrest in these models is indeed irreversible as claimed by 
the authors.  
 
Here it was found that fibroblasts, which escaped from growth arrest, had gone 
through phenotypic changes including senescent cell morphology and expression 
of SA-β-Gal. Interestingly, both senescent markers were reversible, and growth 
recovery after PUVA treatment was coupled with loss of all these senescence-
like features. Besides morphological changes and SA-β-gal expression, another 
senescence-associated marker, matrix-metalloprotease-1(MMP-1), which was 
up-regulated for up to 90-110 days after PUVA treatment, also completely 
returned back to control levels in regrowing fibroblasts. The long-term induction 
of MMP-1, particularly if unbalanced by its inhibitor TIMP-1, will contribute to the 
degradation and disorganization of extracellular matrix proteins, like interstitial 
collagens and elastin, a hallmark in aging of the connective tissue (Kligman 
1969; Scharffetter-Kochanek et al. 2000; Schwartz et al. 1993). The evident 
switch from the enlarged and SA-β-gal positive state to non-enlarged proliferating 
fibroblasts with loss of SA-β-gal as well as MMP-1 expression indicated that 
those currently accepted and used senescent markers, indeed, are not restricted 
to replicative cellular senescence.  
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4.2.2. Senescence controlling genes are up-regulated in PUVA-treated 
fibroblasts in a sequential and interrelated manner 
To understand the mechanisms underlying PUVA-induced senescence-like 
growth arrest, the question is addressed whether it shares similar control 
pathways with mechanisms involved in replicative cellular senescence. 
Increasing evidence indicates that the molecular machinery that triggers and 
maintains the growth arrest of the senescent state is critically dependent on 
p53/p21Cip1 and Rb/p16INK4a function (Shay et al. 1991b). Specifically, both 
p16INK4a and p21Cip1 have been implicated in replicative cellular senescence 
(Brown et al. 1997; Noble et al. 1996). However, the manner in which it regulates 
the senescence machinery remains poorly understood. The data herein reveal 
that several cell cycle controlling proteins were upregulated in a sequential order. 
p53 and p21Cip1 seem to be involved in the initiation of the growth arrest, while 
p16INK4a is most likely engaged in maintaining the long-term growth arrest.  
 
p53 and p21Cip1 were concomitantly up-regulated after PUVA treatment. The 
tumor suppressor p53 is known to induce growth arrest or apoptosis in response 
to genotoxic stress. p53 levels transiently increase in oxidative stress or 
oncogenic Ras-induced premature senescence (Chen et al. 1998; Dimri et al. 
2000; Serrano et al. 1997). Induction of p53 has been also observed in 
replicative senescence. p53 DNA binding and transcriptional activity were found 
to be increased several fold, although an increase in p53 protein or mRNA 
expression was not detected in replicative senescence (Atadja et al. 1995; Vaziri 
et al. 1997). In vivo, increased expression of p53 protein was observed in PUVA-
treated skin sample (Hannuksela-Svahn et al. 1999; Zhao et al. 1999). One of 
the downstream target genes of p53 is p21Cip1. p21Cip1 is an universal inhibitor of 
cyclin-dependent kinases, which can mediate both G1 and G2 arrest (Chen et al. 
1995a; Harper et al. 1993; Macip et al. 2002). The importance of p21Cip1 and p53 
in replicative senescence in vitro has been demonstrated in experiments blocking 
p21Cip1 and p53 expression in senescent cells (Bond et al. 1994; Gire and 
Wynford-Thomas 1998; Ma et al. 1999). As one of the major signal pathways 
characterized in replicative senescence, however, p53/p21Cip1 are unlikely to be 
the only pathway activated and responsible for the long-term senescence-like 
growth arrest induced by PUVA. This conclusion is related to the observation that 
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expression of p53 and p21Cip1 after initial up-regulation for 4 weeks returned to 
base levels. Thus, for maintaining the long-term growth arrest lasting for 3 
months or even longer, other pathways have to be involved. One candidate could 
be p16INK4a, which was induced 1 week after PUVA treatment and maintained a 
high expression level during the three months growth arrest stage. It has been 
postulated that high expression of p21Cip1 may be necessary for the entry into the 
arrest state, whereas p16INK4a may be responsible for the maintenance of the 
senescent cell cycle arrest (Stein et al. 1999). The herein reported data are in 
good correlation to this model and the observations of other groups (Alcorta et al. 
1996).  
 
Although the expression of p16INK4a, p21Cip1 and p53 has been investigated in 
different experimentally induced SIPS-models like 5-bromodeoxyuridine 
(Michishita et al. 1999), hydroxyurea (Yeo et al. 2000), hydrogen peroxide (Chen 
et al. 1998; Chien et al. 2000), histone deacetylase inhibitors (Ogryzko et al. 
1996) or glucose-6-phosphate dehydrogenase deficiency (Ho et al. 2000), no 
uniform model for the role of these genes in the development of SIPS has been 
defined. Furthermore, the response pattern of these genes following PUVA 
treatment has not been addressed in detail although knowledge on its function is 
of great interest for PUVA therapy because of the high incidence of skin cancer 
limited to the histogenetic compartment of epidermal cells. Therefore, we were 
interested in the role of these tumor suppressor genes in the growth arrest 
following PUVA treatment in the non transforming compartment of the dermal 
fibroblasts. Unexpectedly, PUVA-treated fibroblasts with a null-mutation in either 
of the p53, p21Cip1 or p16INK4a genes were still growth-arrested with enlarged cell 
morphology. Thus, the cell growth regulators p53, p21Cip1 and p16INK4a are not 
exclusively required for the induction of PUVA-induced senescence-like growth 
arrest and may be replaced by each other and/or additional control genes. 
Recently,  a similar response of p53, p21Cip1 and p16INK4a deficient cell lines has 
been described for the induction of stress-induced replicative senescence by 5´-
bromodeoxyuridine (Michishita et al. 1999).  
 
In summary, the data show that several cell cycle control pathways are 
sequentially activated after PUVA treatment. Up-regulation of p53/p21Cip1 
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occurred 1-2 day after PUVA and possibly played a pivotal role for initiating the 
growth arrest, while p16INK4a might be involved in maintaining the long-term 
growth arrest. The exact pathways controlling PUVA-induced long-term growth 
arrest are far from being clear, and may involve several other pathways. As a 
study focusing on the senescence-like features in the long-term growth arrest, it 
was found that both of the two known pathways involved in cellular senescence, 
namely p53/p21Cip1 and pRb/p16INK4a, are also up-regulated after PUVA 
treatment.  
 
4.2.3. PUVA treatment leads to elevated ROS production which is related to 
mitochondria and NADPH oxidase 
Many studies suggest that ROS may play a pivotal role in the induction of 
replicative cellular senescence. For example, examination of cells in culture 
suggests that “older” cells at higher CPD have higher levels of ROS than 
“younger” cells at lower CPD (Hagen et al. 1997). When cells were treated with 
antioxidants or grown in conditions of low oxygen, their life span is distinctly 
prolonged (Chen et al. 1995b; Yuan et al. 1995). Treatment of primary fibroblasts 
with a sublethal concentration of H2O2 was shown to induce a state resembling 
replicative senescence (Chen et al. 1998). Moreover, ROS were involved in the 
oncogenic Ras-induced senescence program (Lee et al. 1999). Based on the 
previous evidence linking oxidative stress to aging, in this thesis the possibility 
was explored whether PUVA treatment induces the senescence-like growth 
arrest as well as phenotypic changes by altering the intracellular levels of ROS. 
The results indicate that PUVA treatment leads to an increase in intracellular 
ROS, the source of which appears to be both mitochondria and the NADPH 
oxidase. This conclusion is based on the finding that only depletion of functional 
mitochondria in conjunction with inhibition of NADPH oxidase leads to the 
suppression of the enhanced ROS levels after PUVA treatment. 
 
Under normal conditions the main source for ROS production are mitochondria. 
Mitochondria utilize over 90% of the oxygen consumed by mammalian cells, and 
up to 4% of this oxygen is transformed into ROS. It is generally accepted that 
defects in the respiratory-chain, which is located in the mitochondrial membrane, 
results in enhanced production of ROS and other free radicals. As an index for 
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mitochondrial membrane integrity, previous studies showed that reduced 
mitochondrial membrane potential (∆Ψ) led to increased generation of ROS 
(Zamzami et al. 1995). In line with this, our data show that ∆Ψ is significantly 
decreased 2 weeks after PUVA treatment and further decreased at later time 
points post PUVA treatment.   
 
Since ATP production is driven by ∆Ψ, lower ∆Ψ should lead to lower ATP 
production. However, this is not the case in PUVA-treated fibroblasts. With a 
decreasing ∆Ψ value, the ATP level of the PUVA-treated cells remained constant. 
Therefore, there must be an alternative mechanism to circumvent the energy loss. 
Interestingly, mitochondria still proliferate although cell proliferation is stopped 
after PUVA treatment. Thus the seemingly paradox results between constant 
ATP generation and a decrease in ∆Ψm may be explained by enhanced 
mitochondria proliferation. This means that proliferation of mitochondria may 
function as a compensatory response to restore an adequate mitochondrial 
function for ATP production. Since ∆Ψ decreased time-dependently after PUVA 
treatment, it is most likely though speculative that newly produced mitochondria 
at least in part still have defects in their electron chain, which would lead to more 
ROS production. In fact, an increase in intracellular ROS was observed time-
dependently after PUVA treatment. Alternatively, the following scenario may be 
responsible for the enhanced ROS generation: initially enhanced ROS levels or 
mitochondrial DNA damage contributes to the further mitochondrial damage and 
ROS leakage. The mitochondrial biogenesis occurring in parallel may finally 
overcome the number of severely damaged ROS-overproducing fibroblasts. 
According to this explanation ∆Ψ should be restored gradually to normal or 
almost normal levels at the time point when cells start to regrow. However, this 
has not been observed, as the ∆Ψ of PUVA-treated fibroblasts was not increased 
at 11 weeks post PUVA treatment compared to PUVA-treated fibroblasts 
analyzed 16 days and 4 weeks after PUVA treatment. One explanation could be 
that PUVA-induced damages and the subsequent repair in fibroblasts are 
heterogeneous. Thus, the determination of ∆Ψ value might be overwhelmed by 
those heavily damaged fibroblasts, though a subpopulation of fibroblasts already 
gained a high ratio of healthy mitochondria to damaged mitochondria. At least 
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regrowing fibroblasts revealed the same ∆Ψ value as mock-treated control 
fibroblasts.   
 
The molecular mechanisms involved in the control of mitochondria biogenesis 
are still poorly understood. It is a complex process that involves proliferation 
(increasing the number of mitochondria) and differentiation or maturation 
(increasing the activity of individual mitochondria) (Fernandez-Moreno et al. 
2000). Mitochondria biogenesis is controlled both by the nucleus genome and the 
mitochondria genome (Attardi and Schatz 1988). Thus, the integrity of both 
mtDNA and the genomic DNA encoding mitochondrial components are critical for 
cellular energy generation and maintenance of functional mitochondria. Due to 
effects of PUVA in generating DNA monoadducts or interstrand crosslinks, both 
genomic DNA and mtDNA are preferred targets. In addition, mitochondria are not 
equipped with a similarly efficient repair system like that in the nucleus, and DNA 
interstrand crosslinks in mitochondria are most likely maintained and not repaired 
(Cullinane and Bohr 1998). Thus, even though fibroblasts contain hundreds of 
mitochondria and each mitochondrion contains several copies of mtDNA, this 
might not be enough to guarantee that all the newly replicated mtDNA is identical 
and has no mutations or deletions. If new mitochondria have defects in the 
mtDNA, the enhanced ROS production will be hardly prevented. 
 
However, PUVA-induced ROS production was definitely not solely due to the 
uncontrolled ROS leakage from the defective mitochondria electron chain. In fact 
mitochondria depleted Rho0 fibroblasts still revealed enhanced ROS production 
after PUVA treatment, which may be related to NADPH oxidase. At least, Rho0 
fibroblasts in conjunction with inhibition of the NADPH oxidase reveal a complete 
abrogation of enhanced ROS generation 3 and 6 weeks after PUVA treatment. It 
is currently not clarified why mitochondria depletion or NADPH oxidase inhibition 
alone does not show any decrease in ROS levels after PUVA treatment. The 
herein reported data would be compatible with a concept that NADPH oxidase 
compensates for a lack of mitochondrial ROS production in Rho0 fibroblasts. In 
fact, preliminary data suggest that the expression of the fibroblast-related 
NADPH oxidase is enhanced in Rho0 PUVA-treated fibroblasts (data not shown). 
Although NADPH oxidase is classically regarded as a key enzyme of neutrophils, 
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where it is involved in the production of reactive oxygen species in defense 
against infections, recent studies demonstrate that virtually all eukaryotic cell 
types have a similar oxidase system. NADPH oxidase is a membrane associated 
multisubunit enzyme consisting of a plasma membrane-associated 
flavohemoprotein complex which comprises two subunits, gp91phox and 
p22phox, and several cytosolic components including p40phox, p47phox, 
p67phox, and the small GTPase Rac. Since functional assembly of NADPH 
oxidase requires translocation of those cytosolic proteins into the membrane, 
ROS production via NADPH oxidase in PUVA-treated Rho0 fibroblasts suggests 
that it may play an important physiological role instead of acting only as 
damaging reagents. 
 
The physiological role of NADPH oxidase related ROS production in non-
phagocytic cells is currently unclear. Previous studies have established an 
important role for ROS in cell proliferation and activation of growth-related 
signaling pathways. For example, ROS have been implicated in the mitogenic 
response to platelet-derived growth factor (PDGF) (Sundaresan et al. 1995), 
phenylephrine (Nishio and Watanabe 1997), thrombin (Patterson et al. 1999) and 
epidermal growth factor (EGF) (Bae et al. 1997). Moreover, the addition of 
exogenous ROS to vascular smooth muscle cells was reported to induce cell 
proliferation, while suppression of ROS resulted in increased apoptosis (Baas 
and Berk 1995; Brown et al. 1999; Tsai et al. 1996). There is also growing 
evidence that increased ROS production is functionally associated with the 
regulation of gene expression and the activation of many transcription factors, 
such as NFκB (Cominacini et al. 2000; Sulciner et al. 1996). Increased activation 
of NFκB, in turn, has been reported to increase cell survival (Baichwal and 
Baeuerle 1997). Interestingly, it was lately found that increased ROS production 
induced by oncogenic H-Ras could enhance the DNA repair capacity via the 
Ras/PI3K/Rac1/NADPH oxidase-dependent pathway (Cho et al. 2002). This 
finding provides first evidence that ROS, which are generally accepted as DNA 
damaging reagents, on the other hand also facilitate DNA repair. As promoters of 
many DNA repair genes contain redox sensitive transcription factor-binding sites, 
involvement of ROS in the regulation of DNA repair activity might occur through 
the activation of redox-sensitive transcription factors (Cho et al. 2002). PUVA 
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treatment also leads to various DNA damages, however, so far it is not clear 
whether NADPH oxidase related ROS production also plays a role for facilitating 
DNA repair.   
 
Two key studies demonstrated that overexpression of NADPH oxidase in NIH 
3T3 cells leads to a proliferative phenotype (Irani et al. 1997; Suh et al. 1999). 
Interestingly, overexpression of Renox, an NADPH oxidase in kidney, in the 
same cell line was also found to lead to senescence (Geiszt et al. 2000). The 
latter finding may reflect a similar function of NADPH oxidase activation after 
exposure of fibroblasts to PUVA treatment. So far we have little knowledge on 
NADPH oxidase activation in PUVA-treated fibroblasts. It is unclear how the 
NADPH oxidase is activated. In addition, its exact role in PUVA-induced 
senescence-like growth arrest, and whether it drives cells at risk for 
tumorigenesis, remains poorly understood. To address these questions will be an 
interesting challenge for further studies.  
 
4.2.4. Enhanced ROS concentration of reactive oxygen species is 
responsible for the enlarged morphology of fibroblasts but not for the 
enhanced expression of SA-β-galactosidase after PUVA treatment 
Based on the previous evidence linking oxidants to cellular senescence and 
aging, the possibility was explored in this study of whether the PUVA-induced 
senescence-like phenotypic changes may be causally related to the enhanced 
ROS levels in fibroblasts after PUVA treatment. The herein reported results 
suggest that PUVA-induced high ROS level is essential for the senescence-like 
phenotypic changes after PUVA treatment. In fact, PUVA-treated fibroblasts 
grown in the presence of the ROS-scavenging antioxidant N-acetyl cystein (NAC) 
are rescued from the PUVA-induced cytoplasmic enlargement. However, the 
long-term growth arrest after PUVA treatment was not affected. Reduced ROS 
level in the presence of NAC did not result in earlier regrowth after PUVA 
treatment. So far little is known which signal pathways ROS are engaged to 
change cell morphology. Possibly, it is due to its active role on cell proliferation 
and activation of growth-related signaling pathways such as mitogen-activated 
protein kinase (MAPK) and AKT pathways. In this regard, cell enlargement might 
also be related to the increasing number in mitochondria found after PUVA 
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treatment, as mitochondria proliferate in response to new metabolic requirements 
by the regulation of ATP levels or lipid metabolism. In fact, mitochondrial DNA 
depleted Rho0 fibroblasts show an elongated small phenotype and not the 
flattened, enlarged cell morphology post PUVA treatment (data not shown). In 
contrast to the active role of ROS in morphological changes of fibroblasts, 
scavenging ROS by NAC did not lead to any effect on the senescence-
associated β-galactosidase. This either suggests that SA-β-galactosidase is not 
downstream of ROS, or alternatively, that low levels of ROS maintained in NAC-
treated PUVA-fibroblasts are already sufficient to up-regulate SA-β-galactosidase.  
 
The PUVA-induced changes are a model particularly suited to study mechanisms 
of stress-induced premature senescence. Further investigations into the 
downstream signaling molecules following PUVA-induced ROS production and 
its linkage to the senescent phenotypic changes might provide important insights 
for senescence as well as new therapeutic strategies to combat aging. 
 
4.3. PUVA treatment of human dermal fibroblasts leads to an early onset of 
replicative senescence related to oxidative telomere shortening 
PUVA-treated fibroblasts, although escaping from the long-term growth arrest, 
seem to retain memory of the damaging PUVA effects. PUVA-treated fibroblasts 
cultured in their regrowing state reach the stationary phase at a much lower 
overall cumulative population doubling compared to mock-treated control 
fibroblasts. These data support the view that preceding damage affects a 
counting mechanism contributing to the overall limited proliferation potential of 
PUVA-treated fibroblasts.  
 
Telomere shortening is thought to serve as a “replicometer” (counting the finite 
number of cell divisions) and as a trigger of replicative senescence (Harley et al. 
1990; Harley and Villeponteau 1995). In the absence of telomerase, human 
telomeres shorten by 30-200 bp per population doubling (PD) (Harley et al. 
1990). After 50-100 PD, this process depletes the telomere reserve of primary 
human cells and results in replicative senescence. Therefore, in this thesis it was 
studied whether the reduced life-span is related to telomere length, which in 
addition to the end-replication problem is eroded by PUVA-induced telomere 
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damage. Onset of replicative senescence in vitro is mainly dependent on 
telomere length. Therefore, it is predicted that telomere shortening occurring in 
addition to the regular DNA replication will drive fibroblasts into senescence at a 
lower CPD. The results, indeed, indicate that ROS-induced telomere shortening 
represents the alternative mechanism responsible for the additional telomere 
shortening in PUVA-treated fibroblasts. Although the telomere length in PUVA-
treated fibroblasts seems to be constant during the growth arrest stage, a 
significant reduction in telomere length (~1-1.5 kb) is found in regrowing 
fibroblasts post PUVA treatment compared to mock-treated fibroblasts at exactly 
the same CPD. Clearly, this substantial difference is generated at the very 
beginning of regrowth, while thereafter regrowing fibroblasts showed a similar 
shortening rate in telomere length comparable to mock-treated control 
fibroblasts. After 2 weeks from the emergence of growth foci until newly growing 
fibroblasts reached confluence, and thereafter at different CPDs, genomic DNA 
for telomere length determination was collected. The question of how a more 
than 1-1.5 kb telomere reduction could occur within 1-2 weeks after regrowth of 
PUVA-treated fibroblasts was addressed. Under standard culture conditions, 
human dermal fibroblasts could divide at most 7-9 PD in 2 weeks, and the 
telomere reduction, thus, should be less than 500 bp. This is shown in Figure 29, 
where regrowing fibroblasts from CPD 20.9 to CPD 28.4 results in a small 
telomere decrease of <500 bp. Accordingly, the end-replication problem is 
apparently not sufficient to fully explain this reduction. No telomere length 
changes occurred during the growth arrest stage of fibroblasts after PUVA 
treatment, but definitely are observed after regrowth of fibroblasts within the first 
cycles of DNA replication. Thus, it is possible that single strand breaks were 
generated in the telomere region during the growth arrest stage which, if not 
repaired, might lead to telomere loss during DNA replication when separation of 
DNA double-strands occurred, as has previously been suggested in an other 
SIPS model (von Zglinicki et al. 2000). In addition, telomeres have long single-
stranded 3’ overhangs at both ends with an average of 130-210 bases being 
essential for the stabilization of the “telomeric t-loop” (Blackburn 2000; Campisi et 
al. 2001). It was suggested to be generated due to the end replication problem 
and possibly to the action of a C-strand-specific exonuclease, with a 5’ – 3’ 
exonuclease, which specifically trims back the completely synthesized telomere 
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ends to form a 3’ overhangs for the T-loop formation  (Makarov et al. 1997). 
Single strand breaks in this overhang and subsequent loss during DNA double 
strand separation and replication most likely drive telomere length reduction.  
Here it is reported that single strand breaks are formed and accumulate in the 
telomere region with time after PUVA treatment as determined by denaturing gel 
electrophoresis (Figure 30). A clear pattern of telomere reduction could be 
observed in denatured telomeres which gave strong support for the hypothesis 
that single strand breaks contribute to telomere reduction. Although the length of 
double-stranded telomeres is constant during the whole growth arrest period 
after PUVA treatment, the length of single stranded telomeres at 11 weeks post 
PUVA treatment is nearly identical to that of regrowing fibroblasts. This finding 
may indicate that separation of telomere double strands of growth-arrested 
fibroblasts results in telomere fragment loss. Thus, the two steps leading to 
telomere shortening, such as single strand breaks and telomere fragments loss, 
occur at different time post PUVA treatment. Single strand breaks are generated 
during the growth arrest stage, while telomere fragment loss most likely occurs 
during DNA replication and cell proliferation. Increased shortening of single-
stranded telomere during the growth arrest stage, in addition, indicates that 
single strand breaks in this region are not efficiently repaired. The reason and 
underlying mechanism of a potential telomeric DNA repair deficiency is not 
understood. Nevertheless, this finding might have far-reaching consequences. 
Accumulation of DNA damage and the inability of efficient DNA repair have been 
suggested as a causal factor in aging (Chen et al. 1995b; de Boer et al. 2002). 
As telomeres serve as a biological clock for cellular senescence, the herein 
reported data that single strand breaks of telomere are not repaired not only 
provide a reasonable explanation for accelerated telomeres shortening after 
PUVA treatment, but also imply a rationale for understanding DNA damage 
related cellular senescence and aging processes. 
 
There is increasing evidence suggesting that oxidative stress is causally involved 
in telomere erosion (Proctor and Kirkwood 2002; von Zglinicki 2000, 2002). 
Reduction in telomere length occurs five to ten times faster in fibroblasts 
subjected to chronic hyperoxia, a rather mild oxidative stress compared to mock-
treated fibroblasts (Vaziri et al. 1997; von Zglinicki et al. 1995). On the other 
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hand, the rate of telomere loss decreases by half if human dermal fibroblasts are 
treated with the spin trap α-phenyl-t-butyl-nitrone (PBN), a potent free radical 
scavenger (von Zglinicki et al. 2000). These data indicate that telomere 
shortening could be the result of oxidative stress. However, it has also been 
suggested that the accelerated telomere shortening under oxidative stress 
observed in the above reports might be an artifact resulting from the increased 
replicative demand on a subpopulation when a significant proportion of the cells 
are forced to drop out of the cell cycle by stress (Dumont et al. 2001; von 
Zglinicki 2002). In other words, if only a subpopulation of cells starts to regrow 
after PUVA treatment, while a significant proportion of the cells are still growth-
arrested, the small population of regrowing fibroblasts will have to divide many 
times until confluences with subsequent accelerated telomere shortening 
(Dumont et al. 2001). So far, there is no agreement on whether telomere 
shortening occurs due to oxidative damage or to proliferation of a small 
subpopulation after stress-induced premature senescence. PUVA treatment 
leads to a dramatic increase in ROS production during the growth arrest stage, 
as well as a significant telomere reduction in regrowing fibroblasts thereafter. In 
addition, scavenging ROS by N-acetyl cystein (NAC) could prevent telomere 
erosion and replicative senescence occurs at a later CPD in fibroblasts after 
PUVA treatment compared to simply PUVA-treated fibroblasts. In addition, 
compared to other SIPS-models with low concentrations of peroxide and its 
derivatives, where growth arrest was investigated only for several days or at 
most weeks, our long-term growth arrest model induced by PUVA has the 
definite advantage that its long-lasting oxidative stress results in a subsequent 
clearly visible loss of telomere length.  
 
Several lines of evidence support the notion that oxidative stress plays an 
important role in the accelerated decrease of telomere length in PUVA-treated 
fibroblasts. First, based on a simple mathematical analysis of the data, it can be 
shown that the significant telomere reduction following PUVA treatment can not 
be solely be explained by the fact that it is due to the repetitive division of a 
subpopulation of fibroblasts as has been explained above (Name it S-hypothesis 
for brief; “S” stands for subpopulation). Second, treatment with NAC, an 
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antioxidant, during the growth arrest period protected fibroblasts from telomere 
reduction as mentioned above. 
 
In the PUVA-induced growth arrest and regrowth model, the S-hypothesis could 
be mathematically described as follows. In the CPD calculation, it is proposed 
that regrowing fibroblasts derive from the total fibroblast population (2×105 cells) 
of growth-arrested fibroblasts instead of a subpopulation: 
 
 
 
Cr : CPD of growth resuming fibroblasts when reaching confluence in the dish. 
C0 : CPD of fibroblasts before PUVA treatment. 
 
However, the CPD calculated here might be not the real CPD of regrowing 
fibroblasts, since it may be that only a subpopulation of fibroblasts starts to 
proliferate, while others are still growth-arrested.  
 
To obtain the real CPD, it is mandatory to know the exact number of fibroblasts, 
which escaped from the growth arrest. However, this is difficult to determine. 
When considering the extreme case that only one fibroblast out of the 2×105 
growth-arrested fibroblasts escapes from growth arrest and finally divides 
multiple times so that it is responsible for the occurring confluence (~106 cells), 
the following equation would result:  
 
 
 
 
 
 
1 fibroblast  - ------- divide N times (N = PD) ---------- 106 fibroblasts (confluence in dish) 
N could be calculated by the equation: 1 × 2N = 106 
N = Log 106 / Log2 ≈ 20 (PD) 
Thus, Cr = C0 +20 (PD) 
2×105 fibroblasts ---------- divide N times (N = PD) ---------- 106 fibroblasts (confluence in 
dish) 
N could be calculated by the equation: (2×105) × 2N = 106 
N = Log [106 / (2×105)] / Log2 ≈ 2.3 (PD) 
Thus, C  = C  +2.3 (PD) 
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As shown by the BrdU incorporation experiments the number of regrowing 
fibroblasts is definitely more than one and less than the total seeded fibroblast 
number within the dish. Accordingly, the real CPD of regrowing fibroblasts should 
fit into the following equation: 
 
 
Based on the assumption that no other factors than CPD contribute to telomere 
length, then the telomere length of regrowing fibroblasts should be: 
 
 
 
Tr (Cr): telomere length of regrowing fibroblasts, CPD = Cr. 
Tn (C0 + x): telomere length of mock-treated control fibroblasts, CPD = (C0 +x). 
 
According to the above equation, in any case the telomere length of regrowing 
fibroblasts at a certain CPD should be at least higher than that of mock-treated 
control fibroblasts at a CPD of 20 more in numerical value (Tn (C0 +20) ≤ Tr (Cr)). 
By contrast, as shown in Figure 29, the telomere length of regrowing fibroblasts 
with a CPD of 20.9 is still shorter than that of mock-treated control fibroblasts 
with a CPD of 41. Thus, the observed increase in telomere shortening rates after 
PUVA treatment is too large to be explained by the S-Hypothesis, suggesting 
other factors contributing to telomere reduction. 
 
In this thesis ROS have been identified as a major factor responsible for telomere 
shortening. NAC incubation during the growth arrest stage significantly protects 
PUVA-treated fibroblasts from telomere reduction (Figure 31). Thus, it is clear 
that the significant reduced telomere length of fibroblasts after PUVA treatment is 
at least in part related to the high level of ROS production. These data are in line 
with previous findings from the von Zglinicki’s group and confirm the idea that 
oxidative stress is an important determinant for telomere length (Saretzki and von 
Zglinicki 2002; von Zglinicki 2002). In addition, it is of clinical importance to know 
whether PUVA leads to significant ROS production and has profound effects on 
telomere length, since PUVA therapy is widely used for many skin disorders.  
C0 +2.3 ≤ Cr ≤ C0 +20 
Tn (C0 +20) ≤ Tr (Cr) ≤ Tn (C0 +2.3) 
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However, the data stem from in vitro experiments. Therefore, it has to be proven 
that the in vitro data hold true for the in vivo situations as well. Thus, increasing 
the antioxidative defense capacity in patients during and after PUVA treatment by 
antioxidants or other means possibly could be of advantage for patients to 
prevent premature aging, a major side effect of long-term PUVA treatment. 
 
So far it is hard to say whether the reduced total life span of PUVA-treated 
fibroblasts is exclusively controlled by oxidative telomere reduction. Although 
NAC treatment evidently reversed telomere reduction in PUVA-treated 
fibroblasts, the total life span is only in part restored (Figure 32).  Nevertheless, 
the fact that NAC-treated fibroblasts with a longer telomere length partly 
recovered their total life-span implies that oxidative telomere erosion plays a 
central role for the reduced life-span of PUVA-treated fibroblasts.  
 
Recently, it has been demonstrated that replicative cellular senescence in culture 
is not only induced by an intrinsic cell division counter mechanism (replicative 
senescence), but can also be induced by extrinsic factors such as culture 
conditions (premature senescence). Epithelial cells, for instance, seem to 
experience a telomere length-independent senescent cell cycle block via the pRb 
pathway (Kiyono et al. 1998). In this context the question was addressed whether 
an alternative pathway – in addition to telomere shortening – is activated and 
contributes to the early onset of senescence in regrowing fibroblasts after PUVA 
treatment.  
 
p53/p21Cip1 and/or p16INK4A/Rb are the two main pathways known to be involved 
in replicative senescence. Replicative senescence of human cells can be 
abrogated by suppression of both pathways. For instance, suppression of these 
pathways by SV40 large T antigen or the human papillomavirus E6 and E7 
oncogenes can fully suppress replicative senescence, leading to a cell population 
with an extended lifespan (Counter et al. 1992; Shay et al. 1991a). 
 
Herein it is shown that during PUVA-induced growth arrest, both p53/p21Cip1 and 
p16INK4A/pRb are up-regulated. Although p53 and p21Cip1 expression returned to 
the control level after fibroblasts regrow, p16INK4a is still expressed at a low while 
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up-regulated level. However, it is not clear whether p16INK4a is induced in 
response to short telomeres or rather serves as an alternative mechanism 
contributing to the early onset of senescence. Although it is widely assumed that 
critically shortened telomere ends can initiate a signaling cascade that eventually 
results in the upregulation of p21Cip1 and/or p16INK4a, it has also been shown that 
aging-related p16INK4a up-regulation could be induced under suboptimal culture 
conditions independent of telomere dynamics (Dickson et al. 2000; Kiyono et al. 
1998; Munro et al. 2001). In addition, introduction of hTERT into pre-senescent 
fibroblasts blocked the upregulation of p21Cip1 (Modestou et al. 2001) but the high 
level of p16INK4a was not reduced. Although a study from the Wright and Shay 
laboratory (Ramirez et al. 2001) found that p16INK4a was not induced and 
telomerase-mediated telomere maintenance is sufficient to generate cells with 
infinite replicative potential under optimal cell culture conditions. Nevertheless, 
these results suggest that p16INK4a can be induced both by certain culture 
conditions or other kinds of stresses as well as telomere shortening. 
Maintenance of up-regulated p16INK4a levels in regrowing fibroblasts after PUVA 
treatment definitely is not due to insufficient culture conditions since mock-treated 
control fibroblasts under the same conditions do not reveal enhanced p16INK4a 
expression. Thus, enhanced p16INK4a expression might be due to PUVA-induced 
damage or the high ROS production. However, it is unclear why p16INK4a level is 
maintained in the regrowing phase. 
 
In summary, replicative senescence in vitro is a complex and heterogeneous 
process. It may be dependent on the telomeric ‘clock’, the chronic exposure to 
various types of stresses, or a combination of both. The molecular pathways of 
senescence have begun to be unraveled, and their further characterization will 
undoubtedly provide a more complete picture. Using the PUVA-induced 
premature senescence as a model for stress-induced premature senescence, in 
this thesis the underlying mechanisms of the early onset of replicative 
senescence have been studied. Our data support the idea that telomere length is 
not only dependent on cell proliferation, but also on oxidative stress from 
endogenous origin which is undoubtedly involved and contributes to accelerated 
telomere reduction. In addition, maintenance of up-regulated p16INK4a expression 
might be an additional mechanism contributing to early onset of senescence. 
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However, a causal relationship cannot be concluded from the present data. The 
data might have profound clinical implications. They are the first data showing 
that PUVA treatment leads to early onset of senescence, which is related to 
oxidative telomere reduction and possibly to p16INK4a activation. In the clinical 
situation, senescence appears to be a relevant factor in determining treatment 
outcome and warrants further investigation, especially for PUVA and other kinds 
of chemotherapies, which induce DNA or other cellular damages. It is extremely 
important to investigate the cellular response after treatment, i.e., apoptosis or 
senescence. Such information could be of great value in choosing an appropriate 
photo-chemotherapeutic strategy and may explain some of the controversy 
concerning the clinical use of chemotherapies. 
 
4.4. Initiation of the long-term growth arrest 
The efficacy of PUVA treatment on many skin diseases is believed to be related 
to its proliferation inhibiting effects. However, the mechanism of how PUVA 
treatment initiates growth arrest in many different cell types is not completely 
understood. Since psoralens are known to intercalate within DNA in a dark 
reaction and form mono- and bifunctional adducts with pyrimidine bases following 
UVA irradiation (Song and Tapley 1979), it has been proposed that psoralen-
DNA interstrand crosslinks are responsible for the proliferation inhibition as it 
blocks DNA replication (Tokura et al. 1991). However, this is still rather 
speculative and lacks substantial evidence that, apart from crosslink formation 
other mechanisms are not involved. The results here indicate that PUVA-induced 
long-term growth arrest is unlikely to be due to psoralen-DNA interstrand 
crosslinks, at least under the conditions, which have been used for PUVA 
treatment. It is herein found that fibroblasts with more interstrand crosslinks 
(ICLs) were not necessarily growth-arrested as is the case for PUVA-treated 
fibroblasts where 8-MOP was present only during the pre-incubation step (8-
MOP-PRE), while cells with less ICLs could be growth-arrested as is the case for 
PUVA-treated fibroblasts without the 8-MOP pre-incubation step (8-MOP-UV).   
 
Herein it was therefore studied which additional factors are responsible for the 
long-term growth arrest. We first proposed that it might be due to PUVA-induced 
damage of cellular membrane or other cytoplasmic components. In fact, different 
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cellular components including DNA, proteins and lipids have been shown to be 
photo-modified by 8-MOP (Schmitt et al. 1995). Fractionated cellular components 
of the rat epidermis after treatment with 8-MOP and UVA showed that only 17% 
of the 8-MOP was bound to DNA, while 57% was bound to protein and 26% to 
lipids (Beijersbergen van Henegouwen et al. 1989). In addition, it was reported 
that a cell membrane receptor represent also a major target for psoralens (Laskin 
and Lee 1991; Yurkow and Laskin 1987). In this thesis by separation of the 
nuclei and cytoplasts of PUVA-treated fibroblasts and reconstructing new cell-
hybrids, which have either undamaged cytoplasts or undamaged nuclei, it was 
studied whether PUVA-induced changes in the cytoplast and/or nucleus play a 
key role for the initiation of the growth arrest. The results suggest that combined 
8-MOP and UVA irradiation leads to changes both in cytoplasts and nuclei. 
Reconstructed cells with PUVA-cytoplasts, although initially growth-arrested, 
revealed an overall shorter growth arrest. Compared to simply PUVA-treated 
fibroblasts with a growth arrest stage longer than three months, fusions of PUVA-
cytoplasts with mock-treated nuclei reveal growth arrest for only 20-26 days 
(PUVA-2w) and 8-12 days (PUVA-4w) after fusion, respectively. These data 
indicate that the damages or changes in cytoplasts induced by PUVA treatment 
could be repaired in a relatively short phase of 5-6 weeks. Unfortunately, fusions 
of PUVA-treated nuclei with mock-treated control cytoplasts reveal growth arrest 
for two weeks and thereafter all hybrids die. Thus, the experiments do not allow 
to fully estimating the overall contribution of PUVA-induced damages in 
karyoplasts. However, it is nevertheless highly interesting that PUVA-induced 
damages in the cytoplasts are able to initiate and maintain the growth arrest for 
26 days. The underlying mechanism is unknown. 
 
As discussed above, psoralen-DNA crosslinks, although formed after PUVA 
treatment, do not appear to be the key player responsible for the long-term 
growth arrest. However, this does not necessarily mean that other kinds of DNA 
damages were not involved and responsible for the growth arrest. Psoralens are 
multifunctional agents, forming two types of monoadducts and a diadduct (or 
crosslink) (Song and Tapley 1979). Although the number of interstrand crosslinks 
is obviously lower in PUVA-treated fibroblasts without pre-incubation of 8-MOP 
(8-MOP-UV) compared to PUVA-treated fibroblasts with pre-incubation where 8-
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MOP was not present during UVA irradiation (8-MOP-PRE), there is no evidence 
that DNA monoadducts were also lower in 8-MOP-UV fibroblasts. As to the two 
different procedures of PUVA treatment which generate different numbers of 
interstrand crosslinks, it is possible that 8-MOP-UV induces more psoralen-DNA 
monoadducts although treatment with 8-MOP is transitory compared with 8-
MOP-PRE. ICL formation is a three-step process (Figure 37) with 1) intercalation 
between DNA base pairs and formation of weak bands with the pyrimidine bases, 
2) the first four-center photocycloaddition reaction to form either of two 
cyclobutyltype monoadducts, 3,4-monoadduct or 4’,5’-monoadduct, 3) with 
absorption of a second UVA photon by the 4’,5’-monoadduct leads to a second 
four-center photocycloaddition at the pyrone end of the molecule and subsequent 
formation of a crosslink (Gasparro 1988). Although photoreaction is a fast step, 
intercalating into DNA double strand at sites suitable for crosslink formation (with 
adjacent pyrimidines in opposite strands) may not be as fast. Therefore, it is 
highly questionable whether within three minutes 8-MOP-UV could have enough 
time for intercalating into the right DNA sites. On the other hand, as can be seen 
from Figure 37, weak bonds formed between DNA and psoralen after 
intercalation occur in a dark reaction. Once psoralen has intercalated into a DNA 
double strand, it may not be easy to be washed out. For 8-MOP-PRE fibroblasts, 
although free 8-MOP was likely to be washed away shortly before/during the 3-
minute irradiation, intercalated 8-MOP is unlikely to be washed away, and these 
8-MOPs may be responsible for the total ICL formation.  
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Figure 37. Psoralen-DNA mono- or bi-adduct formation. Psoralens react with 
DNA in three steps. First the psoralen intercalates into the DNA double strand in 
the absence of UV radiation and form weak bonds with pyrimidine bases. Upon 
UV irradiation, cyclobutane monoadducts with a pyrimidine base are formed. If 
the initial photoreaction occurs at a 5’-TpA site, the 4’5’-monoadducts can absorb 
a second photon and undergo another cyclobutyl reaction with the adjacent 
thymine at the opposite strand resulting in the formation of a bi-adduct (psoralen-
DNA crosslink). 
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In fact, the question of which adduct(s) is (are) responsible for various biological 
effects of PUVA is an active field of investigation. Cross-link formation appears to 
be a relatively low yield reaction compared to monoadducts. Hyodo et al. showed 
that mouse FM3A cells treated with 8-MOP and UVA contained ~ 2 cross-links 
per 1 million base pairs (Hyodo et al. 1982). Under similar conditions, however, 
human lymphocytes were shown to contain 120 adducts per 1 million base pairs 
(Gasparro et al. 1985). Thus, only a small fraction of all adducts appears to be 
crosslinks. We have no direct evidence that more monoadducts were formed in 
8-MOP-UV cells. However, the total photoadducts could be calculated according 
to previously published data. It has been determined previously that photoadduct 
formation in 8-MOP/UVA-treated cells (human and murine) is independent of cell 
type. The number of photoadducts formed can be directly related to the 
combined dose of 8-MOP and UVA (Gasparro et al. 1997), which is a linear 
correlation between photoadduct number and the product of 8-MOP 
concentration in ng/ml and the UVA dose in J/cm2 (8-MOP concentrations over 
the range 10 – 20000 ng/ml and UVA dose over the range 1-10 J/cm2). There are 
about 4 adducts per million base pairs when the product of 8-MOP and UVA is 
100. Therefore, the photoadducts formed in the herein PUVA-treated fibroblasts 
system are about 18 adducts per million base pairs. 
 
In summary, our data suggest that PUVA-induced long-term growth arrest was 
not mainly related to psoralen-DNA interstrand crosslinks. While nuclei seem still 
the primary target, PUVA also induces changes in the cytoplast region, repair of 
which need about 5-6 weeks, which finally contribute to the initiation and initial 
maintenance of growth arrest.  
 
5 Perspectives 
The herein presented data indicate that PUVA-induced senescence-like growth 
arrest is reversible in a large proportion of cells. The finally returning growth 
capacity is not due to immortalization, transformation or loss of function of the 
senescence controlling genes p53, p21 and p16. These findings strengthen the 
view that PUVA-induced changes do not fully reflect replicative senescence, but 
rather represent a long-term transient phenocopy of senescence. PUVA 
treatment leads to enhanced ROS production which contributes to the 
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senescent-like phenotypes. Elevated ROS production seems related to both 
mitochondrial dysfunction and NADPH oxidase activation. PUVA-treated 
fibroblasts cultured in their regrowing state reach the stationary phase at a much 
lower overall cumulative population doubling compared to mock-treated control 
fibroblasts. The reduced total life-span in PUVA-treated fibroblasts is due to 
oxidative stress-induced telomere reduction as the abrogation of ROS production 
by the antioxidant NAC rescues telomere length reduction and partly restored 
total life-span of PUVA-treated fibroblasts. These data support the view that 
preceding damage affects a counting mechanism contributing to the overall 
limited proliferation potential of PUVA-treated fibroblasts.  
 
The model reported here is particularly suited to elucidate mechanisms 
underlying long-term senescence-like growth arrest, the related functional 
changes, and the release of cells thereof. In general, the following directions 
might be of interest for further studies: 
− The characterization of the molecular mechanisms of enhanced ROS 
production as well as their active role involved in the long-term growth arrest 
which is largely unknown. The activation of NADPH oxidase after PUVA 
treatment might provide a hint on the signal pathways involved and should be 
further studied. 
−  As a main source of ROS production, the role of mitochondria deserves 
further investigation. It has already been shown that the number of 
mitochondria increased after PUVA treatment. Thus, it would be interesting to 
know what mechanisms are underlying the biogenesis of mitochondria, the 
role of mitochondria in PUVA-induced growth arrest, as well as the 
relationship between mitochondria and the senescent phenotype. 
− As to the mechanism on how PUVA treatment leads the long-term growth 
arrest, the herein reported data suggest that the formation of psoralen DNA 
interstrand crosslinks seems not to be the main reason. However, whether it 
is due to psoralen-DNA monoadducts or damages of other cellular 
components is so far unknown, and might be of interest for further 
investigation. 
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Answers to these questions will provide further insight into molecular 
mechanisms of stress-induced premature senescence and replicative 
senescence of fibroblasts in vitro which may have relevance for fibroblasts within 
the dermis in vivo. Definition of distinct molecular pathways may allow specific 
targeting for novel preventive and therapeutic strategies. 
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Summary 
Following psoralen photoactivation (PUVA) human dermal fibroblasts undergo 
long-term growth arrest as well as morphological and functional changes 
reminiscent of cellular senescence. In the absence of molecular data what 
constitutes normal senescence, it has been difficult to decide whether these 
PUVA-induced changes reflect cellular senescence or rather a mimic thereof. By 
contrast to replicative senescence, PUVA-induced growth arrest was reversible. 
Ninety to 120 days post PUVA treatment, cells start to regrow. As cellular 
senescence has been proposed to serve as a barrier for tumorigenesis, the 
escape from senescence was studied in regard to immortalization and 
transformation. Regrowing fibroblasts did not show telomerase activity which is 
a main way to ensure immortalization. Anchorage-independent growth, a 
hallmark of transformation, was not detected. In addition, the senescence control 
genes p53, p16 and p21 did not show obvious mutations. Together with the 
observation that regrowing fibroblasts underwent replicative senescence, these 
results indicate that regrowing fibroblasts were neither immortalized nor 
transformed. 
PUVA-induced senescence features were reversible. Enlarged cell morphology, 
expression of senescence-associated (SA) β-galactosidase and matrix-
metalloprotease-1 were lost when fibroblasts resumed growth. Senescence 
control genes p53 and p21 were maintained for 1 month, whereas upregulation 
of p16 was maintained during the whole growth arrest. ROS levels were elevated 
increasingly after PUVA treatment with a maximum of 20-fold at six weeks post 
PUVA, which is both due to mitochondria and NADPH oxidase. Scavenging of 
ROS by the antioxidant N-acetyl cystein (NAC) prevented PUVA-treated 
fibroblasts from cytoplasmic enlargement but not from SA-β-galactosidase 
expression suggesting a role of ROS in the induction of phenotypical but not of 
functional senescent changes. 
Interestingly, PUVA-treated fibroblasts cultured in their regrowing state reach the 
stationary phase at a much lower cumulative population doubling than control 
fibroblasts. The reduced total life-span was due to oxidative stress induced 
telomere erosion as scavenging of ROS by NAC rescued cell from telomere 
erosion and partly restored the life-span. These data support the view that the 
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preceding damage affects a counting mechanism contributing to the overall 
proliferation potential. 
The initiation of the growth arrest was studied, and the amount of interstrand 
cross-links was not correlative. To further study whether damaged cytoplasts or 
damaged nuclear DNA are responsible for the growth arrest,  nuclei and 
cytoplasts of PUVA-treated fibroblasts were fused with control cytoplasts or 
nuclei to reconstruct hybrids with either undamaged cytoplasts or undamaged 
nuclei. Fused cells with PUVA-cytoplasts, although growth arrested, start to 
regrow earlier post-PUVA at about day 40. Fused cells with PUVA-karyoplasts 
did not adopt a flattened phenotype and die after 2 weeks. These data indicate 
that PUVA-induced changes in the cytoplasts contribute to growth arrest, but 
may not be exclusively, while the contribution of the nuclear damage after PUVA 
cannot be fully evaluated by these experiments. 
Collectively, these data suggest that PUVA-induced changes do not fully reflect 
replicative senescence but rather represent a long-term transient phenocopy. 
The model reported here is particularly suited to elucidating mechanisms 
underlying long-term senescence-like growth arrest and related functional 
changes. 
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Zusammenfassung 
Replikative Seneszenz bezeichnet das irreversible Ende der Teilungsfähigkeit 
somatischer Zellen. In der Dermatologie werden hyperproliferative 
Hauterkrankungen mit der Kombination aus oraler Aufnahme des 
Photosensibilisators 8-Methoxypsoralen (P) und Ultraviolett-A (UVA) Bestrahlung 
als PUVA-Therapie behandelt. Humane dermale Fibroblasten reagierten auf 
PUVA mit Verlust der Teilungsfähigkeit und morphologischen und funktionalen 
Kennzeichen einer seneszenten Zelle. Im Gegensatz zur unumkehrbaren 
replikativen Seneszenz wurde nach drei Monaten eine Wiederaufnahme der 
Proliferation beobachtet. Die vorliegende Arbeit beschäftigt sich mit den 
molekularen Mechanismen des PUVA-induzierten Arrestes und der 
Wiederaufnahme des Wachstums im Vergleich zur replikativen Seneszenz als 
Folge erschöpfter Teilungsfähigkeit.  
Ein Zusammenhang zwischen direkten und indirekten DNA-Schäden nach 
Psoralen-Photoaktivierung und dem Wachstumsarrest konnte experimentell nicht 
gezeigt werden. Zellhybride aus Zytoplasten PUVA-behandelter und 
Karyoplasten unbehandelter Fibroblasten arretierten nach wenigen Tagen für ein 
bis zwei Monate. Diese Ergebnisse weisen auf die Bedeutung von Schäden des 
Zytoplasmas und der Membranen hin. Vergrößertes Zellvolumen, Expression 
von Matrixmetalloproteinase-1, SA-beta-Galaktosidase und von p16, p21 und 
p53 als Zeichen der replikativen Seneszenz waren innerhalb der Arrestphase, 
nach der Wiederaufnahme der Proliferation jedoch nicht mehr nachweisbar. 
Wachstumsarretierte Fibroblasten steigerten die Produktion reaktiver 
Sauerstoffintermediate in den Mitochondrien oder durch NADPH-Oxidasen bis 
auf das 20-fache. Nach Reproliferation zeigten die Fibroblasten eine "molekulare 
Narbe" in Form einer verminderten Lebensspanne. Ursächlich war die 
Sauerstoffradikal-abhängige Telomeren-Erosion. N-Acetylzystein schützte als 
Antioxidans vor den morphologischen Veränderungen und zumindest teilweise 
vor der Reduktion der Lebensspanne. Da reproliferierende Fibroblasten weder 
Adhäsions-unabhängig wuchsen noch de novo Telomeraseaktivität zeigten, 
wurden Immortalisierung und neoplastische Transformation als Ursachen der 
Reproliferation ausgeschlossen.  
Eine PUVA-"Therapie" von Fibroblasten führt zu einem deutlich von der 
replikationsabhängigen zellulären Seneszenz unterscheidbaren 
Alterungsphänotyp. Diese Phänokopie der replikativen Seneszenz scheint 
geeignet, die Ursachen und Mechanismen der zellulären Seneszenz im 
molekularen Detail zu untersuchen.  
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